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SUMMARY
The cellular and humoral immune responses to insulin in type I 
diabetic patients (IDDM) were investigated in order to assess the 
immunogenicity of therapeutically administered insulin 
preparations.
In vitro lymphocyte proliferation (stimulation index (SI)) to 
human, pork and beef insulins was determined in 63 patients 
undergoing human insulin therapy. Approximately 40% of the 
patients gave significant SI values to at least one type of 
insulin. The cellular immune response to insulin was found to be 
partially regulated by suppressor cell activity.
The effects of transferring from beef to human insulin therapy 
was investigated in 31 patients. The type of therapy did not 
appear to influence the cellular immune response to insulin, 
implying that beef insulin was no more immunogenic than human 
insulin in these patients.
Serum immunoglobulin levels were determined in terms of 
anti-insulin IgG, anti-insulin IgG subclasses, total IgE and 
total IgM levels using an enzyme linked immunosorbance assay. 
Anti-insulin IgG was found to be significant in 55% of 76 
patients undergoing human insulin therapy. Most responses were 
low; only 4 patients possessed high concentrations of antibody, 
all of whom had been administered PZI beef insulin at some time. 
Patients on human insulin therapy only showed no or very low 
levels of anti-insulin antibody in their sera.
Insulin therapy was found to stimulate preferentially IgGl and 
IgG3 subclasses wereas the levels of IgG2 and IgG4 varied 
considerably from patient to patient. The levels of anti-insulin 
IgG4 and total IgE were found to correlate negatively with age 
and positively with the patients' daily insulin dose requirement. 
The level of anti-insulin IgG2 decreased with insulin dose. A 
strong correlation between anti-insulin IgG4 and IgE was also 
established.
Transferring patients from beef to human insulin did not have a 
significant effect on the levels of anti-insulin IgG or its 
subclasses. The levels of IgE, however, decreased when the 
patients were transferred to human insulin therapy.
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Diabetes Mellitus is a disorder of metobolism associated 
with deficiency of insulin. The disease, which is 
characterised by hyperglycaemia, is chronic and affects 
the metabolism of carbohydrate, protein, fat, and 
electrolytes. The metabolic derangement is frequently 
associated with permanent and irreversible functional and 
structural changes at the cellular level. The vascular 
system is particularly susceptible.
Clinical complications of diabetes may arise. These 
characteristically affect the eye, the kidney and the 
nervous system. Examples of such complications include 
ketoacidosis, neuropathy, nephropathy, retinopathy, 
atherosclerosis and lowered resistance to infections.
Diabetes mellitus is the commonest of the endocrine 
disorders. In its various forms, diabetes afflicts about 
5 per cent of the population in most western societies 
(Notkins, 197S).
On the basis of aetiology, two main categories of 
diabetes are recognised, namely primary and secondary 
diabetes. There are two main types of primary 
(idiopathic) diabetes: insulin dependent juvenile onset
(IDDM) or type I diabetes; and a non-insulin dependent 
maturity onset (NIDDM) or type II diabetes mellitus. IDDM
l
usually occurs in childhood and adolescence, but it may 
also occur at all ages (Irvine, 1980). In Table 1.1. the 
main features of IDDM and NIDDM are compared.
Table 1.1.
Contrasting features of insulin dependent (IDDM) and
non-insulin dependent (NIDDM) diabetes mellitus.
(Modified from Reeves, 1980 and Rossini, et. al ., 1985).
IDDM NIDDM
Age at onset Usually <30 Usually >40
Prevalence 0 .2 -0 .5% 2-4%
Onset - Rapid or gradual Insidious
Seasonal variation - Present ? Absent
Insulitis at onset Present in 50-70% ? Absent
Insulin deficiency - Absolute Relative
Anti-pancreatic
humoral immunity - 60-85% at onset 5%
Ant i-pancreat ic
cell-mediated immunity - 35-50% at onset <5%
Associated with
other endocrinopathies - Frequent Infrequent
Concordance in
identical twins - <50% Invariable
Association with HLA Present Absent
IDDM is thought to be an autoimmune disease in which the 
beta cells of the pancreas are destroyed by inflammatory 
mononuclear cells which infiltrate the islets of 
Langerhans (Rossini, et. al., 1985). This process is 
referred to as "insulitis" and results in insulin 
deficiency and clinical diabetes. The immunological 
attack on the beta cells usually begins several years 
before the presentation of clinical IDDM and is referred 
to as the asymptomatic "prediabetic" period (Palmer,
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1987). IDDM is thought to be initiated by virus, stress, 
environmental toxin or an aberrant immune response 
(Gepts, w., 1983). Antibodies directed against islet 
antigens are often found in the blood of newly diagnosed 
IDDM patients and in individuals during the “prediabetic" 
period. These antibodies include islet cell antibodies 
which are directed to the cytoplasm and cell-surface, 
antibodies to an islet protein of 64-KD molecular weight, 
and insulin autoantibodies (IAA) (Palmer, 1987).
Insulin autoantibodies are found in individuals who have 
not received exogenous insulin. Their characterization, 
shows them to be of the IgG isotype, with a similar 
binding constant and capacity to those of insulin 
antibodies from insulin-treated diabetic patients
(Goldman, et. al., 1979) However, unlike the insulin 
antibodies induced by insulin therapy that have both 
lambda and kappa light chains, IAA from some patients
with insulin autoimmune syndrome have been found to be
exclusively kappa light chains (Palmer, 1987).
The role of IAA in IDDM, and whether it is
pathophysiologically involved in the beta cell 
destructive process is unknown. It is possible that IAA 
may not be involved, but are only markers of the beta 
cell destructive process. IAA formation may be activated 
during the beta cell destruction process; IAA would then 
be considered a result of, rather than a cause of the 
beta cell damage. Alternatively, IAA may not be
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necessarily markers of the beta cell lesion of IDDM, but 
may tend to occur in individuals genetically predisposed 
to autoimmunity, and a small proportion of these people 
may in turn be predisposed to IDDM. The finding of IAA 
in individuals with other autoimmune disorders such as 
Graves' disease, systemic lupus erythematosis and in 
individuals treated with drugs such ' as penicillamine 
suggest that IAA can occur and not be a marker of beta 
cell damage (Palmer, 1987).
The distribution of circulating lymphocytes may also be 
altered in IDDM patients. Although some investigations 
report normal numbers of peripheral blood B- and T-cells, 
others claim a decrease in the number of T-lymphocytes. 
Furthermore, the numbers of helper/inducer T-cells (0KT4, 
Leu 3A) have consistently been found to be unchanged when 
compared with controls. However, the numbers of 
peripheral blood suppressor/cytotoxic T-cells are 
reported by some workers to be decreased when compared 
with those of non-diabetic subjects (Rossini, et. al., 
1985). Suppressor-T cell activity is also reported to be 
defective when lymphocytes from newly diagnosed diabetic 
patients are stimulated either by the mitogen 
concanavalin A (con. A) or by pancreatic antigens 
(Baschard, et. al., 1980). However, the suppressor cell 
activity is normal in established diabetics. This 
deficiency in suppressor cell activity is thought by some 
workers to contribute to the progression of the 
autoimmmune process in IDDM. IDDM shows a significant
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assocuation with HLA antigens (see below), particularly 
with HLA-DR3 and HLA-DR4. An abnormal suppressor T-cell 
function has also been reported in non-diabetic subjects 
who are HLA-DR3 and/or DR4 positive. Therefore, an immune 
regulation abnormality of this kind may be related more 
generally to HLA-DR3 • and HLA-DR4 (Rossini, et. al., 
1985).
Interferon production (Baratono, et. al., 1980) and
interleukin-2 (IL-2) (Kaye, et al., 1986) synthesis is 
also reported to be depressed in IDDM patients. Such 
defects do not appear to be related to the adequacy of 
metabolic control. However, it is possible that a 
cytokine required to modulate or suppress immunocyte 
activity may be deficient in IDDM. So far no evidence 
for such a hypothesis has been presented. Further 
investigation is therefore, necessary.
Pathogenesis of IDDM is thought to be genetically linked. 
The class II antigens HLA-DR3 and HLA-DR4 are present in 
increased frequencies in patients with IDDM in comparison 
with control populations (Wolf et.al., 1983; Irvine, 
1980). Where both DR3 and DR4 occur together in the same 
individual, the risk of developing IDDM increases even 
further.
HLA-B8 and B15 antigens are also significantly associated 
with IDDM in Caucasians (Irvine, 1980). A more variable 
association is observed with HLA-B18 and HLA-B40
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(Cudworth and Festenstein, 1978), and HLA-B8 / W15
(Irvine, 1980). Diabetes associated with HLA-B8 and W15 
is further characterized by early age at onset, 
non-obesity, lymphocyte infiltration of the islet of 
langerhans, reduction in the functioning beta cells and 
anti-pancreatic cell mediated immunity. The frequency of 
HLA-B8 is also reported to be high in Graves' disease and 
in idiopathic Addison's disease. This suggests the 
possibility of HLA-B8 or an HLA-B8  associated immune 
response gene being the common denominator for the 
development of endocrine autoimmunity (Irvine, 1980).
The possession of DR2, and/or -HLA-B7 (which is often 
associated with HLA-A3) on the other hand, is thought to 
confer resistance to the development of IDDM.
The HLA-D region has recently been studied in great 
detail using recombinant DNA technology. DNA probes and 
genomic blotting techniques have revealed five to six 
alpha genes, or heavy chains, (one DRa, three or four DCa 
related and one SBcO. There are also seven beta genes 
(three DRb, two DCb and two SDb) (Steinmetz, M. , and 
Hood,C., 1983). HLA-DC, which is in linkage
disequilibrium with HLA-DR, is associated with IDDM, 
while HLA-SB is not (Rossini et. al., 1985). In fact, 
HLA-DC £>-chain sequences are reported to be more strongly 
associated with IDDM than are HLA-DR antigens (Owerbach 
et. al., 1983).
The HLA genotype also appears to influence the patients'
6
age-at-onset before and after the age of 16 (Irvine,
1980). ie. there is a higher frequency of the genotypes 
DR4/x and DR4/4 and a lower frequency of other genotypes 
in patients with age at onset before the age of 16. 
Therefore, the presence of DR4 without DR3 appears mainly 
to increase the risk of developing IDDM before the age of 
16, whereas DR3 increases the risk in all the age groups. 
This implies that DR3 and DR4 (or associated factors) act 
by two different mechanisms and that there are two peaks 
for the age at onset for IDDM, one at about the age of 12 
to 14 years and one in the twenties.
Based on the above findings and the pattern of linkage 
disequilibrium within HLA, Cudworth and Festenstein 
(1978) have proposed a concept which involves double axes 
of susceptibility and a single axis of HLA factors 
conferring protection against the development of IDDM. 
This is illustrated in Figure 1.1.
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Figure 1.1.








DR2-D2-- — B 7 — — A3
HLA axis of "Susceptibility" (SI + S2) and "resistance" 
(R) to IDDM. (modified from - Irvine, 1980).
There is a progressive increase in relative risk from 
right to left along the HLA chromosome. The main 
susceptibility axis (SI) is defined by the primary 
association of DR3-D3, and the secondary association with 
B8, B18 and Al. The S2 axis is constructed in the same
manner, DR4 representing the primary and B18, B40, C3 and 
A2 forming the secondary associations. The D(DR) 
determinants are probably in a stronger linkage 
disequilibrium with the gene which increases the 
predisposition to the disease. In contrast, subjects who 
are DR2, with a secondary association with B7 and A3, 
have a significantly reduced risk of developing diabetes. 
This is probably because of linkage disequilibrium with 
genes which confer protection, forming the resistance Cor 
R) axis.
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Recently, there has been growing evidence to suggest that 
a highly variable locus close to the human insulin gene 
on chromosome 11 may be associated with IDDM (Hitman, et. 
al., 1985; Neumer, et. al., 1988; Yokoyama, et. al., 
1985). The IgG heavy-chain (Gm) gene complex has also 
been reported to be assocaited with IDDM and other 
autoimmune diseases (Nakao. et. al., 1981).
Thus the study of HLA asociations is beginning to shed 
light on the nature of an indiuvidual's proneness to 
develop insulin dependent diabetes. Genes associated 
with particular HLA phenotypes may determine the degree 
of immune responsiveness to viruses, for example 
Coxsackie B4, which are known to cause beta cell 
necrosis. The ease with which such viruses replicate in 
the beta cells may also be determined by the HLA 
phenotype. Other levels of genetic influence may relate 
to the severity of the autoimmune response and the 
potential for B-cell regeneration after virus-induced 
injury.
INSULIN
Type I diabetic patients are treated daily with 
heterologous insulin preparations of human, pork or beef 
origin.
Insulin is a small (5.75 Kd molecular weight) globular
9
protein composed of two polypeptide chains (A and B) that 
are linked by two disulphide bridges. Insulin is 
synthesised as a pro-insulin which consist of A and B 
chains linked by a connecting (C) peptide. (Structure of 
the pro-insulin is illustrated in Figure 1.2.). The 
C-peptide is cleaved by converting enzymes to yield the 
insulin molecule. The concentration of circulating 
C-peptide is often used to determine the natural history 
of beta cell function in diabetic patients (Block et. 
al. , 1972) as exogenously administered insulin
preparations do not contain the C-peptide.
-COOh
C O N N E C T I N G  
PEPTIDE ,
B - C H A I N
The structure of the porcine proinsulin molecule (after Shaw & Chance, 1968). The black circles 
indicate residues comprising the A and B chains of insulin; open circles indicate ihe connecting (or C) 
peptide. Residues 31 and 32, 62 and 63 are lost during cleavage of proinsulin to form free insulin and 
C-peptide.
The two main insulin analogues used to treat diabetic
patients are pork and beef insulins. However, in the
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United Kingdom, beef and pork insulins have been or are 
in the process of being phased out of clinical use as 
human insulin becomes more readily available. Beef 
insulin differs from human insulin by three amino acid 
exchange (Table 1.2.). Pork insulin differ only by one 
exchange. The C-peptides contain a much greater number 
of different residues compared to the human counterpart: 
ten for pork insulin and fourteen for the beef insulin 
molecule.
Table 1.2.
Species variation in amino acid sequence of human, pork 








Human Threonine Iso-leucine Threonine
Pig Threonine Iso-leucine Alanine
Ox Alanine Valine Alanine
Insulin was first isolated in 1921 by Frederick G. 
Banting, Charles H. Best and others. It was used to 
treat patients with diabetes in the following year. 
Traditionally, insulin preparations had been purified by 
sequential recrystallization, but further examination of 
recrystallized material by gel chromatography in the late 
1960's revealed the presence of contaminants which could 
be separated into three different fractions: (1 )
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contained high molecular weight impurities, (2 ) contained 
proinsulin, intermediatory insulin and insulin dimer and 
(3) contained arginine insulin, ethylester insulin and 
insulin monomer deaminated to a variable degree (Steiner 
et. al.,1968; Schlichtkrull et. al., 1972, reviewed by 
Reeves G.W., 1980). These contaminants were highly
immunogenic and patients' sera contained high antibody 
titers to these antigens. Preparations obtained by 
removal of the (1 ) and (2 ) components were referred to as 
'single peak' (sp). These 'sp' insulin preparations were 
still capable of inducing an antibody response but the 
amount produced depended on the physical state of the 
insulin preparation used therapeutically (Andersen, 
1973).
Uncontaminated insulin monomer were separated by anion 
exchange chromatography which lead to the development of 
monocomponent (me) highly purified insulins of pork and 
beef origin. These were less immunogenic as 
contaminating substances such as pancreatic polypeptide, 
glucagon, and vasoactive intestinal peptide (vip) which 
can induce antigenic reactions and the development of 
lipo-atrophy, were removed (Bloom et. al., 1979).
Recrystallized beef insulin when dissolved in 
physiological media produced an acid solution with a 
short duration of action. Adjustment of pH with an 
acetate buffer to form neutral soluble insulin caused 
less discomfort at the injection site but several
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injections per day were necessary for adequate control. 
Various modifications were made to prolong the metabolic 
effect. Hagedorn et. al., in 1936 discovered that 
combining of the acidic insulin molecule with the highly 
basic protamine derivative from fish sperm in the 
presence of a moderate concentration of zinc ion yielded 
a stable complex with' prolonged duration of action. This 
became known as neutral protamine Hagedorn (NPH) or 
isophane insulin. Other workers showed that a further 
increase in zinc and protamine concentration extended the 
period of action upto 3 days (Scott and Fisher, 1936). 
Protamine consisted of 8 6  per cent arginine and was 
considered non-immunogenic although apparent
hypersensitivity has been experienced by some patients 
(Reeves, 1980).
The discovery that the activity of insulin could be 
prolonged by combining with zinc alone (Hallas-M^ller, 
et. al., 1952) lead to the introduction of insulin-zinc 
suspensions whose duration of action could be adjusted by 
varying the relative proportions of non-crystalline (ie. 
amophous) and crystalline material within the 
insulin-zinc suspension. These 'lente' preparations 
contained a much higher zinc concentration than the 
isophane or soluble preparations. Highly purified 
insulin preparations were developed which were comparable 
with the classical 'neutral' preparations. 'Isophane' 
and 'lente' preparations and a twice daily combination of 
soluble and isophane preparations provided the most
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flexible regime for the majority of insulin dependent 
diabetic patients.
In the late 1970's insulin of recombinant DNA origin was 
first produced and was first tested in human subjects in 
1980 (Keen, 1980). Shortly afterwards 'semisynthetic' 
human insulin became available. It is a product 
manufactured from pork pancreatic insulin by the trypsin 
catalysed removal of the B30 alanine and its replacement 
by threonine (Markussen, et. al., 1983).
Most recombinant DNA human insulin is made by inserting 
synthetic genes for the A and B chains into plasmids at a 
promotor gene site. For example, at J>-galactosidase or 
tryptophan synthetase, and then into Escherichia coli 
K12 (Crea, et. al., 1978). Following fermentation the 
chimeric gene product is cleaved, purified and the chains 
combined to make active insulin (Miller and Baxter,
1981). Today, human insulin from recombinant DNA 
proinsulin is a major commercial source.
Complications associated with Diabetes and Insulin 
Therapy
The administration of insulin to IDDM patients results in 
both cellular and humoral responses which, in a minority 
of patients, may lead to immunological complications. 
Insulin resistance and insulin allergy in the form of the
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immediate or delayed type are two of the more common 
side-effects of insulin therapy.
Insulin resistance
The daily insulin dose requirement of a pancreatectomized 
diabetic is 40-50 units (Reeves, 1980). Most patients 
achieve good control of their diabetes with around 2 0  to 
60 units per day. Patients requiring more than 200 units 
in the absence of ketosis are diagnosed as showing 
"insulin resistance". Patients with insulin resistance 
show much higher levels of circulating antibody (Berson &~ 
Yallow, 1959). However, the relationship between the 
level of insulin antibody and insulin dose in patients 
requiring only moderate levels of insulin has been a 
matter of debate. For example, Asplin, et. al., (1978), 
failed to find a relationship between insulin antibody 
and daily insulin dose. Much of the discrepancy has been 
due to (a) variations in diabetic management and 
attainment of 'control', (b) variations in insulin 
preparations used to treat the patients and (c) 
variations in the methodology used to detect the insulin 
antibody. Despite these shortcomings, there is a 
reasonably clear distinction between the antibody levels 
seen in resistant and non-resistant patients (Reeves, 
1980). The majority of patients showing a high daily 
insulin requirement (for example, more than 1 2 0  units), 
possess high levels of IgG insulin antibody in their
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serum, (Berson & Yallow, 1959).
Skip et. al., (1965) has reported an incidence of 0.1 per 
cent of diabetic patients studied by them to show insulin 
resistance. Of the 107 IDDM patients studied in the 
present investigation, three are known to show insulin 
resistance (ie. requires more than 2 0 0  units per day). 
Therefore, insulin resistance is not uncommon even with 
highly purified and human insulin therapy. Insulin 
resistance may occur transiently during infection or 
episodes of ketosis and also in association with 
neoplasia, liver disease, other endocrine disorders and 
rare syndromes such as lipo-atrophic diabetes. In some 
patients a deficiency of insulin receptors on cell 
membranes is reported and in others the production of 
antibodies reactive with the insulin receptor may also 
lead to insulin resistance (Reeves, 1980).
Insulin allergy.
Insulin allergy is reported to develop in some patients 
during the initial period of insulin therapy and is 
characterized by the development of transient urticarial 
wheals or red nodules. Acidic soluble insulin 
preparations are known to give rise to painful reactions 
at the injection site in some patients. In contrast, 
less complications are reported with the use of buffered 
neutral preparations, although faulty injection technique 
may cause discomfort with any kind of insulin
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preparation. Most studies implicate antibody of class 
IgE in the acute allergic response (Witters, et. al., 
1977). It has been suggested that some cases of insulin 
allergy may be due to the presence of zinc in long acting 
insulin preparations (Reeves, 1986).
Li po-a trophy.
Lipo-atrophy at the site of insulin injection occurs in 
about 25 per cent of patients treated with conventional 
beef insulins and is more common in female than in male 
patients (Reeves, 1980). Insulin lipo-atrophy is a local
form of immune complex disease in which insulin and 
contaminating proteins react with insulin antibody and 
complement to produce inflammatory destruction of
subcutaneous tissue. Histological analysis of the
lipo-atrophic areas shows mild inflammatory changes with
a peri-vascular lymphocytic infiltrate. Patients treated 
from the onset with highly purified insulins do not 
usually show any signs of lipo-atrophy (Poulsen & 
Deckert, 1976).
Most patients treated with conventional insulins produce 
complexes composed of insulin and anti-insulin antibodies 
(Reeves, 1986). Whether these complexes are involved in 
the pathogenisis of diabetic complications is debatable. 
For example, levels of circulating immune complexes have 
been found to be increased in the sera of patients with 
diabetic retinopathy when compared with patients without
l?
retinopathy matched for duration of diabetes (Irvine, et. 
al., 1987). Because the patients used by Irvine included 
many who never received insulin, it is clear that 
complexes containing antigens other than heterologous 
insulins are involved.
Other complications which may be a side effect of insulin 
therapy include atherosclerosis. Coronary heart disease 
was found to be more prevalent among diabetic women 
especially in those receiving insulin therapy (Garcia, 
et. al., 1974). Most insulin-dependent diabetic patients 
have increased levels of circulating insulin which can 
retain its metabolic activity and stimulate arterial 
smooth muscle cell proliferation as well as lipid 
synthesis within the arterial wall (Stout, 1979). 
Therefore, it is possible that insulin therapy in 
conduction with insulin antibody production may have a 
role in exacerbating the underlying proneness of diabetic 
patients to develop atherosclerotic disease.
The above immunological complications are found in a 
minority of patients. However, most diabetic patients 
undergoing insulin therapy show cellular and antibody 
responses to insulin, which do not necessarily lead to 
any adverse effects.
In the following chapters the immune response to insulin 
in two groups of patients is examined. Group I consisted 
of IDDM patients on human insulin therapy for more than
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six months. Group II comprised of IDDM patients on beef 
insulin who later were transferred to human insulin 
therapy.
The main objectives of this study were to investigate the 
in vitro cellular immune responses to pork, beef and 
human insulins in order to assess the level and 
specificity of response to the three types of insulin, 
and to examine the possible associations between the 
cellular immune response to insulin and the clinical 
background of the patients.
Group II patients, were used to investigate the effects 
of transferring from beef to human insulin therapy on the 
in vitro cellular immune response to human, pork and beef 
insulins. The effects of changing from beef to human 
insulin therapy on the level of their anti-insulin 
antibody titer were also examined.
An Insulin-specific, Peripheral Blood Mononuclear Cell 
(PBMC) proliferation assay was employed as a measure of 
cellular immune response with emphasis on suppressor cell 
activity. The humoral immune responses to pork, beef and 
human insulins were determined using the Enzyme Linked 
Immunosobent Assay (ELISA) with emphasis on serum 
anti-insulin IgG concentration and anti-insulin IgG 
subclass distribution.
The presence of other Ig Isotypes (namely, IgE and IgM), 
in the patients' sera, were also determined.
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CHAPTER II
2. CELLULAR IMMUNE RESPONSE TO INSULIN
2.1. INTRODUCTION
Treatment of type I diabetic patients with either 
heterologous insulin (pork insulin (PI), beef insulin 
(BI)) or autologous insulin (human insulin (HI)) induces 
the production of anti-insulin antibodies in the serum of 
most patients (Pickup, 1986). A cellular immune response 
to insulin, in the form of insulin-specific lymphocyte 
transformation, is also observed in some IDDM patients 
(Mann, et. al., 1983; Nell, et. al., 1983). In a 
minority of these patients immunological complications 
may result even with the use of highly purified and human 
insulin preparations (Reeves, i985; Pickup, .1986). 
Immunological complications associated with insulin 
therapy are discussed in detail in Chapter I 
'Introduction' .
Most complications related to insulin therapy, implicate 
insulin antibody as the culprit. However, antibodies are 
produced by transformed B-lymphocytes as the final step 
in the expression of the humoral immune responses. The 
initial step is the interaction of the insulin molecule 
with antigen presenting cells and T-lymphocytes with 
subsequent blast transformation of the T-lymphocytes to
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cells capable of promoting the transformation of the 
B-lymphocytes to effector cells of the plasma cell 
series. Therefore, in order to understand the humoral 
immune response to insulin, it is necessary to 
investigate the cellular response. Moreover, in vitro 
assays of T-cell stimulation may yield more subtle 
information on insulin reactivity than antibody studies.
Compared to the numerous investigations on the antibody 
response to insulin, few workers have concentrated on the 
the cellular immune response to therapeutically 
administered insulin and its relationship to the clinical 
background of patients.
T-cell proliferation assays are commonly used as a 
measure of cellular immune response to insulin in type I 
diabetic patients. In the past, most of these studies 
have implicated the amino acid differences between 
autologous insulin and immunizing insulins as the 
critical epitopes on the insulin molecule recognized by 
T-cells (Mann, et. al., 1983; Scheinin, et. al., 1933). 
Recent investigations, however, show that recognition of 
amino acid exchanges is not the only factor determining 
insulin immunity. Results from experiments using T-cell 
clones (Parker & Reeves, 1989) demonstrate that the 
potential immunogenic epitopes recognized by T-cells are 
more numerous and complex than anticipated from results 
with inbred animals.
T-cell populations obtained from type I diabetic patients
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react with epitopes present on foreign and self insulin 
(Nell, et. al., 1983; Nell, et. al., 1985; MacCuish, et. 
al., 1975; Page-Faulk, et. al., 1975; Naquet, et. al.,
1988). Some of these epitopes may be shared between 
different species of insulin (for example, BI, PI, Rabbit 
Insulin.(RI) and HI), due to the high degree of sequence 
homology. T-cell reactivity to such "common epitope(s)" 
present on HI is thought to lead to autoimmunity (Nell, 
et. al., 1985).
Although, it's structure was not precisely identified, 
one such epitope was reported to consist of a complex 
determinant formed by the association of the A-chain loop 
with the N-terminal residues of the B-chain (Nell, et. 
al., 1985). Recently, it has been shown that autoreactive 
T-cells recognize two conformational epitopes of human 
insulin formed by interactions between A-chain and 
B-chain residues (Naquet, et. al., 1988). One epitope 
is associated with the A-chain loop and is present in the 
A1-A14/B1-B16 peptide, and the other in the 
A16-A21/B10-B25 peptide. These two epitopes are present 
in amphipathic oC-helical regions of the insulin molecule.
Studies with inbred animals show that the immune response 
to epitopes on the insulin molecule is controlled at the 
cellular level by the major histocompatibility complex 
(MHC)-linked immune response genes (Erb, 1980; Glimcher, 
et. al., 1983; Jensen & Kapp, 1985; Rosenwasser, et. 
al., 1979). Recently, several studies (Mann, et. al.,
22
1983; Scheinin et. al., 1983; Sklenar, et. al., 1982; 
Miller, et. al., 1987; Naquet, et al., 1988; and Parker 
& Reeves, 1989) have reported an association between 
class II MHC encoded gene products and the response to 
therapeutic insulin components in diabetic patients and 
therefore, support the concept that similar immune 
response genes are present in the outbred human 
population.
Individuals whose lymphocytes respond to either BI or 
both BI and PI are reported to express an increased 
frequency with respect to the normal population of the 
HLA-DR4 and HLA-DR3 antigens respectively. Furthermore, 
HLA-DR (DR3, DR4, and DR5) and HLA-DQ (DQw2/DQw3) 
antigens can restrict these T-cell responses to human 
epitopes. It is thought that responses to HI epitopes is 
restricted by oC- and ^ D-chains of DQw2 and DQw3 molecules 
which produce hybrid molecules in DR3/4 heterozygotes 
(Naquet, et. al., 1988).
Miller, et. al., (1987), observed that human 
T-lymphocyte responses to mamalian insulins are 
polyclonal and include T-cells with auto-immunity for 
human insulin. They report that different T-cells 
recognize the same epitopes. For example, A-loop of beef 
insulin, in association with either DR1 or DRw6 . The 
response pattern of T-cell lines (TCL) that cross-react 
with pork or human insulin suggest that some T-cells have 
slightly different fine specificity for the A-chain loop
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region where beef insulin differs from pork and human (A8  
and A10). One TCL (P4/1) derived by pork insulin 
stimulation reacts with both beef and pork but not human 
insulin. Thus, the B-chain terminus (B30) where beef and 
pork insulin differ from human insulin may be an 
important component in the epitope recognized by this 
clone. This residue (B30) is topographically associated 
with the A-chain loop on the surface of the insulin 
molecule (Blundell, et. al., 1972), and may form a
conformational determinant recognized by these T-cells.
It is thought that A-loop residues interact with la and 
display other portions of the molecule for recognition by 
T-cells (Miller, et. al., 1987). This is further
substantiated by Glimcher, et. al., 1983) who found that 
the immunogenic moiety recognized by T-cell hybridomas is 
formed by the amino acid sequence of the B-chain
(possibly involving amino acid B3) and by the interaction 
of the B-chain with the A-chain loop region. The 
preferred antigenic moiety recognized by these T-cell 
hybrids depends upon tertiary conformation, thus,
although the group II T-hybrids can respond to isolated 
B-chain, they are triggered more easily by native 
molecule.
Insulin-specific suppressor T-cells
Suppressor cell activity in IDDM patients is reported to 
be depressed at the time of diagnosis and normal in the
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remission period (Buschard, et. al., 1902). Horowitz 
et. al., (1977) found decreased suppressor T-cell 
function in 6 of 9 patients with IDDM; not all were newly 
diagnosed. In comparison, all control subjects showed 
normal suppressor cell activity. The decrease in the 
number of functional suppressor cells is thought to 
contribute to the acceleration of the auto-immune process 
of type I diabetes. Indeed, many physicians in recent 
years have employed immuno-suppressive drugs such as 
cyclosporin A in order to retard the autoimmune process 
in newly diagnosed diabetics (Herold and Rubenstein, 
1980). ~
Although the present study is not necessarily concerned 
with the auto-immune aspects of IDDM, it would be of 
great interest to determine whether a deficient 
suppressor cell activity exist in established diabetic 
patients which may lead to all sorts of immunological 
complications. As most IDDM patients retain some beta 
cell function, lack of immunoregulation by suppressor 
cells may contribute to the greater loss of beta-cell 
secretory capacity, which in turn may influence diabetic 
control and insulin dose requirement.
Most studies investigating the possible role of metabolic 
control on suppressor cell activity have used assays 
which were non-specific, eg., the use of Concanavalin A 
to stimulate suppressor T-cells. However, it is well 
established that suppressor cells are antigen-specific.
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ie., they recognize and distinguish between antigenic 
moieties (Baskin & Rosenthal, 1980; Kontainen, 1982; 
Jensen & Kapp, 1985). Therefore, lack of any 
relationship between suppressor cell activity and 
patients' clinical background which has been reported in 
the past (Buschard, et. al., 1982) may be due to 
inappropriate methodology. That insulin-specific
suppressor cells exist, there is little doubt. How these 
suppressor cells function is discussed below.
In some inbred animals and diabetic patients there is no 
apparent antibody response to the immunizing insulin. For 
example, mice bearing the H-2to haplotype, develop 
insulin-specific antibody responses after immunization 
with beef and sheep insulin, but not pork or autologous 
insulin. H-213 mice injected with pork insulin develop 
memory helper T-cells that support secondary responses to 
beef, but not pork insulin in adoptive recipients and in 
vitro. Pork insulin stimulates a heteroclitic pattern in 
H-2to mice since the primed T-cells support secondary 
responses to beef insulin but not to the immunizing 
antigen.
Non-responsiveness is not due to a lack of insulin 
specific B-cells but to a lack of functional helper 
T-cells. ie., non-immunogenic variants of the insulin 
molecule prime memory helper T-cells but are unable to 
trigger the primed T-cells to co-operate with B-cells. 
This is because pork insulin also primes dominant pork
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insulin-specific suppressor T-cells in H-2to mice (Jensen 
& Kapp, 1985). The heteroclitic response pattern 
observed can be explained by the differing antigenic fine 
specificities of pork insulin-primed helper and 
suppressor T-cells.
Whereas the helper T-cell is cross-reactive for pork and 
beef insulins, the suppressor T-cells recognize pork but 
not beef insulin. The net effect, in the presence of 
both regulatory subpopulations is helper activity for 
secondary responses to beef but not pork insulin. This 
implies that suppressor and helper T-cells recognize two 
different epitopes on the same insulin molecule or, at 
least, that responsiveness to insulin and insulin 
suppression are under different genetic control 
(Kontianien, 1982).
Jensen and Kapp (1985) suggest that, in mice at least, 
suppressor T-cells recognize determinants on the A-chain 
loop, since that is the only site where the primary amino 
acid sequence differs between pork and beef insulins. 
This conclusion is verified by the observation that 
H-2to mice immunized with pork or rat insulin (rat insulin 
is homologous to mouse insulin and the A-chain loop of 
pork and mouse is identical) contain primed helper 
T-cells and dominant suppressor T-cells that recognize 
mouse insulin.
Parker and Reeves (1989), using an in vitro human
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lymphocyte priming assay, also came to the conclusion 
that the epitope recognized by human insulin-specific 
suppressor cells reside in the A-chain. They found that 
secondary challenge with an insulin which is more foreign 
than that used for priming can elicit a greater response 
at the end of secondary culture in vitro. This is most 
apparent when cultures primed with pork insulin are 
challenged with beef insulin. It was postulated that the 
in vitro response to pork insulin is regulated by cells 
activated by suppressor epitope(s) present on both human 
and pork insulins. If such an epitope is located within 
the A-chain loop (ie., residue A8-A10) then this would 
explain the enhanced response when challenged with 
insulin in which these residues are altered (eg., beef 
and ovine insulins) because this would interfere with the 
suppressive effect.
Suppressor T-cells are thought to mediate their function 
via soluble mediator molecules (suppressor factors) 
(Kontiainen, 1982). These suppressor factors are not 
always genetically restricted and may act across species 
barriers. For example, antigen specific suppressor 
factors of monkey or human origin can be tested on mouse 
cells (Lamb et. al., 1979). Using antigens under Ir 
gene control it has also been demonstrated that both 
responder and non-responder strains produce these 
suppressor factors. (Baskin and Rosenthal, 1980).
Insulin-specific suppressor factors resemble other human
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secreted antigen specific suppressor factors in that they 
carry the factor constant (function related) and DR 
determinants, and in acting across a species barrier 
(Kontiainen, 1982). However, whether the suppressor 
factor is analogue specific is debatable. For example, 
both beef and pork insulins induce suppressor factors 
that abolish pork insulin specific T-helper cell activity 
(these same factors do not affect keyhole limpet 
haemocyanin (KHL) specific T-helper cells). This lack of 
insulin analogue specificity was not observed when 
immunoabsorbtions were performed; all detectable 
suppressor activity in pork insulin induced suppressor 
factors was absorbed out when pork insulin 
immunoabsorbents were used but not when beef insulin 
immunoabsorbents were used. Beef insulin suppressor 
factor activity was equally specific for beef insulin 
immunoabsorbents (Kontiainen, 1982).
This discrepancy between lack of analogue specificity at 
the functional level and specificity with
immunoabsorbance, may be due to several reasons: 
contamination by either analogue in culture media; 
alternatively, multiple, partially overlapping suppressor 
cell inducing determinants exist which are probably 
influenced by the physicochemical forms of the insulin 
molecule. ie., insulin is mainly monomeric at 
concentrations < 1 ug.ml- 1  and mainly hexameric at doses 
> 30 ug.ml-1. The determinants recognized may well be
located in the B-chain as beef insulin-specific
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suppressor factor of H-213 mice (with T-helper cells 
recognizing A-chain determinants) was not absorbed by 
beef A-chain (Kontiainen, 1982).
Thus insulin antigen seems to trigger suppressor pathways 
in addition to insulin antibody, delayed hypersensitivity 
or allergic reactions. The suppressor pathways probably 
act to diminish unwanted reactions towards this self 
antigen ie., act as specific immunoregulation.
In contrast to the numerous investigations into the 
antibody specific immune response to insulin, the 
possible role of T-suppressor cells in the 
immunoregulation of insulin therapy in type I diabetics 
has been rather neglected.
Since human insulin has come into clinical use quite 
recently (many of the patients used in this study were 
transferred from pork and beef insulins to human insulin 
during the last three years), this study takes the 
opportunity to investigate the cellular immune response 
to this autologous insulin in greater detail with a 
larger number of patients than previously reported 
(Naquet, et al., 1988).
Furthermore, insulin-specific suppressor cell activity in 
diabetic patients has not been investigated in detail, 
although, Naquet, et. al., (1988) using a different 
methodology to the one used here has made a preliminary 
study which involved a limited number of patients (four
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families). In this chapter the clinical importance of 
insulin-specific suppressor T-cells (0KT8 +ve), and their 
possible role in the regulation of cellular immune 
response to insulin is discussed.
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2.2. PATIENTS, MATERIALS & REAGENTS
2.2.1. PATIENTS
Type I diabetic patients, who were otherwise healthy 
out-patients with well controlled diabetes, were divided 
into 2 groups on the basis of their insulin therapy. The 
third group comprised of healthy non-diabetic volunteers 
whose mean age, sex, and Body Mass Index (BMI) were 
matched with those of the diabetic patients, (see table
2.1.). All diabetic subjects were Caucasians.
Group I: Type I diabetic patients on human insulin
therapy for more than six months.
Group II: Type I diabetic patients on highly purified
beef insulin (Neusulin & Neuphane) therapy who later were 
transferred to human insulin (Human Velosulin (emp) & 
Insulatard (emp)). - Blood and serum samples were taken
while the patients were on beef insulin, 3-8 months after 
they were transferred to human insulin, and 1 2  months 
later.
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Table 2 . 1 .
Group III: Healthy non-diabetic control subjects.
Group I Group II Group III
N 63 31 2 2
Mean Age (years) 36.2 41.6 35.7
(range) (16-54) (21-56) (19-52)
Sex 35 male 
28 female
2 1 male 
1 0 female
























Group I: Most patients were administered one or two of
the following insulin preparations twice daily:
Human Actrapid (Novo); short acting, highly purified
synthetic human human neutral insulin (emp).
Human Monotard (Novo); intermediate-acting, highly
purified synthetic human insulin zinc suspension (emp).
Human Ultratard (Novo); long-acting, insulin zinc
suspension (crystalline) human insulin (emp).
Human Insulatard (Nordisk & Wellcome); intermediate
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acting highly purified human isophane insulin (emp).
Human Mixatard 30/70 (Nordisk & Wellcome); Biphasic prep. 
Highly purified human insulin (emp), 30% neutral soluble 
insulin and 70% isophane insulin.
Humulin Soluble (Eli Lilly); short-acting human soluble 
insulin (prb).
Humulin Isophane (Eli Lilly);intermediate-acting human, 
isophane insulin (prb).
Group II; 1st sample - All patients had been receiving 
twice daily preparations of the following insulin types: 
Neusulin (Wellcome); short-acting, highly purified beef 
insulin. Neuphane (Wellcome); intermediate acting, highly 
purified beef insulin. 2nd & 3rd samples were taken when 
the patients were undergoing the following insulin 
therapy:
Human Velosulin (Nordisk and Wellcome); short-acting, 
highly purified neutral soluble human insulin (emp).
Human Insulatard (Nordisk & Wellcome); intermediate 
acting highly purified human isophane insulin (emp).
All insulin preparations were U100. emp = enzyme 
modification of pork insulin; prb = produced from 
proinsulin synthesised by bacteria using recombinant DNA 
technology.
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2.2.2. MATERIALS & REAGENTS
(i) Preparation of culture medium : RPMI 1640 medium 
(Flow Laboratories, Ltd., England) was obtained as a x 10 
strength media in 500 ml unit quantities. Antibiotic 
solution: Penicillin (5,000 ug.ml"1) and Streptomicine
(5,000 ug.ml"1) sterile solution (Flow Labs. Ltd.), was 
stored at -20°C. 200mM, sterile L-Glutamine solution
(Flow Labs., Ltd.), was stored at -20°C. Sodium 
bicarbonate was also obtained as a sterile 7.5 % w/v 
NaHC03 (Flow Labs., Ltd). Foetal Bovine Serum (FCS) 
(Gibco Ltd., England). The FCS came heat inactivated at 
56°C for 30 minutes. It was stored at -20°C. Human AB 
Serum was obtained from Southmead Hospital, Bristol.
Table 2.2.
Human AB serum and additives were aliquoted into sterile 
30 ml Sterilin Universal tubes and stored at -20°C until 




200 mM L-Glutamine 1 ml 2mM
5000 u.ml" 1 Benzyl Penicillin > 50 u.ml" 1
5000 u.ml- 1  Streptomycin } 1 ml 50 ug.ml" 1
7.5 % w/v Sodium bircarbonate 2.67 mis 23.8 mM
Human AB Serum (or FCS) 1 0 mis 1 0 %
Preparation of single strength medium form xlO
concentrations:- Deionized distilled (d.d) water was 
sterilized by autoclaving at 121°C for at least 20
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minutes. 1 0 0  mis culture media was prepared as follows: 
To each bottle of 75.33 mis of d.d. water, 10 mis of x 10 
RPMI 1640 medium and 1 tube of Human AB serum and
additives were added. The pH of the culture medium was
found to be between pH 7.2 and 7.4.
(ii) Insulin solutions : Crystalline zinc beef, pork and 
human (biosynthetic-recombinant DNA) insulins were kind 
donations of Eli Lilly Co., Lilly Corporate Center, 
Indianapolis, IN., U.S.A.
Beef
Type of Insulin 
Pork Human
Potency 26.6 U.mg“i 26.8 U mg-*. 26.3 U mg-i
Proinsulin <0 .0 0 1 % <0 .0 0 0 1 % -
Glucagon <0 .0 0 1 % <0 .0 0 0 1 % -
Zinc <0.7% <0.9% 0.4%
Water 9% 7% 8.3%
Mol. Wt. ND* 5778 daltons 5808 daltons
ND* - not determined.
5 mgs ml- 1  of the crystalline insulin was made up in 
dilute acid (5 x 10- 3  M HC1, pH 2.5), filter sterilized 
and stored at 4°C (for upto one week) in 200 ul 
aliquotes. For the proliferation assay, aliquots of these 
stock solutions were diluted further with RPMI 1640 
medium supplemented with 10 % AB serum and additives.
(iii) Phytohemagglutinin (PHA)-Purified, phaseolus spp. 
(5ml, dried) (Wellcome Foundation Ltd., UK). The content 
was reconstituted with 1 ml of sterile d.d. water to 
give a concentration of 10 mg ml- 1  and stored at 4°C. 
This stock solution was diluted 1:100 with RPMI 1640
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medium (containing 10 % Human AB serum and additives) to 
a concentration of 100 ug ml-1. The diluted PHA was 
filter sterilized using 0 .2 um Milipore filter and
aliquoted into 100 ul volumes to be stored at -20°C.
(iv) Lymphocyte separation medium (density = 1.077 
g.ml-1; 500ml bottle) (Flow Labs., England).
(v) Phosphate Buffered Saline (PBS) (Dulbecco 'A') pH
7.3, was obtained as tablets (Oxoid Ltd., England). Each 
tablet was dissolved in 1 0 0 mis of d.d. water and
sterilized by autoclaving. The sterile PBS was stored at 
4°C.
(vi) Methyl [3 H]- Thymidine (925 G.Bq m mol-1; 37M.Bq,l 
M.Ci) (from Amersham, UK). IMei ml"1, was diluted 1:100 
with RPMI 1640 media containing 10% human Ab serum and
additives to give a concentration of 10 uCi ml"1.
(vii) LKB Optiphase 'Safe' (FSA Laboratory Supplies, 
Loughbrough, Leics, England).
(viii) PBS-Azide (PBSA), PBS with 0.2 % sodium azide.
(ix) 5 x 10" 2 M Tris buffer pH 9.5 (Sigma Chem., Ltd., 
England) was made up in d.d. water and sterilized by 
autoclaving.
(x) 40 % Formaldehyde.
(xi) White Cell Staining Fluid : 3 % Acetic acid and 0.1 
% Methylene Blue made up in d.d. water.
(xii) Mounting Fluid (DABCO) for Fluorescence microscopy 
was made up of the following : 90 mis of Glycerol, 10 mis of
PBS (150mM Sodium Chloride; 150mM Sodium Phosphate, pH 7.2) and 
DABCO (1,4-Diazabicyclo-[2,2,2,] octane; Triethylene diamine) from 
Sigma Chem. Co., Dorset, U.K.
(xiii) Fluorescein conjugated anti-immunoglobulin (Rabbit 
anti-mouse/FITC) (Nordic Immunological laboratories, 
Madienhead, Berkshire) - the content of the tube was 
reconstituted wit)v*2 mis of cold sterile water, spun down 
to remove insoluble particles and divided into 100 ul 
aliquotes and stored in the dark at -20°C.
(xiv) Affinity purified
Sheep anti-Mouse IgG (5 mg) (Nordic Immunological 
laboratories, Madienhead,. Berkshire).
(xv) Monoclonal antibodies (raised in mice) : 0KT4 and 
0KT8 supernatants were kindly donated by Dr. K. Moore 
and Mr. A.M. Nesbitt of TENOVUS Laboratories, 
Southampton General Hospital, Southampton.
(xvi) Sterile 96-well, polystyrene round-bottomed 
microtiter plates (Corning Glass Works, Corning, N.Y. 
14831).
(xvii) Individually packed 0.2 urn Nitrocellulose filters 
(from Milipore) were used to sterilize solutions which 
could not be autoclaved.
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(xviii) Siliconized pasteur pipettes : pasteur pipettes 
were coated by twice drawing up dimethylsilane solution 
(BDH Chemicals., UK) into them. The pipettes were allowed 
to air dry and then immersed in a large volume of freshly 
collected distilled water for a minimum of 30 minutes. 
The siliconized pipettes were dried in a warm air oven, 
sealed in autoclave bags and sterilized by autoclaving.
(xix) ILAC0N Titer-tek cell Harvester and filter paper 
(Flow Labs., Skatron, Lier, Norway).
(xx) 100 x 15 mm polystyrene bacteriological petri dishes 
(Sterilin, Feltham, England).
(xxi) 25 ml Universals and 10 ml conical tubes (Sterilin, 
Feltham, England.
(xxii) Microscope slide and coverslip.
(xxiii) Improved Neubauer Hemocytometer.
(xxiv) Beckman TJ- 6  centrifuge.
(xxv) Fluorescent Microscope.
(xxvi) Phase-Contrast Microscope.
(xxvii) Class 2 Flow cabinet (Flow Labs., England).
(xxviii) CO2 Humid Incubator.




2.3.1. Separation of Peripheral Blood Mononuclear Cells
(Boyum, 1968)
Blood samples from diabetic patients were taken 1 to 3 
hours after their first insulin dose of the day. 
Peripheral blood mononuclear cells (PBMC) were isolated 
from heparinized blood by the Ficoll-Hypaque gradient 
separation technique using modification of Boyum's 
gradient centrifugation method (Boyum, 1968).
A 1:1 mixture of blood and PBS was layered over 5 mis of 
lymphocyte separation medium (specific density of 1.077 
g.ml-1) and centrifuged at 400 x g for 30 minutes in a
Beckman TJ - 6  centrifuge. Cells at the interface were
harvested and washed three times with PBS containing 5 % 
AB serum before being suspended at a density of 10s cells 
ml- 1  in RPMI 1640 medium containing 10 % Human AB serum 
and additives.
The cells were checked for viability using trypn blue 
stain and examined under phase contrast microscope. For 
all suspensions viability was found to be > 95 per cent.
From 20 mis of blood, between 1.55 x 107 and 3.65 x 107
cells were obtained, depending upon the individual 
subject.
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2.3.2. "Pannina^-EractiQriatiQn of T-Cell Subpopulatlon
(Wysocki & Sato, 1978; Moore & Nesbitt, 1986)
Antibody molecules adsorb on to polystyrene surfaces and 
bind antigen (Catt & Tregear, 1967). Therefore, it is 
possible to coat polystyrene dishes with antibody 
specific for cell surface antigens and permit cells to 
bind to such dishes. The fractionated cells are 
recovered in high yield with low levels of contamination 
by other cell types. The recovered cells retain 
immunogenic functions (Wysocki & Neverley, 1978).
T-cell3 defined by anti-leu2 and 0KT8 antibodies mediate 
most cytotoxic and suppressor functions. T-cells defined 
by anti-leu 3 and 0KT4 antibodies mediate most 
helper/inducer functions (Damle et. al., 1983). On the 
basis of this phenotypic classification 0KT8 monoclonal 
antibody was used to "pann-out" CD8
(suppressor/cytotoxic) cells in order to investigate 
insulin specific suppressor cell activity in an in vitro 
cellular proliferation assay.
2.3.2.(a) Direct "Panning"
2 ml of 0KT8 supernatant was diluted with 3 mis of 50mM 
Tris buffer (pH 9.5) and poured into each polystyrene 
petri dish. Following 90 minutes incubation at room
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temperature, with occasional swirling, the
buffer-antibody solution was decanted and the petri dish 
was washed four times with PBS containing 1 % Human AB 
serum. The AB serum blocks any remaining binding 
sites on the plate.
1-2 x lO7 peripheral blood mononuclear cells were 
resuspended in 5 mis of PBS containing 5% Human AB serum 
and gently poured into each antibody coated petri dish. 
The plates were incubated on a level surface at 4°C for 
70 minutes, with gentle swirling every 10-15 minutes. 
Following incubation, the non-adherent cells were 
transferred to a second antibody-coated petri dish for a 
further 70 minutes incubation period.
The adherent cells remaining on the first petri dish were 
gently washed four times to remove any non-adherent 
cells. Cells bound to the petri dish were recovered by 
vigorous pipetting and washing with PBS containing 5 % AB 
serum.
The above procedure was repeated with the second petri 
dish and the adherent cells were pooled. The 
non-adherent cells were also pooled into a separate tube. 
This 'double panning' technique gave rise to two cell 




Polystyrene petri dishes were coated by adding affinity 
purified sheep anti-mouse IgG (25 ug per plate) in 5 mis 
of 0.05 M Tris buffer (pH 9.5) and incubated at room 
temperature for 90 minutes. Following incubation the 
plates were washed 3 times with PBS (containing 1 %
serum) to remove excess antibody and incubated with PBS 
containing 1 % AB serum for 15 minutes at room
temperature. The plates were washed twice and stored at 
-20°C to be used for upto 3 months or at 4°C overnight 
(0 /N).
Peripheral blood mononuclear cells (1 x 107) were 
incubated with 500 ul of 0KT8 culture supernatant at 
4°C for 30 minutes. The cells were washed twice with 
PBS-5 % AB serum. The cells were resuspended in 5 mis of 
PBS-5 % AB serum and added to the sheep anti-mouse IgG 
coated petri dish.
After 60 minutes at room temperature (with gentle 
swirling every 10-15 minutes) the non-adherent cells, 
depleted of CD8 + cells, were harvested. The petri dishes 
were gently washed four times with PBS-1 % AB serum and 




Indirect immunofluorescence was used to assess the purity 
of the separated cell populations. 1 x 1 0 s cells were 
coated with the primary unlabelled monoclonal antibody by 
incubating the cells with 50 ul of 0KT8 or 0KT4 
supernants at 4°C for 15 minutes. This was followed by 
four washes with cold PBS containing 0.2% sodium azide 
(PBSA, the azide prevents capping). The cells were 
resuspended in 1 0 0 ul of 1 in 2 0 diluted rabbit 
anti-mouse IgG/FITC (Nordic, The Netherlands) and 
incubated at 4°C for 15 minutes. Excess fluorescein 
conjugated anti-mouse IgG was removed by four more washes 
with PBSA. The final wash was followed by resuspension 
of the cells with 20 ul of PBSA, 5 ul of which was 
mounted on to microscope slides. The cells were fixed 
and dried: the slides were placed into a sealed container 
with 40 % formaldehyde for 15 minutes and allowed to dry 
0/N at 4°C in a damp atmosphere. The cells were finally 
covered with a drop of DABCO-permanent mounting fluid, 
covered with a cover slip and sealed with nail polish.
The cells were examined using a fluorescence microscope 
under x20 and xlOO objectives. The results in Table 2.3. 
gives the mean percentage of positively labeled cells + 
standard deviation of 153 observations. Contaminating 






Label Unfractionated 0KT8 -ve 0KT8 +ve
0KT4 56.0% + 7 62.7% -i- 5 3.0% + 2
0KT8 27.4% + 8 2.3% + 4 74.1% + 4
Total 83.4% 65% 77.1%
Contaminating
cells 16.6% 35% 22.9%
In order to validate the "panning” technique Flow
Cytofluorography was employed using a Coulter EPICS 
Profile Analyzer, with kind permission of Mr. C. Axton 
of Lilly Research Centre Ltd. The Coulter EPICS profile 
analyzer is an optical/electronic device that measure 
cell size and detects the presence of cell-bound
fluorochrome-labeled antibodies.
Figure 2.1. shows three such cytofluorographs:
FS refers to 'Forward Scatter' signal. It is a measure
of cell size. As dead cells give rise to a smaller 
forward scatter signal than live cells, this parameter is 
particularly useful in discriminating between viable and 
non-viable cells. It is also able to distinguish between 
nucleated cells and mammalian erythrocytes.
LSS gives the 90° Light Scatter (or Side Scatter) value. 
It is a measure of the heterogeneity of cell structure. 
Thus cells with large numbers of cytoplasmic granules or 
other organelles scatter more light than erythrocytes or
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lymphocytes. Simultaneous measurement of FS and LSS 
allows identification of lymphocytes, monocytes and 
granulocytes in peripheral blood.
Figure 2.1.(a) shows the *X-Y' dot display of scatter 
signals generated by Peripheral Blood Mononuclear Cells 
(PBMC) separated using the protocol outlined in section
2.3.1. 80.9% of the PBMC was found to be Lymphocytes 
(Square 1 ), and 6 % was found to be granulocytes and 
monocytes (Square 2).
Figure 2.1.(b) : 100 ul of 1 xlO6 unfractionated cells 
was labeled with 10 ul of T4-Phycoerythrine (LFL2) and 10 
ul of T8 -Fluorescein isothiocyanate (LFL1). Following 15 
minutes incubation the cells were analysed on the Coulter 
EPICS profile analyzer. The results show that 40.9% of 
the unfractionated cells are T4 positive (LFL2) and 19.3% 
are T8 positive (LFL1).
Figure 2.2.. : gives the cytometric profile of 0KT8-ve
cell population (prepared by "panning” - see section
2.3.2. (a)). The cells were labeled with T4-Phycoerythrine 
(LFL2) and T8 -FITC (LFL1). The results show that 41.7% 
of the cells are T4 positive and only 1.7% are T8  
positive. This indicates that the 0KT8-ve cell 
population contains few contaminating T8 +ve cells, 
although there appears to be other contaminating cells 
which are not lymphocytes. Since, the aim of the 
"panning” technique is to deplete the 0KT8-ve cell 
population of T8 ^v* (suppressor/cytotoxic) cells only,
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Figure 2.1.(a).
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the contaminating granulocytes, monocytes and 
B-lymphocytes should not affect the objective of the 
proliferation assay. ie. that of measuring suppressor 
cell activity.
2.3.4. Insulin Specific Lymphocyte Proliferation Assay
1 x 10B Peripheral blood mononuclear cells suspended in 
RPMI 1640 medium supplemented with 10 % AB serum and
additives, were cultured in 2 0 0  ul volume, either in the
absence of insulin or in the presence of 1 0 and 1 0 0 ug
ml- 1  human, pork and beef insulins. The assay was
performed in triplicate cultures in a 96-well
round-bottomed microtiter plate. After 7 days of
incubation at 37°C, 5 % CQz humid atmosphere, the cells 
were pulsed with 0.25 uCi well" 1 3 H-Thymidine (3H-TdR) 
(specific activity of > 25 Ci mMol"1) and incubated for a 
further 24 hours before harvesting (section 3.3.5).
Non-specific lymphocyte transformation was measured using 
the mitogen, PHA at a concentration of 1 ug ml-1. The
cells were culture in RPMI 1640 medium supplemented with 
10 % AB serum and additives. 3H-TdR was added on day two
and the cells harvested on day three.
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2.3.5. Cell Harvesting and Scintillation Counting
Cells were washed from the 96-well microtiter plate, 12 
wells at a time, and deposited on to the filter discs 
(Titer-tek filter paper) of a memi-automatic Ilacon 
harvester. The cells were washed with water for 10 
seconds followed by 5 % Trichloacetic acid (TCA) for 30 
seconds and methanol for 20 seconds. The filter discs 
were dried overnight at room temperature and placed in 
plastic insert tubes.
The filter discs were laied flat at the bottom of each 
insert, and 4 mis of scintillation fluid (Optiphase 
'Safe', LKB) was added. The incorporation of 3 H-TdR into 
DNA was determined using a LKB Wallac 1215 Rackbeta 
Liquid Scintillation Counter.
Optimum culture conditions and kinetics of lymphocyte 
proliferation responses to insulin.
In order to optimize the in vitro lymphocyte responses to 
insulin, multiple culture parameters were examined by 
using PBMC from two insulin dependent diabetic patients 
and a non-diabetic control subject. These parameters 
included serum source, antigen concentration and 
kinetics. The resulting protocol which outlines the 
optimum culture conditions is described in section 2.3.4.
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Figure 2.3.
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Kinetics Of PBMC Proliferation In Response To Insulin
0KT8-ve and unfractionated peripheral blood mononuclear 
cells (1 x 10® well-1) from one insulin-dependent 
diabetic subject (*A) and from two non-diabetic control 
subjects (*B + *C) were cultured without insulin and with 
50 ug ml-1 human insulin on day 0. 0.25 uCi well-1
3H-TdR was added for the last 24 hours of culture. The 
effects of mitogen, Phytohemagglutinin-P (PHA), was also 
investigated by culturing the cells in 1 ug ml-1 PHA.
The results are expressed as mean (+ Standard Error (SE)) 
3H-TdR uptake of triplicate cultures, and illustrated in 
Figure 2.3.
Figure 2.3. indicates that optimum cellular
proliferation occurs between days 8 and 9. For this 
reason and because of convenience cells were cultured 
for 8 days.
Dose Response Of Peripheral Blood Mononuclear Cells To 
Human, Pork And Beef Insulins
Figures 2.4.(a), (b) and (c) illustrates the PBMC dose 
response curves to human, pork and beef insulins 
respectively. Peripheral blood mononuclear cells (PBMC) 
were cultured with varying concentrations of human, pork 
and beef insulins for 8 days at 37°C in 5 % CO2 , humid
atmosphere. The cells were pulsed with 3H-TdR for 24 
hours prior to harvesting. 3H-TdR uptake was determined
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by the standard liquid scintillation method. The results 
are expressed as C.P.M. ± Standard Error (SE).
Figure 2.4. shows a peak response to human and beef 
insulins at 10 ug ml-1 a similar peak is obtained between 
80 to 160 ug ml-1 with all three types of insulin. Thus 
the cells were cultured at 10 and lOOug ml”1 insulin (see 
section 2.3.4.).
Foetal Calf Serum (FCS) versus Human AB Serum
0KT8-ve and Unfractionated PBM cells were cultured in 
RPMI 1640 medium supplemented with Foetal Calf Serum 
(FCS) or Human AB Serum. All other conditions of the 
assay were as described in the standard protocol (see 
section 2.3.4.). The effects of FCS and human AB serum 
is summerised in Table 2.4.
Table 2.4. shows that a high background reading is 
obtained with FCS. This has been reported by other 
workers (Nell et. al., 1983). Human AB serum, in 
comparison, gives low background readings, and seems to 
support response to insulin more efficiently. The use of 
FCS in culture medium was terminated and human AB serum, 
which was tested for anti-insulin antibodies and found to 
be negative (< 7.25 ug ml-1), was used instead.
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Table 2.4.
Effects of FCS 
(SI) values:










*A 0 1957+213 1 1507+215 1
1 0 % P10 1851+458 0.95 545+72 0.36
FCS P100 767+181 0.39 909+101 0.60
BIO 1195+303 0.61 290+71 0.19
B100 551+202 0.28 360+1 0.24
1 0 % 0 862+141 1 522+59 1
AB P10 2055+225 2.38 426+56 0.82
Serum P100 1121+239 1.30 1139+380 2.18
BIO 1892+280 2.19 705+365 1.35
B100 1472+302 1.71 820+32 1.57
*B 0 2112+618 1 1497+260 1
1 0 % P10 2213+434 1.05 1161+89 0.78
FCS P100 763+265 0.36 479+129 0.32
BIO 1870+249 0.89 1123+230 0.75
B100 1195+196 0.57 980+76 0.65
1 0 % 0 579+81 1 1096+251 1
AB P10 1505+221 2.60 1331+154 1 . 2 1
Serum P100 1234+324 2.13 1240+117 1.13
BIO 1600+123 2.76 1893+154 1.73
B100 821+150 1.42 1152+96 1.05
*A and *B are diabetic patients. Results are expressed 
in Counts Per Minute (C.P.M.) + Standard Deviation.
SI=Stimulation Index. Insulin concentration=10 and 100 
ug ml-1 P=pork and B=beef insulins.
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Figure 2.4.
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"Edge Effect" of Microtiter Plates.
Depending upon the type and make of a microtiter plate, 
there is often a variation in readings obtained in the 
outer wells compared to those of the central wells. This 
is commonly referred to as the "edge effect" of 
microtiter plates. It is therefore, necessary to 
eliminate such variation. The edge effect of Corning 
polystyrene microtiter plate (Corning Glassworks, 
Corning, NY) was thus investigated :
5 x 10° cells, in 200ul of RPMI 1640 medium supplemented 
with 10 % AB serum and additives, were placed into each
well of a 96-well round-bottomed microtiter plate.
Following 7 days incubation at 37°C, 5 % CO2 in humid
atmosphere, the cells were pulsed with 3 H-TdR for a 
further 24 hour period.
The cells were harvested on the the 8 *^* day using a 
semi-automated cell harvester and 3H-TdR incorporation 
counted using the standard scintillation procedure 
(section 2.3.5.). This experiment was carried out with 4 
different plates. Table 2.5.(a), shows the result of one 
such plate. All plates gave similar results.
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Table 2.5.(a)
"Edge effect" of microtiter plate:
No.of Mean Standard % Coeff.
wells CPM Error (SE) of
variation
Consecutive circle A 36 29590 1179 4.0 %
of wells, starting B 28 26760 980 3.7 %
from outer circle C 2 0 28577 1238 4.3 %
(A) to the central D 1 2 25647 895 3.5 %
circle (D) of the 
plate.
Mean CPM of all 4 circles + Standard Deviation (SD) - 27644
+ 1773.
Analysis of Variance was carried out to determine whether 
a significant "edge effect" existed. This is shown in 
Table 2.5.(b).
Null hypothesis : "The population means xA, xB, xC and xD 
are different from each other and therefore it follows 
that there is an "edge effect" of signals produced when 
Corning microtiter plates are used".
Table 2.5.(b).
Analysis of Variance in readings obtained with 















Total 95 3.37x10® _
Between Groups 3 2.07x10s 6 .8 8 xl0 7 2 . 0 0 2
Within Groups 92 3.16x10® 3.44xl07
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Since, Fcalculatdd valus( 2 .0 0 2 ) < Ftabla(2.72) at P-0.05, 
the null hypothesis was rejected, i.e. the difference 
between the means of the four groups, A,B,C and D was not 
significant (P=0.05). Therefore, the Corning polystyrene 
microtiter plate did not display any 'edge effect" and 
any variation in signal obtained in future experiments 
could not be attributed to the physical make-up of the 
microtiter plate.
Inter- and Intra- Assay analysis
The reproducibility of the insulin specific proliferation 
assay was determined by taking blood samples from two 
diabetics (*A & *B) and one control subject (*C) on 4
consecutive months. Unfractionated peripheral blood 
mononuclear cells were cultured with 1 0 and 1 0 0 ug ml- 1  
human insulin. Results are tabulated in Table 2.6.(a). 
The coefficient of variation between samples were less 
than 1 1 % for most cultures indicating that the assay was 
very reproducible.
The Intra-assay variability was also assessed using the 
optimal conditions described in section 2.3.4. For each 
insulin concentration, cells from a diabetic patient 
(*A), was cultured in 6 replicate wells on the same 
plate, (see Table 2.6.(b). The coefficeient of variation 
for intra-assay was less than 15%.
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Table 2.6.(a).









1 2 . 2 1 2. 15 2.17 2.49 1.06 1.53
2 1.78 2.39 2.70 2.35 1.25 1.32
3 1.81 2.83 2.63 3.20 1.31 1.49
4 2.07 1.65 2 . 6 6 3.08 1.17 1.57
Coeff. of
Variation 1 0 .6 % 2 !. 8 % 9.8% 3.5.2% .9-9% 7.4%
Cells cultured in presence of 10 and 100 ug.ml*1 H=human
insulin. Please note: subjects *A, *B and *C are not the












0 P10 B10 H10
1 2176 4495 3106 3503 2337 4632 3872 3845
2 2303 5250 3407 3788 1722 3666 4420 4084
3 1987 4268 3874 4561 1900 3171 3844 4690
4 1999 4825 4136 4492 2 0 0 2 4164 2988 4688
5 1045 3911 3033 4388 1926 3659 3306 4335
6 2178 5436 3655 4385 1883 - 3565 3676
*C.V. 8 % 12.5% 12.3% 10.4% 10.5% 14.4% 13.6% 1 0%
Cells were cultured in the presense of 10ug.ml~1 P10=pork 
insulin; B10=beef insulin; H10=human insulin, or 0=no 
insulin. *C.V. - Coefficient of Variance.
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2.4. RESULTS
The cellular immune response to insulin was determined 
using an insulin stimulated lymphocyte transformation 
assay. It is presumed that the assay measured primary 
immune response to insulin in normal non-diabetic control 
subjects and secondary responses in the IDDM patients.
The results are expressed as Stimulation Indices (SI) 
which were calculated using the following equation:
3H-TdR incorporation (Mean CPM) 
of triplicate culture with Insulin 
Si = --------------------------------------------------------
Mean CPM of triplicate culture without Insulin
The data were analysed using a general purpose statistical 
package - 'INSTAT' (Ref. Burn R.W., et. al., 1987). The 
statistical significance in difference of unpaired data 
were analysed using Students t-test or Mann-Whitney U test 
depending upon the distribution of the data. Normal 
distribution of data were assessed by plotting histograms. 
One of the pre-requisites of a t-test is that the F-ratio 
must not be significant, ie, the standard deviation of the 
two groups of data being compared should not be 
significantly different. Thus where the F-ratio was 
significant and/or the data did not give a 'normal' or 
'normalizable' distribution, non-parametric tests were 
used; independent and paired data were analysed using 
Mann-Whitney U and two-sample Wilcoxon tests respectively.
2.4.1. Patients on Human Insulin Therapy
Table 2.7 shows the in vitro insulin induced proliferative 
response (stimulation index (SI)) by non-diabetic control 
subjects. In table 2.8., the SI values for individual 
Group I diabetic patients are tabulated. In Table 2.9., 
SI values of Group I patients and control subjects are 
compared. The results show that, in the presence of beef 
(BI) and pork (PI) insulins, there is significant 
difference in SI of diabetic patients and controls. 
However, when the cells were cultured in the presence of 
autologous insulin (human insulin-HI) the difference in 
response between the two groups was not significant.
When 0KT8 +ve cells were removed from the peripheral blood
monuclear cells to give a 0KT8-ve cell population and 
cultured in the presence of HI, PI and BI, the SI of




Insulin induced proliferative response (Stimulation Index) in
non-diabetic control subjects:
Pa tient Type & Concentration Of Insulin (in culture)
Number H10 HI 00 P10 P100 BIO B100
1 0.64 0.96 2.07 1.04 1.40 0. 71
2 0.59 0.47 0.40 0.45 0.53 0.35
3 0.48 1.52 1.84 0. 70 1.05 0. 71
4 0.66 0.47 0. 70 0. 41 0.64 0.53
5 0.93 2.02 0.62 0. 73 1.07 1.86
6 0. 70 1.01 0.92 0.82 0.58 0. 75
7 0. 64 2.19 0. 75 1.13 0.90 0. 73
8 0.93 1.31 0. 79 0. 77 0.67 0. 72
9 1.28 1.10 1.23 0.99 0.85 0.90
10 0.55 1.18 0.65 0.83 0. 73 0. 77
11 2.31 1.76 2.37 1.16 2.52 0.95
12 0.61 0.53 0.65 0. 79 0.91 0.88
13 1.43 1.20 0.54 3.02 0.84 2.69
14 1.31 0.53 0.48 0.88 1.26 1.06
15 0. 72 0.46 0.65 0.86 0.53 0.68
16 0. 69 0.88 1.00 0.43 0.45 0.67
17 0.65 0.57 0.41 0.67 0.87 1.12
18 0.84 0.59 0.50 0.45 0.47 0.55
19 1.37 0. 79 0.59 0. 72 0.89 0.82
20 1.19 0.95 1.56 1.12 0. 79 2.10
21 0.48 0.80 0.55 0.97 0.45 0.82
22 2.17 2.29 1.00 0.64 0.90 2.40
N 22 22 22 22 22 22
mean 0.96 1.07 0.92 0.89 0.88 1.04
SD 0.51 0.57 0.56 0.53 0.45 0.63
*PR >1.98 >2.21 >2.03 >1.94 >1.77 >2.30
median 0. 71 0.95 0.68 0.81 0.85 0.80
Cells were cultured in the presence of: H=human insulin; 
P=pork insulin; B=beef insulin at 10 and 100 ug.ml-1. 
N=number of patients. ND=not determined. SD=standard 
deviation. *PR=positive response = > mean + 2SD
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Table 2.8.
Insulin induced proliferative response (Stimulation Index) in
Group I diabetic patients:
Patient Type & Concentration Of Insulin (in culture)
Number H10 HI 00 P10 P100 BIO B100
1 ND ND 1.04 0. 76 0.88 1.02
2 ND ND 1.13 1.21 1.05 1.18
3 ND ND 2.44 2.55 0. 62 0. 76
4 ND ND 1.61 1.26 1.49 1.89
5 ND ND 0.94 0.82 1.09 1.04
6 ND ND 0.82 2.18 1.35 1.31
7 ND ND 1.18 1.28 1.34 1.59
8 ND ND 1.11 0.85 0.95 0.96
9 ND ND 1.15 2.79 0.69 0.91
10 ND ND 1.81 2.83 1.65 1.96
11 ND ND 1.66 2.47 1.79 2.12
12 ND ND 0. 75 0.97 0.49 1.17
13 ND ND 1.30 1.34 1.13 1.28
14 ND ND 0.96 0. 72 7.26 1.31
15 ND ND 1.43 0.99 1.27 0.48
16 ND ND 1.96 1.66 1.45 1.74
17 ND ND 1.24 1.97 0.67 1.55
18 ND ND 1.77 1.73 1.12 1.47
19 ND ND 0.67 1.01 1.33 1.25
20 ND ND 1.25 2.29 2.51 1.65
21 ND ND 0.84 0.56 0.51 0.48
22 1.33 1. 66 0.65 1.22 1.37 1.49
23 0. 74 0.56 0. 77 0.80 1.00 0.88
24 1.32 ND 0.48 0.54 0.42 0.47
25 2.00 0.43 1.61 1.27 1.82 2.13
26 0.43 0.47 0.61 0.61 0.43 0.40
27 0.81 0.84 0.49 0.50 0.61 0.55
28 0.54 0.55 0.45 0.46 0.47 0.57
29 2. 70 2.02 0.58 0.48 1.41 0.90
30 0.66 0. 65 0. 76 0. 43 0. 75 0. 76
31 1.08 0.82 1.64 0.84 1.32 1.17
32 1.96 2.38 1.82 1.69 1.39 1.68
33 2.21 2.15 1.93 1.47 2.25 1.96
34 1.58 2. 79 2.49 4.24 2.21 4.36
35 4. 73 2.45 3.58 3. 60 1.65 2.18
36 0.81 0.94 0. 77 0.93 0. 74 1.12
37 1.49 3.52 2.02 1.65 8. 76 3.28
38 2.17 2.22 1.00 0. 64 0.90 3.40
39 1.10 1.62 1.94 1.80 1.44 1.73
40 ND 0.93 ND 1.50 ND 1.23
41 ND 0.57 ND 0.50 ND 0.49
42 ND 0.47 ND 0.54 ND 0.66
43 1.68 1.79 0.92 1.05 3. 74 1.95
44 0.54 0.63 0.94 1.05 1.01 0.64
45 0.51 0.98 0.90 2.86 1.13 2. 77




Patient Type & Concentration Of Insulin (in culturej
Number H10 HI 00 P10 P100 BIO B100
47 1.65 1.10 1.59 1.91 1.30 1.15
48 1.00 0. 72 0.96 0. 74 l.odf 1.25
49 1.04 2.91 1.25 2. 75 1.02 2.85
50 0.92 ND 0.66 0.41 0.41 ND
51 2.14 2. 35 2.01 1. 71 0.95 3.29
52 1.20 1.51 0.90 ND 2.11 ND
53 0.80 1.29 1.09 1.27 2.20 0.40
54 0.84 0. 79 1.09 0. 73 0.99 0.97
55 0.40 1.02 0. 76 1.02 0.47 0.68
56 0.48 0.89 1.18 3.08 0. 76 1.93
57 1.07 1.67 1.07 1.76 1.04 1.75
58 0.86 0.85 0.80 3.14 1.11 3.37
59 0.53 ND 0.57 0.88 0.54 0.55
60 1.90 0.94 1.97 1.19 1.63 0. 76
61 0.89 0. 71 2.00 1.29 0. 77 0.99
62 0. 78 0.67 0.59 1.35 0.82 1.36
63 1.15 1.84 ND ND 1.37 1.65
N 39 39 59 61 60 61
mean 1.26 1.35 1.23 1.42 1.41 1.47
SD 0.81 0.80 0.61 0.87 1.38 0.87
median 1.04 0.98 1.09 1.22 1.10 1.25
Cells were cultured in the presence of: H=human insulin; 
P=pork insulin; B=beef insulin at 10 and 100 ug.ml-1. 




Comparison of cellular immune response to insulin by 
Group I diabetic patients and control subjects:
Insulin-specific SI of unfractionated cells.
Insulin Type 
H10 H100
& Concentration in vitro 














































































Cells were cultured in the presence of 10 
ug.ml-1 of: H=human insulin; P=pork insulin 
N=Number of observations. SD=standard 





Comparison of cellular immune response to 
Group I diabetic patients and control 
Insulin-specific SI of 0KT8 -ve Cell population.
insulin by 
subjects:
Insulin Type & Concentration in vitro 














































































Cells were cultured in the presence of 10 and 100 
ug.ml-1 of: H=human insulin; P=pork insulin; B=beef
insulin. N=number of observations. SD=standard deviation. 
z=standard normal deviate. NS=not significant.
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Using an indirect method, insulin specific suppressor cell 
activity was measured. It is assumed that 0KT8 +ve cells 
carry out most suppressor/cytotoxic functions, thus 
removal of these cells remove suppressor cell activity. 
The percentage (%) suppression was measured using the 
following equation.
Response (SI) of Unfractionated cells
% Supp.= 100  --------------------------------------- x 100
Response (SI) of 0KT8 -ve cells
The formula makes the following assumptions:
1. A decrease in response by unfractionated cells 
compared to that of the 0KT8 -ve cell population is due to 
the presence of suppressor (0KT8 +ve) cells and their 
activity.
2 . % suppression may be positive or negative depending
upon the ratio of help and suppression which is thought to 
be carried out by CD4'*' and CD8 -*- (0KT8-*") cells
respectively.
In Table 2.11., the insulin specific % suppression 
obtained with cells from Group I diabetic patients are 
tabulated. In Table 2.12., these results are compared 
with that obtained with cells from control subjects.
Table 2.12. shows that the insulin-specific suppressor 
cell activity of diabetic patients and control subjects 
did not differ significantly.
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Table 2.11.







Insulin (in culture) 
PI 00 BIO B100
1 ND ND -40.54 -72. 73 -120.0 -61.91
2 ND ND 46.95 53.46 26.06 57.25
3 ND ND -106.8 -119.8 19.48 -8.571
4 ND ND -30.89 -44.83 -41.91 -85.29
5 ND ND -113.6 -64.00 -55. 71 -62.50
6 ND ND 36.92 8.403 21.97 5. 755
7 ND ND 12.59 44.83 -10. 74 7.558
8 ND ND -68.18 -11.84 -7.955 -41.18
9 ND ND 28.57 -57.63 71.25 -2.247
10 ND ND -43.65 -116.0 -18.71 5.314
11 ND ND -43.10 -56.33 2.186 23. 74
12 ND ND -33.93 11.82 10.91 -7.339
13 ND ND -51.16 -127.1 -16.50 -82.86
14 ND ND 30.94 59.32 11.46 36.10
15 ND ND 11. 73 -8. 791 -23.30 50.00
16 ND ND 6.220 -0.606 -29.46 -83.16
17 ND ND -18.10 -38. 73 2.899 1.274
18 ND ND -58.04 -18.49 4.274 -58.07
19 ND ND -81.08 -42.25 -177.1 -140.4
20 ND ND -2.459 -10.10 -258. 6 26.34
21 ND ND 0.000 9.677 28.17 46.67
22 37.26 37.12 74.81 59. 74 29.38 46.21
23 71.43 52.94 -2.667 23.81 55.95 34.33
24 96.82 ND 93.24 93.84 94.27 68.46
25 37.30 62.28 -292. 7 -273. 5 -313. 6 -232.8
26 48.19 62.10 12.86 8.955 32.81 58. 76
27 -52.83 -90.91 -2.083 3.846 7.576 -77. 42
28 22.86 24.66 28.57 8.000 17.54 -62.86
29 -315.4 -281.1 -28.89 -23.08 -95.83 -95.65
30 7.042 45.38 -105.4 -26.47 18.49 30.91
31 6.897 18.81 -67. 35 40.43 -18.92 30.36
32 7. 547 11.85 -41.09 21.03 -21.93 37. 08
33 -45.40 10.04 -50. 78 -26. 72 -82.93 -27.27
34 56.59 -4.494 32.88 -38.11 -13.92 -7.13
35 -729.8 -400.0 -616.0 -471.4 -189.5 -581.3
36 14. 74 -36.23 3. 750 -34. 78 21.28 4.274
37 3.247 -114.6 -29.49 -24.06 -187.2 -54. 72
38 13.89 9.016 25.93 46.22 47.98 28. 72
39 -23.60 -80.00 -139.5 -119.5 -89.47 -84.04
40 ND -30.99 ND -240.9 ND -68.49
41 ND 34.48 ND 19.36 ND 5. 769
42 ND 66.43 ND 61.97 ND 48.03
43 -11.26 -16.23 19.30 -52.17 -605. 7 23.83
44 83.13 77.26 74.53 75.97 71.94 80.55
45 73.98 48.96 74. 72 66.19 63. 78 -264.5




Patient Type & Concentration Of Insulin (in culture)
Number H10 HI 00 P10 PI 00 BIO B100
47 -150.0 -80.33 -96.30 -73.64 -154.9 -98.28
48 -66.67 54.14 -41.18 -15.63 -43.06 -6.838
49 0.952 -28.19 -8.696 -32.21 58.20 -42.50
50 63. 78 ND 76.34 39. 71 66.12 ND
51 -23. 70 12.31 18.95 23.66 12.84 -51.61
52 19.46 -75.58 13.46 ND -70.16 ND
53 59.39 64.46 65. 72 5.93 -5. 769 77.65
54 16.83 57.53 41.40 68.26 46. 77 59.41
55 40.30 -37.84 5.000 45.16 24.19 32. 67
56 33.33 4.301 51.04 23.00 49.33 38.92
57 -8.081 45.78 -25.88 17.37 19.38 -13.64
58 8.511 44.81 50.00 67.86 10.48 63.57
59 17.19 ND -42.50 -3.529 -22. 73 77.99
60 19.49 -100.0 -42. 75 56.25 -18.98 41.54
61 -7.229 57.23 -56.25 -10.26 39.37 6.604
62 58.29 -17.54 -37.21 -58.82 -26.15 -27.10
63 -13.86 -159.2 ND ND -44.21 -81.32
N 39 39 59 61 60 61
mean -14.5 -19.5 -24.7 - 2 0 -30.4 -25
SD 136.7 97.8 101 90 109.8 102
median 13.9 10 -2.7 -3.5 -1 . 8 1.3
Cells were cultured in the presence of: H=human insulin; 
P=pork insulin; B=beef insulin at 10 and 100 ug.ml”1. 




Comparison of % Suppression of non-diabetic controls and 
Group I IDDM patients.
Insulin Type & Concentration in vitro
H10 H100 P10 P100 B10 B100
CONTROLS: N 2 2 2 2 2 2 2 2 2 2 2 2
mean S. 39 -0 . 8 -14.6 -7.4 -16 0.69
SD 43.3 46.6 95.8 67.7 1 1 0 49
median 18 7.6 24 7.4 17.9 9
GROUP I N 39 39 59 61 60 61
PATIENTS: mean -14.5 -19.5 -24.7 - 2 0 -30.4 -25
SD 136.7 97.8 1 0 1 90 109.8 1 0 2
median 13.9 1 0 -2.7 -3.5 -1 . 8 1.3
Mann-Whitney U= 426 429 537 634 550 588
z= 0.05 0.33 1.19 0.39 1.15 0 . 8 6
Probability >z= NS NS NS NS NS NS
Non-parametric two-sample test for independent data 
(Mann-Whitney U test). H=human insulin; P=pork insulin; 
B=beef insulin at 10 and 100 ug.ml-1.
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2. 4.1. (a ) Insulin Stimulated Cellular Proliferative
Response Of Group I Diabetic Patients
The differential secondary immune response to different 
types and concentration of insulin in culture were 
examined. In Table 2.13. the effect of insulin 
concentration on the SI of unfractionated and 0KT8 -ve 
cells are assessed using a two-sample Wilcoxon test for 
paired data.
In most diabetic patients the SI is higher with 100 
ug.ml- 1  than with 1 0 ug.ml-1, ie. there is a dose 
response. However this dose response effect is only 
significant with beef insulin. Interestingly, the removal 
of 0KT8 +ve cells from culture gives a significant dose 
response with all three species of insulin.
Proliferative response to human, pork and beef insulins 
were compared. This is shown in Table 2.14
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Table 2.13.
Effects of insulin concentration on SI:
Insulin Unfractionated Cells 0KT8 -ve Cells
concentration H P B H P B
N 36 56 58 36 56 58
1 0 ug.ml- 1 mean 1.29 1.27 1.45 1.43 1.3 1.35
SD 0 . 8 6 0.61 1.42 0 . 8 6 0.82 1.19
1 0 0  ug.ml- 1 mean 1.44 1.5 1.53 1.64 1.72 1 . 6 6
SD 0.83 0 . 8 8 0.87 0.84 1.7 1.41
Wilcoxon T= 243 6 6 6 553 191 521 606
SD= 63.7 1 2 2 . 6 129.2 58.5 129 129
z= 1.41 1.07 2.34 2.28 2.76 2.31
Probability^ NS NS 0.01 0.023 0.006 0.02
z=standard normal deviate. NS=Not Significant. SI 
obtained with: H=human insulin; P=pork insulin; B=beef
insulin.
Table 2.14.
Difference in lymphocyte proliferative responses (SI) to 
human, pork and beef insulins. Mann-Whitney U test:














H10 U = 708 1151 1142 1009 1178
N=39 z = 0.53 0.82 0.34 1.16 0.08
H100 U = 703 952 1068 935 1141
N=39 z = 0.58 1.44 0 . 8 6 1.69* 0.35
P10 U = 1107 1108 1665 1770 1628
N=59 z = 0.31 0.31 0.71 0.27 0.90
P100 U = 1065 1155 1656 1670 1808
N=61 z = 0 . 8 8 0.24 0.73 0.83 0.27
B10 U = 1127 1127 1770 1696 1608
N=60 z = 0.31 0.31 0.03 0.70 1.15
B100 U = 1014 1108 1567 1790 1596
N=61 z = 1.24 0.58 1 . 2 2 0.36 1 . 2 2
Cells cultrured in presence of: 10 and 100 ug.ml-1
H=human, P=pork and B=beef insulins. * P<0.05
U=Mann-Whitney U value. z=standard normal deviate. Top 
right triangle refers to OKTB-ve cells; bottom left 
triangle refers to unfractionated cells.
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Table 2.15. shows that there is no detectable difference 
in the overall proliferative response with regards to 
species of insulin and/or concentration. Sequential 
comparison of individual patient's data using a two-sample 
Wilcoxon test for paired data showed that at 100 
ug.ml-1, the SI response to beef insulin was significantly 
higher than with human insulin (P<0.05). However, 
correlation coefficient determinations between human, pork 
and beef insulin-induced SI (and % Suppression) in group 
I diabetic patients showed a highly significant 
correlation between the three responses (see Table 2.15.).
Comparison of the SI of 0kT8-ve cell populations and the 




Spearman's Rank Correlation Coefficient (r®) of SI and % 
suppression between the three types of insulin.
Stimulation Index (SI)
H10 H100 P10 P100 B10 B100
H10 N= 34 34
% r= 0.54** 0.67***
s H100 N= 34 34
u r= 0.46** 0.62***
p
p P10 N= 34 55
R r= 0 .52*** 0.47**
E
S P100 N= 34 55
S r= 0.33NS 0.57***
I
0 BIO N= 34 55
N r= 0.56*** 0.53**
B100 N= 34 55
r= 0.49** 0.55***
**=P<0.01 ; ***=P<0. 001; r=Spearman's rank correlation
coefficient value. The top right triangle shows the 
correlation in SI obtained with 10 and 100 ug.ml-1 
H=human; P=pork; and B=beef insulins. The Bottom left 
triangle gives the correlation in X suppression obtained 
with the three types of insulin in culture.
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2.4.1. (b ) Relationship Between Patient's Clinical
Background and Cellular Immune Response to Insulin.
One of the main objectives of this thesis was to 
investigate whether the in vitro cellular immune response 
to the various types of insulin would have any clinical 
relevance, ie. was there a relationship between 
insulin-specific stimulation index (and % suppression) and 
the clinical background of the patients.
Patients 'age', 'duration of disease', 'duration of 
insulin therapy' and 'daily insulin dose' were all 
considered for their potential effect on the cellular 
immune response to insulin. No correlation existed 
between these factors and stimulation index using 
unfractionated cells.
There was, however, a significant correlation between 
suppressor cell activity (measured as % suppression) at 1 0  
ug.ml- 1  human insulin and patients' 'Age'. This is 
illustrated in Figure 2.5., which shows a decrease in 
suppressor cell activity with age. Spearman's rank 
correlation coefficient values for % suppression and 
clinical background are tabulated in Table 2.16.
A statistically significant correlation between patients' 
daily insulin dose and % suppression was also observed 
when the patients cells were cultured with 1 0 ug.ml- 1  
human insulin. This is illustrated in Figure 2 .6 .(a). 
Computer assisted Spearman's Rank Correlation Coefficient 
test was used to determine the significance level.
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Kendel's Rank Correlation Coefficient (Wardlaw A.C., 1985) 
was determined by hand for verification. Almost identical 
results were obtained.
This correlation was even stronger, when only patients 
with extremely high (>1.06 U/D/Kg) and low (<0.407 
U/D/Kg)) daily insulin dose requirement were used. Thus 
when data for patients with mean dose + SD (0.73 (U/D/Kg) 
+0.33) were removed prior to analysis, the following 
correlation emerged: r=0.867; N=ll; P<0.001). Figure
2 .6 .(b) illustrates the relationship between % suppression 
and patients daily insulin dose requirement.
Table 2.16.
Relationship between % suppression and patients' clinical 









N 34 34 55 55 55 55
AGE (years) -0.36 -0.08 -0.08 0. 13 -0.13 -0.17
P<0.05 NS NS NS NS NS
DURATION OF -0 . 1 2 -0.18 -0.04 0.03 0.07 -0.05
DISEASE (yrs) NS NS NS NS NS NS
DURATION OF -0 . 1 2 0.19 -0.04 0.03 0.07 -0.05
INSULIN THERAPY NS NS NS NS NS NS
DAILY INSULIN 0.387 0.292 -0 . 0 2 -0 . 0 2 0.06 0.03










* Values for patients on high (>1.06 U/D/Kg) and low 
(<0.407 U/D/Kg) insulin dose only, (U/D/Kg=units/day/Kg 
body weight). H=human insulin; P=pork insulin; B=beef
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Finally, in order to investigate the effects of cellular 
immune response (SI) and suppressor cell activity (% 
suppression) on the patients' diabetic control (measured 
in terms of percentage glycosylated heamoglobin - % HbAl), 
Group I diabetic patients were divided into two sub-groups 
on the basis of their % HbAl value. Table 2.17. shows the 
results of a two-tailed non-parametric test for 
independent data (Mann-Whitney U test).
Blood samples were taken for HbAl determination on the 
same day proliferation assays were performed. HbAl was 
measured by the column chromatographic technique of Kynoch 
and Lehmann (1977) by clinical research technicians, 
department of immunology, Royal United Hospital (R.U.H).
The mean % HbAl value for Group I patients was 11.7 %. 
Patients with % HbAl value of < 11 % are said to have good 
diabetic control and those with a % HbAl value >13 % are
said to show poor diabetic control (Dr. Reckless, 
Consultant Physician, R.U.H., Bath).
Table 2.17. shows that the SI, in the presence of all 
three types of insulins (at lOOug.ml-1), was significantly 
higher in patients with poor diabetic control than in 
patients with good diabetic control. The % suppression 




Comparison of SI of patients with good and poor diabetic 
control:
Insulin Type & Concentration in vitro
H10 H100 P10 P100 B10 B100
PATIENTS WITH N 11 12 17 19 17 18
GOOD DIABETIC mean 1.18 1.24 1.04 1.12 1.09 1.24
CONTROL SD 0.75 0.67 0.44 0.66 0.46 0.55
<11% HbAl median 0.92 0.93 0.94 0.99 1.09 1.21
PATIENTS WITH N 8 8 16 16 16 16
POOR DIABETIC mean 1.61 2.02 1.42 1.91 2.14 1.84
CONTROL SD 1.38 0.98 0.75 1.13 2.39 1.15
>13% HbAl median 1.27 2.25 1.13 1.81 1.39 1.76
Mann-Whitney U 37.5 21 87 89 102 83.5
z — 0.54 2.08 1.77 2.09 1.22 2.09
Probability (P)= NS 0.04 0.078* 0.037 NS 0.037
H=human insulin; P=pork insulin; B=beef insulin at 10 and 
100 ug.ml'1. *=not significant.
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2.4.1.(c) Results Of Individual Patients
A Positive Response was defined as one which exceeded the 
control (SI) response to insulin by more than 2 standard 
deviations. In Table 2.7. the 'positive response' values 
of each ligand and concentration are also tabulated.
In Table 2.8. the SI of individual Group I patients are 
listed. It show that approximately 40% (25 out of 63) 
diabetic patients on human insulin therapy gave positive 
proliferative response (SI) to at least one type of 
insulin. In comparison, approximately 18% (4 out of 22) 
control subjects gave a positive response.
Of the positive responders, 24% (10 out of 41) gave
positive response to human insulin, 21% (13 out of 63)
responded to pork insulin and 24% (15 out of 63) responded 
to beef insulin. In Figure 2.7., stimulation indices of 
patients giving maximum responses to human, pork and beef 
insulins are illustrated. It shows that, although the 
proportion of patients giving a positive response to all 
three types of insulin is similar, the majority (12 out of 
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2.4.1.(d) Responder Status
A positive responder (as opposed to a 'positive response') 
was defined as any individual who gave a positive response 
to at least one type of insulin. On the basis of this 
definition, group I diabetic patients were divided into 
two sub-groups: Responders and Non-responders.
Patients' 'age', 'diabetic control', 'dose', 'duration of 
insulin therapy' and 'duration of disease' were all
considered to have a potential relationship with the in 
vitro insulin specific-suppressor cell activity and
insulin stimulated lymphocyte proliferation. These
factors were considered in relationship to the level of 
stimulation and % suppression (discussed earlier see Table 
2.16.) and to the category of response and non-response, 
see Tables 2.18. and 2.19.
Although the difference in 'age', 'duration of disease', 
'duration of insulin therapy' and 'dose' was not
significant between the two groups, responders were found
to have significantly higher HbAl values than
non-responders (P<0.001). This reiterates results 
discussed previously (ie. Table 2.17. shows that
responsiveness is associated with poor diabetic control).
Group I patients were also divided into two further
sub-groups: those giving positive suppression and those
giving a negative % suppression value with human insulin 
(10 and 100ug.ml~). In Table 2.19. the clinical
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background of patients with positive and negative % 
suppression are compared.
Patients showing human insulin-specific suppressor cell 
activity were found to have a higher daily insulin dose 
requirement than those who showed no suppression (i.e. 
negative suppression).
Table 2.18.
Relationship between patients' clinical background and 
responder status:
Patients' Clinical. Background
Age DID DIT ->HI Dose HbAl
RESPONDERS: N 24 24 24 24 24 2 0
14 male; mean 37.3 14.4 13.6 1.42 0.69 1 2 . 8
10 female. SD 10.7 1 1 . 2 1 1 0.81 0.29 2.35
median 35 10.5 10.5 1 . 17 0.64 13.4
NON-RESPONDERS: N 37 37 37 37 37 30
19 male; mean 35.5 13.2 12.4 1.76 0.80 10.99
18 female. SD 9.79 8.93 8.53 1.55 0.38 . 2.05
median 35 1 2 1 1 1 . 0 1.77 11.05
Mann-Whitney U 388 432 423 444 342 144
z 0.83 0.18 0.32 0 . 0 1 1.51 3.1
P NS NS NS NS NS 0 . 0 0 2
Non-parametric test (Mann-Whitney U) testing difference in 
median of the two group=0. DID=Duration of Disease(years); 
DIT=Duration of Insulin Therapy(years); — >HI=Duration of 
Human Insulin therapy (years); HbAl=% glycosylated
haemoglobin; Dose (units/day/Kg) N=Number of patients. 




Relationship between suppressor cell activity (% 
suppression) and patients' clinical background.
Patients' Clinical Background
Age DID DIT Dose % HbAl
PATIENTS WITH N 16 16 16 16 18
+VE SUPPRESSION: mean 32 15.4 15.4 0.90 12.07
SD 1 1 1 0 1 0 0.41 2.25
median 32.5 13 13 0.70 1 2 . 2
PATIENTS WITH N 8 8 8 8 6
-VE SUPPRESSION: mean 38.5 12.9 1 1 . 8 0.42 10.63
SD 8.59 1 1 . 1 1 1 . 1 0 . 2 2.41
median 37 1 1 1 1 0.34 11.4
Mann-Whitney U 45.5 54 52 13.5 35
std. normal deviate: z 1.13 0.58 0.74 3.09 1.27
significance level: P NS NS NS 0 . 0 0 2 NS
N=number of patients. DID=duration of disease (years); 
DIT=duration of insulin therapy (years); Dose (U/Day/Kg 
body weight); X HbAl=glycosylated haemoglobin. SD=standard 
deviation.
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2.4.2. Patients Transferred From Bovine Insulin To
Human Insulin Thenanv
Group II individuals consisted of IDDM patients who were 
transferred from beef insulin to human insulin therapy. 
Blood samples were taken while the patients were being 
administered beef insulin, 3-8 months after they were 
transferred to human insulin, and 1 2 months later.
The effects of this change in therapy on insulin 
stimulated lymphocyte proliferation and suppressor cell 
activity were investigated.
2.4.2. (a) Cellular Immune Response (SI) Of Group II 
Patients And Non-diabetic Controls.
The statistics of SI values of Group II diabetic patients 
are tabulated in Table 2.20. The difference in SI of 
Group II patients are compared with those of controls.
The relatively low SI values obtained with Group II 
patients' 1st samples, are probably due to the use of 1 0 % 
Foetal Calf Serum (FCS) in the culture medium. It has 
been shown that FCS supports insulin-specific lymphocyte 
proliferation very poorly, (see 'Methods' section, Table 
2.4. "Foetal Calf Serum (FCS) versus human AB Serum"). 
FCS also gives high background readings in the absence of
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insulin, which makes it impossible to determine how much 
of the stimulation is due to FCS and how much due to 
insulin. Unfortunately, human AB serum, which was found 
to be more appropriate, was not available during analysis 
of the first samples. The second and third samples were 
analysed using 10% human AB serum in the culture media. 
Table 2.20. shows that the SI values obtained with the
diabetic patients' first samples did not differ 
significantly from that of the control subjects. The
second and third samples did however give significantly 
higher SI values than control subjects (with all three 
types of insulin).
In Table 2.21, the difference in % suppression of Group II 
patients and controls are analysed. It shows that, in the 
presence of pork and beef insulins, the % suppression of 
Group II diabetic subjects did not significantly differ
from that of control subjects. In the presence of 10 
ug.ml- 1  human insulin, however, the % suppression values 
of 2nd (P=0.05) and 3rd samples (P=0.02) did significantly 
differ from control subjects. Unfortunately, the 
suppressor cell activity of the 1 st samples were not 
determined because human insulin was not available at the 
time of blood sampling.
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Table 2.20.
Statistical summary of insulin-specific SI of 
unfractionated cells (Group II patients); Comparison with 
SI of controls.
Type & iConcentration of Insulin in vi tro
H10 H100 P10 P100 B10 B100
CONTROLS: N 2 2 2 2 2 2 2 2 2 2 2 2
mean 0.96 1.07 0.92 0.89 0 . 8 8 1.04
SD 0.51 0.57 0.56 0.53 0.45 0.62
median 0.71 0.95 0 . 6 8 0.81 0.85 0.80
GROUP II N — — 2 2 2 2 2 2 2 2
PATIENTS: mean 0.97 1.19 0.92 1.03
1 st SD - - 0.44 1.19 0.57 0.69
SAMPLE median - - 0.92 1 . 0 0 0.80 0 . 8 6
Mann-Whitney U — — 192 169 233 223
z - - 1.17 1.73 0 . 2 2 0.46
P - - NS NS NS NS
2nd SAMPLE N 2 2 2 2 2 2 2 2 2 2 2 2
mean 1.58 1.33 1.29 1.27 1.49 1.65
SD 1.5 0.77 1.25 0.7 1.92 2 . 1
median 1.07 1 . 2 0 0.97 1.14 1.05 1.13
Mann-Whitney U 138 170 155 158 139 181
z 1.87 1 . 0 2 2.05 1.98 2.43 1.44
P 0.06* NS 0.04 0.047 0.015 NS
3rd SAMPLE N 2 2 2 2 2 2 2 2 2 2 2 2
mean 1.92 2.05 1 . 1 1.49 1.49 1.76
SD 2.31 0.65 0.43 0.63 1.19 2 . 2 1
median 1.07 0.98 0.97 1.61 1 . 1 2 1.03
Mann-Whitney U 147 2 1 0 162 8 6 125 183
z 1.85 0.25 1.47 3.37 2.39 0.93
P NS* NS NS 0.0008 0.017 NS
The Mann-Whitney U test. * P - 0.06 (N.3. human insulin 
was not available during the analysis of 1st samples). 1st 
Samples: prior to change from BI to HI therapy; 2nd 
Samples: 3-8 months after transferring to HI therapy. 3rd
Samples: >12 months on HI therapy. H=human insulin;
P-pork insulin; B=beef insulin at 10 and 100 ug.ml~2. 




Comparison of the % suppression of Group II patients and 
control subjects:
Insulin Type & Concentration in vitro
H10 H100 P10 P100 B10 B100
CONTROLS: N 2 2 2 2 2 2 2 2 2 2 2 2
mean 9.39 -0.84 -14.6 -7.38 -15.98 3.58
SD 43.3 46.6 95.8 67.6 1 1 0 37.4
median 18 7.62 24.2 7.44 17.89 9.06
1st N _ _ 2 2 2 2 2 2 2 2
SAMPLE. mean - - -1.91 -19.6 2.70 -10.7
SD - - 53.5 53 47.1 66.4
median - - 1 2 . 6 -7.28 16.98 8.71
Mann-Whitney U _ _ 224 2.09 234 228
z - - 0.42 0.78 0.19 0.34
P - - NS NS NS NS
2nd N 19 19 2 2 2 2 2 2 2 2
SAMPLE. mean -42 -2.65 -32.5 - 1 2 . 1 -9.19 -31.2
SD 93.4 65.4 87.4 66.4 55.6 94.3
median -8.25 10.84 -24.1 1.75 13.7 -2.74
Mann-Whitney U 135 1 . 8 8 2 0 0 237 242 217
z 1.93 0.55 0.99 0 . 1 2 0.47 0 . 6
P 0.053 NS NS NS NS NS
3rd N 2 0 2 0 2 0 2 0 2 0 2 0
SAMPLE. mean -35.4 -28.2 5.47 -36.8 -20.9 -2 0 . 8
SD 86.7 67.2 55.3 82.8 75.3 97.2
median -7.57 -7.63 2 1 . 2 -11.99 -5.96 16.62
Mann-Whitney U 130 176 2 1 2 175 161 206
z 2.27 1 . 1 1 0 . 2 0 1. 13 1.49 0.37
P 0.023 NS NS NS NS NS
Mann-Whitney U test. 1st Samples: prior to change from BI 
to HI therapy; 2nd Samples: 3-8 months after transferring 
to HI therapy. 3rd Samples: >12 months on HI therapy.
H=human insulin; P=pork insulin; B=heef insulin at 10 and 
lOOug.ml-1. SD=standard deviation, z=standard normal 
deviate, P=probability.
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2.4.2.(b) Effects Of Transferring From Beef to 
Human Insulin Therapy
Table 2.22.(a) and 2.22.(b) and 2.22.(c) examines the 
statistical difference in SI of the 1st, 2nd and 3rd 
samples of group II diabetic patients.
According to the results, the in vitro lymphocyte 
proliferation in the presence of beef insulin (and pork 
insulin - samples 1 and 3) increased when the patients 
were transferred from beef to human insulin therapy. As 
discussed earlier, these findings may be due to the 
distortion in SI values caused by the presence of FCS in 
culture medium during analysis of the 1st samples. The 
stimulation index of 2nd and 3rd samples does not 
significantly differ from each other.
In Table 2.23.(a), 2.23(b), 2.23(c)., the % suppressor
cell activity of the three samples are compared with each 
other.
The results show that there is no significant difference 
in % suppression between the three samples. There was, 
however, in many instances a significant correlation in % 
suppression and SI between the various types of insulin, 
this is illustrated in Tables 2.24.(a) and 2.24.(b).
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Table 2.22.(a)
Difference in SI of 1st and 2nd samples:
Type 8c Concentration of Insulin in vi tro
H10 H100 P10 P 1 0 0 BIO B100
N 18 18 18 18
Wilcoxon T 55 57 30 40.5
z 1.31 1 . 2 2 2.4 1.94
(probability) P NS NS 0.017 0.053*
H=human insulin; P=pork insulin; B=beef insulin at 10 and
lOOug.ml~L. z=standard normal deviate. * The increase in
SI Just fails to be significant.
Table 2.22.(b) 
Difference in SI of 2 nd and 3rd samples:
Type
H10
8c Concentration of Insulin in 
H100 P10 P100 B10
vitro
B100
N 13 18 18 18 18 18
Wilcoxon T 80 61 83 60.5 66.5 65
z 0 . 2 2 1.05 0.09 1.07 0.81 0.87
(probability) P NS NS NS NS NS NS
H=human insulin; P=pork insulin; B=beef insulin 
lOOug.ml-1. z=standard normal deviate.
at 10 and
Table 2.22.(c)
Difference in stimulation indices of 1st and 3rd samples:
Type 8c Concentration of Insulin in vitro
H10 H100 P10 P100 B10 B100
N — _ 18 18 18 18
Wilcoxon T - - 52 25 22.5 51
z - - 1.44 2.61 2.72 1.48
(probablity) P - - NS 0.009 0.006 NS
Two-sample Wilcoxon test for paired data. H=human insulin; 




A comparison of the % suppression of 1st and 2nd samples:
Insulin Type & Concentration in vitro
H10 H100 P10 P100 BIO B100
N — — 18 18 18 18
Wilcoxon T - - 51 80 52 51
z - - 1.48 0 . 2 2 1.44 1.48
Probability - - NS NS NS NS
Two-sample Wilcoxon test for paired data.
H=human insulin; P-pork insulin; B=beef insulin at 10 and 
lOOug.ml -1.
Table 2.23.(b)
A comparison of the % suppression of 1st and 2nd samples:
Type & Concentration of Insulin in vitro
H10 H100 P10 P100 B10 B100
N 18 18 18 18 18 18
Wilcoxon T 76 55 60 74 71 77
Zj 0.39 1.31 1.09 0.48 0.61 0.35
Sig. level P NS NS NS NS NS NS
Two -sample Wileoxon test for paired data
H=human insulin; P=pork insulin; B=beef insulin at 10 and
lOOug.ml-'1.
Table 2.23.(c )
A comparison of the % suppression of 1st and 2nd samplesi:
Insulin Type & Concentration in vitro
H10 H100 P10 P100 B10 B100
N —  _ 18 18 18 18
Wilcoxon T - 85 60 43 75
z - 0 1.09 1.83 0.44
Sig. level P - NS NS 0.067* NS
Two-sample Wilcoxon test for paired data. The 
probability (P) values are given for a two-tailed test. 
*P=0.0337 for a one-tailed test; thefore, the %
suppression of 1st samples are significantly lower than 
that of the 3rd sample. H=human insulin; P=pork insulin; 
B=beef insulin at 10 and lOOug.ml-1.
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Table 2.24.(a)
Spearman's Rank Correlation Coefficient of SI and % 
suppression between the three types of insulin. Value of 
(ra): Group II patients - 2nd sample.
Stimulation Index (SI)
H10 H100 P10 P100 BIO B100
H10 N = 18 18
% r= 0.511* 0.392
s H100 N= 18 18
u r= 0.575* 0.402
p
p P10 N= 18 18
R r- 0.699** 0.796***
E
s P100 N= 18 18
S r- 0.276NS 0.639*
I
0 BIO N= 18 18
N r= 0.629** 0.8***





Top right triangle show the correlation in SI obtained 
with H=human; P=pork; and B=beef insulins at 10 and 
lOOug.ml-1. Bottom left triangle gives the correlation in 




Spearman's Rank correlation coefficient of SI and % 
suppression between the three types of insulin. Value of 
(ra): Group II patients -3rd sample.
Stimulation Index (SI)
H10 H100 P10 P100 B10 B100
H10 N= 18 18
% r= 0.262 0.738***
s H100 N= 18 18
u r= 0.498* 0.493*
p
p P10 N= 18 18
R r= 0.307 0.189
E
S P100 N= 18 18
S r= 0.422 0.556*
I
0 BIO N= 18 18
N r= 0.649** 0.15
B100 N- 18 18




Top right triangle show the correlation in SI obtained 
with H=human; P=pork; and B=beef insulins. Bottom left 
triangle gives the correlation in % Suppression obtained 
with the three types of insulin in culture.
Analysis of data from the first samples showed no 
correlation between the response (SI) to beef and pork 
insulins (results not shown). There was however, a 
significant correlation in the % suppression between pork 
and beef insulins at 10 ug.ml- 1  (r=0.47; N=18; P<0.05).
The correlation coefficient values for the response to 
human, pork and beef insulins of the 2nd and 3rd samples 
are tabulated in Tables 2.24.(a) and 2.24.(b) 
respectively. Table 2.24.(a) shows that in the 2nd
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samples there was a significant correlation in SI between 
pork and human insulins, with stronger correlation between 
the responses to beef and pork insulins. The response to 
beef and human insulins neither differed significantly nor 
correlated with each other. The data on % suppression 
however, showed significant correlation between all three 
types of insulin. In Table 2.24.(b) it can be seen that 
for the 3rd sample a significant correlation in SI to all 
three types of insulin exists (at least at one 
concentration level). There was a strong correlation 
between the % suppression with beef and human insulin as 




The present investigation demonstrates that lymphocytes 
from both non-diabetic control subjects and diabetic 
patients, proliferate in vitro in the presence of pork, 
beef and human insulins. Moreover, the lymphocyte 
proliferative response of Group I diabetic patients to 
human insulin does not significantly differ from that of 
control subjects, implying that T-cells from diabetics 
and non-diabetics probably recognize the same epitopes on 
human insulin but not on beef and pork insulins: 
diabetics gave significantly higher SI values to pork 
(P<0.01) and to beef (P<0.02) insulins.
Lymphoid cells have two distinct insulin receptors, the 
immunological receptor on insulin specific B- and T-cells 
and the hormonal receptor on most activated lymphocytes.
It is unlikely that the responses are due to the
stimulation of the hormonal receptor since the insulin 
concentrations (1 0 -1 0 0 ug.ml_1) employed in the culture 
system are in vast excess of the maximum concentration
for physiological hormonal responses (10-8 M) (Blundell
et. al. 1972). Also, the concentration of U-100 
insulin administered therapeutically to the diabetic 
patients, is 3.85 mg.ml-1. Therefore, lymphocytes from 
diabetic patients are most likely exposed in vivo to
insulin concentrations in the range that is optimal for
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in vitro responses. The insulin preparations used in 
culture had very little contamination; proinsulin 
(<0.001%, none in HI) and glucagon (<0.001%, none in HI). 
Therefore, these contaminants are unlikely to stimulate
the lymphocytes. The frequency of non-responsiveness
among diabetics (60%) and controls (82%), also make 
hormonal effects an unlikely explanation for the
responses observed.
The fact that both insulin treated diabetic patients and 
control subjects possess T-cells that are autoreactive to 
human insulin suggests that T-cell autoreactivity to 
human insulin does not necessarily relate to the onset of 
type I diabetes as has been suggested by several papers 
(MacCuish et. al., 1975; Miller et. al., 1987). A
T-cell response to human insulin may reflect anti-self 
immune responses arising in normal and diabetic
individuals from pancreatic B-cell autolysis (Naquet et. 
al., 1988). Intercellular self proteins are thought to 
be routinely released from lysed cells into the blood 
circulation and might in fact be presented to T-cells by 
a variety of cell types in association with self MHC 
antigen (Clavertie, et. al., 1986). Such autoreactive 
T-cell responses would not lead to autoimmune disease if 
they were suitably immunoregulated. Similarly,
autoimmunity to human insulin may stem from recognition 
of "self" epitopes by cells that escape normal immune 
regulation or tolerance mechanisms (Naquet et. al., 
1988). Similar results are reported in mice (Jensen &
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Kapp, 1985), i.e. mice react to autologous insulin.
There was a strong correlation in response to all three 
types of insulins in both groups of diabetic patients, 
especially in the presence of high insulin concentration 
(ICO ug.ml-1). Insulin is known to form dimers and 
hexamers at high concentrations (>30ug.ml_1) (Kontiainen, 
1982), and cells from diabetic patients may react to such 
complexes formed in vitro by all three types of insulin. 
The insulin used in the assay contains between 0.4% to 
0.9% zinc. Zinc is also known to induce insulin to form 
complexes which results in conformational changes on the 
surface of the molecule. These changes, which 
principally involve the shift of amino acid side chains 
out to the surface of the molecule may also exist in the 
monomer (Nell et. al., 1985). Because therapeutic 
insulin preparations contain concentrations that favour 
the formation of complexes including dimers, hexamers and 
larger aggregates, all insulin-treated diabetic patients 
have been exposed to determinants present on these 
complexes. The in vitro response probably reflects 
recognition of such determinants. Also, because the 
zinc-dependent alterations arise at sites not influenced 
by amino acid sequence variation between species, they 
may explain 3ome shared reactivities to human and animal 
insulins.
Interestingly, of the four patients who were on 
zinc-insulin therapy alone (Human Ultratard - crystalline
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insulin-zinc suspension), two gave strong proliferative 
responses to all three types of insulins, one patient 
gave strong responses to pork and beef insulins (his 
cells were not assayed with human insulin) and the fourth 
patient (No.30) gave poor response to all three types of 
insulins, (Table 2.25.). The strong responses vitro
to the three insulins may be due to zinc-insulin therapy.
Table 2.25.
Lymphocyte proliferative response (SI) to human , pork 
and beef insulins by patients on zinc insulin therapy:
Patient Type & Concentration of Insulin
Number H10 H100 P10 P100 B10 B100
1 1 — — 1 . 6 6 2.47 1.79 2 . 1 2
30 0 . 6 6 0.65 0.76 0.43 0.75 0.76
49 1.04 2,91 1.25 2.75 1 . 0 2 2.85
51 2.14 2.35 2 . 0 1 1.71 0.95 3.29
Stimulation Index at 10 and 100 ug.ml-1 of H=human 
insulin; P=pork insulin ; and B=beef insulin.
Another explanation for the high correlation in the 
responses may be that cells from diabetic patients and 
control subjects recognize epitopes that are common to 
all three species of insulin due to the high degree of 
amino acid sequence homology. For example, Nell et. al., 
(1985) found that some subjects require the serine 
residue at position A9 for optimal responses to low 
concentrations of beef insulin. This residue is also 
present in human and pork insulins. In mice, the 
hydroxyl group of this serine residue has been shown to
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influence the immunogenic determinants recognized by some 
mice; in humans it may be recognized by autoreactive 
T-cell3 .
One patient of particular interest was patient number 34 
(see Table 2.8) because of his known allergic reaction to 
insulin at the injection site. He was a 16 year old boy 
with poor diabetic control (HbAl= 16%) and high insulin 
dose requirement (1 . 6  U/day/Kg). He has been an 
insulin-dependent diabetic for over 14 years and has been 
on human insulin (Human Isophane (prb)) therapy for 2 
years. His cells gave a positive proliferative response 
to all three types of insulin with stronger responses to 
beef and pork insulins: maximum SI with HI=2.79; PI=4.24; 
and BI=4.36. The corresponding % suppression values 
were: -4.5% in the presence of HI;-38% with PI; and -7%
with BI. Furthermore his cells showed a dose response 
effect with all three types of insulin. A blood sample 
from this subject was taken on one other occasion and a 
dose response assay showed similar results ie. an 
increase in insulin concentration in culture was 
associated with an increase in SI. The inverse was true 
for the % suppression, when it appeared that at low 
concentrations of insulin, the proliferative response was 
suppressed by 56.6% and 32.9% in the presence of human 
and pork insulins respectively. It would seem also that 
his 0 KT8 -* cells failed to recognise beef insulin, since 
negative % suppression values were observed at both
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concentrations used (10 and 100 ug.ml- 1  of BI). It is 
possible that this patient's suppressor cell3 recognize 
epitopes on the A-chain (A 8-10) where beef insulin 
differs from pork and human insulins by two amino acid 
exchanges. Moreover, the failure of these 0KT8‘K cells to 
function effectively at high concentrations of insulin 
may contribute to hypersensitivity experienced by this 
subject at the injection site where the insulin is 
introduced at high concentrations.
The three patients who were known to show insulin 
resistance (Nos. 1, 40 and 73) did not give a positive 
response with all three types of insulins.
Only one patient (No. 29) responded exclusively to human 
insulin (Table 2.8). One patient (No. 56) responded
exclusively to pork insulin and three patients (Nos. 43, 
52 and 53) responded solely to beef insulin. Patients 1 
to 2 1 are not included in this discussion because their 
response to human insulin was not determined. All other 
patients gave variable degrees of response to at least 
two types of insulin.
These results not only reflect the complexity of the 
immune response to insulin but also the diversity in
genetic background of the outbred human population 
(Scheinin et. al., 1983; Mann et. al., 1983; Naquet et. 
al., 1988; Miller et. al., 1987). The immune response to
insulin is under Ir gene control. For example, HLA-DR4
is reported to be associated with response to beef
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insulin and HLA-DR3 is associated with responses to beef 
and pork insulins (Mann et. al., 1983). Therefore, the 
responses outlined in Table 2.8. may partly reflect the 
distribution of HLA genotype among the diabetic patients.
For many years, the high response to beef and pork 
insulins was thought to be due mainly to the difference 
in amino acid composition of the B-chain of these two 
types of insulin compared to autologous insulin. However, 
since then significant responses to therapeutic human 
insulin (which is identical to autologous insulin in 
terms of amino acid sequence) has been reported even in 
patients who have never been exposed to non-human 
insulins, (Naquet et. al., 1988; Parker & Reeves, 1989). 
Therefore, the results tabulated in Table 3.10. confirm 
the hypothesis that the primary structure of the insulin 
molecule is not the only factor determining its 
immunogenicity.
Other factors affecting the cellular immune response to 
insulin include the preferential recognition of tertiary 
structures by T-cells. For example, Naquet et. al., 
(1988) showed that the epitope(s) recognized by T-cells 
require interaction between several residues present on 
both the A- and the B-chains rather than just the single 
amino acid exchange. The way the antigen presenting 
cells process the insulin molecule may also make it more 
immunogenic. It has been demonstrated that accessory 
cells can take up and degrade antigen by a metabolically
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active process that requires lysosomal enzymes (Unanue 
et. al., 1984). The degraded antigen (potentially in 
the form of peptides, may not possess the same epitopes 
present on the native protein), is then re-presented on 
the accessory cell surface in association with la 
antigens for recognition by T-cells. Similarly, it is 
possible that all three insulin molecules are processed 
by antigen presenting cells in such a way that 
immunogenic determinants are created which are not 
present in the native molecules.
Regulation of the immune response to insulin at the 
cellular level.
The insulin-specific suppressor cell activity of diabetic 
patients did not differ significantly from control 
subjects. Diabetic patients, referred to in this study, 
have long established insulin dependency. Suppressor 
cell activity of such patients is also reported by others 
(Buschard, et. al., 1982) not to be significantly 
different from control subjects. It should be noted 
however, that the suppressor cell activity measured by 
Buschard et. al., (1982) was not insulin-specific. The 
patients' cells were stimulated non-specifically with 
Con. A and the inhibitory effect of these cells were 
assessed by culturing with allogeneic lymphocytes, also 
stimulated by Con. A.
The majority of the Group I diabetic patients, in this
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study, gave strongest proliferative responses to beef and 
pork insulins, yet these patients have been on human 
insulin therapy for at least 6 months and most of them 
have never been exposed to beef insulin. This type of 
heteroclytic response has also been reported by other 
workers (Parker & Reeves, 1989; Naquet et. al., 1989; 
Jensen & Kapp, 1985), and may reflect immune regulation 
at the cellular level. Of the 12 patients who gave 
maximum response to beef insulin (Figure 2.7.(c)) 9
lacked suppressor cell activity to BI. 5 of 8 patients 
who gave a maximum response to pork insulin, gave 
negative % suppression values. It is possible that in 
these patients, the in vitro response to pork and beef is 
regulated by cells activated by suppressor epitope(s) 
present on human insulin. If such an epitope is located 
within the B-chain (B-30 of HI differs from PI and BI) 
then the human-insulin specific T-suppressor cells would 
fail to recognize beef and pork insulins in vitro, thus 
producing a heteroclytic response.
Kontiainen (1982), also concluded that the determinants 
recognized by suppressor cells may be in the B-chain 
since beef insulin suppressor factor of H-2te mice was not 
absorbed by beef A-chain immunoabsorbents in his studies. 
Alternatively, there may well be multiple partially 
overlapping suppressor cell inducing determinants in the 
insulin molecule, which is induced by the physicochemical 
form of insulin i.e. insulin is mainly monomeric at
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concentration <lug.ml_1 and mainly hexameric at doses >30 
ug.ml-1, the presence of zinc also induces formation of 
complexes. Recognition of such overlapping determinants 
and complexes by cells may explain why some of the 
patients also showed suppression against pork and beef 
insulins.
The evidence for the role of 008“*- cell3 in the regulation 
of the immune response to insulin is further 
substantiated by the finding that among Group I diabetic 
patients, there were 45 positive SI responses (Table 
2.8.), 33 (73%) of which were accompanied by negative %
suppression values (Table 2.11). Furthermore, a strong 
negative correlation between % suppression and 
stimulation index was observed - showing that an increase 
in % suppression is associated with a decrease in 
stimulation index. This is shown in Table 2.26.
Table 2.26.




Concentration of Insulin 
P10 P100 B10 B100
N 39 39 59 61 60 61
T a -0.4002 -0.528* -•0.397 -0.341 -0.605 ■0.412
P <0.05 <0.001* <0.01 <0.01 <0.001 <0.01
r a=Spearman's Rank Correlation Coefficient. *Product 
moment correlation coefficient. H=human insulin; P=pork 
insulin; B=beef insulin, at 10 and lOOug.ml-1. N=number 
of patients. P=probabilityf significance level.
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Group I diabetic patients were found to exhibit a 
decrease in % suppression with increase in age (r=-0.36; 
P<0.05). This may be a very important finding in view of 
the importance of suppressor cells. The immune system is 
a fine balance between effector and suppressor elements, 
and immunological tolerance is mediated via the 
generation of a population of suppressor cells. If this 
delicate balance malfunctions in any way, then an excess 
of antibodies as in allergic reactions, or the production 
of aberrant antibodies such as in autoimmune disorders 
might prevail. Alternatively, there could be a lack of 
antibodies which might result in immunodeficiencies 
(Marx, 1975).
Many investigators consider that suppressor T-cells 
normally prevent the production of auto-antibodies and a 
deficiency may contribute to autoimmunity. This may 
explain why diabetic patients experience more 
immunological complications with age, and the progression 
from non-insulin dependency to insulin dependency may be 
due to lack of suppressor cells which would normally 
reduce the autoimmune process. This view is supported by 
Marx (1975) who found that in NZB mice there is a 
decrease in suppressor cell activity with age, which is 
accompanied by the spontaneous developement of a 
condition similar to systemic lupus erythematosus in man. 
The cause of the loss of suppressor T-cells is unknown, 
but viruses and genetic factors probably play a role 
(Marx, 1975). It is suggested that a decline in T-cells
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and T-cell functions, particularly suppressor T-cells in 
conjunction with an increase in B-cells, might be 
correlated to the known increased incidence of 
autoantibodies with old age (Williams & Messner, 1975).
The relationship between % suppression (in the presence 
of lOug.ml-1 human insulin) and the patients' daily 
insulin dose is less easily explained. The rise in % 
suppression with increase in insulin dose is probably due 
to suppressor T-cells being activated in vivo in patients 
requiring higher insulin doses. These suppressor cells 
exert their function in vitro when cultured in the
presence of human insulin but not in the presence of beef 
and pork insulins. This is probably because the 
suppressor cells are human insulin specific.
The results outlined in the present study show that
patients with poor diabetic control gave higher 
insulin-specific stimulation index values than those with 
good diabetic control (P<0.05). Glycosylated haemoglobin 
levels are an indication of diabetic control over the 
previous 4-6 weeks prior to the time blood samples were 
taken from the patients. It is possible that patients 
with poor diabetic control are under insulinized. ie. 
there may be an absolutely reduced level of insulin, or 
at least a relatively reduced insulin level insufficient 
to maintain glucose at normal levels. In the obese and 
non-insulin dependent patients who have come to need
insulin therapy there is clear evidence for insulin
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resistance (Irvine, 1980). The high stimulation index 
values by patients with poor diabetic control may be 
associated with such relative or absolute insulin 
resistance.
Effects Of Transferring From Beef To Human Insulin 
Therapy On The Cellular Immune Response To Insulin.
It is thought that therapeutically administered 
biosynthetic and semisynthetic human insulin preparations 
are less immunogenic (than beef or pork insulins) because 
of the 100 percent amino acid sequence homology with 
autologous insulin. Thus, one would expect immunological 
complications such as insulin resistance, lipoatrophy and 
hypersensitivity of the delayed type to decrease if 
patients are transferred to human insulin therapy. This 
would also be reflected by a decrease in 
insulin-stimulated proliferation when immune cells of 
such patients are challenged with insulin in vitro.
The above hypothesis is refuted by the results obtained 
in the present study. For example, the in vitro 
lymphocyte proliferation to 10 ug.ml”1 beef insulin 
increased when the patients were transferred from beef to 
human insulin therapy.
This was not observed at lOOug.ml-1. There was also a 
significant increase in response between the first and
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third sample at lOOug.ml-1 pork insulin. The cellular 
immune response to human insulin was not determined while 
the patients were on beef insulin therapy. Therefore, it 
is not possible to comment on the possible effects of 
transferring from beef to human insulin therapy on the 
in vitro response to human insulin.
The low response of the first samples (due to the use of 
FCS in culture media) may be responsible for the 
'apparent' increase in SI of the second and third 
samples. There was however, little evidence to suggest 
that therapeutically administered highly purified beef 
insulin is more immunogenic than human insulin as has 
been suggested by many workers (Mann et. al., 19Q3; 
MacCuish et. al., 1975). The higher SI values obtained in 
patients undergoing beef insulin therapy by some workers 
may be due to factors other than just amino acid sequence 
difference. There is much evidence to suggest that the 
pH, purity, solubility and zinc concentration of the 
insulin preparations as well as the mode of 
administration, all contribute towards its immunogenicity 
(Reeves, 1980, 1986). The results outlined in this study 
suggest that the proliferative response to beef insulin 
is stronger compared to human insulin, but this was not 
statistically significant.
It is possible to explain, in part, the proliferative 
response to beef and human insulins in terms of 
immunoregulation at the cellular level. For example, the
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% suppression in the presence of beef insulin decreases 
(P<0.05) when the patients were transferred to human 
insulin therapy. It is possible that while the patients 
are on beef insulin therapy they possess suppressor 
T-cells that are beef insulin specific (perhaps these 
cells recognize epitope(s) on the A-chain: A-8 and 10), 
the response to beef insulin was therefore suppressed. 
After 3-8 months on human insulin, the number of 
suppressor cells recognizing beef insulin have probably 
decreased. The ratio of beef insulin specific 
suppressor:helper cells also decreased thus giving rise 
to a heteroclytic response. ie. the response to beef 
insulin, which is more foreign, increased when the 
patients were on human insulin.
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CHAPTER III
3. HUMORAL IMMUNE RESPONSE TO INSULIN.
3.1. INTRODUCTION
In man, the immune response to insulin was first 
documented by Berson et. al., (1956) who demonstrated 
the presence of insulin binding immunoglobulins in the 
serum of diabetic patients treated with beef and pork 
insulins. Subsequent studies have documented the 
presence of anti-insulin antibodies in most insulin 
treated diabetic patients, even in those on human insulin 
therapy (Andersen, 1972; Asplin et. al., 1978; Di Mario 
et. al., 1986; Pickup, 1986).
A minority of these patients are reported to develop 
allergic reactions and immunological complications which 
may result in asthma, urticaria and anaphylactic shock. 
The presence of very high concentrations of insulin 
antibodies is known to cause insulin resistance with 
subsequent effects on the dose requirements and 
pharmaco-kinetics of the injected insulin (Caugahan, et. 
al., 1983). Recent studies, however, suggest that
moderate concentrations of insulin antibodies are not 
responsible for insulin resistance and may in fact 
improve diabetic control by providing a buffering system 
capable of maintaining a more steady basal level of free 
insulin concentration (Gray, et. al., 1981; Gray, et.
112
al., 1985). In patients with vascular disease, however, 
insulin antibody complexes may have a deleterious effect 
(Andersen, 1976, Reeves, 1980; 1986).
Insulin antibody formation depends on a variety of 
factors, including the pattern of insulin therapy (i.e. 
single or multiple injections per day), mode of 
administration, pH, zinc and protamine content, degree of 
purity and species of origin. For example, beef insulin 
is said to be more immunogenic than pork or human 
insulins, and highly purified insulins induce lower 
insulin antibodies than conventional preparations 
(Reeves, 1980; Wilson, et. al., 1985; Di Mario, et. al., 
1986; Pickup, 1986). The physical state of the insulin 
preparation, irrespective of the species of origin, can 
also influence the degree of anti-insulin antibodies 
produced. Patients who require soluble insulin in 
addition to isophane are reported to show a significant 
enhancement of antibody production (Reeves, et. al., 
1984), and contaminants such as zinc are well documented 
to produce increased levels of antibody (Lunetta, et. 
al., 1986).
Many studies have correlated the anti-insulin antibody 
level in insulin dependent diabetic patients with certain 
HLA antigens (Schernthaner, 1982; Schernthaner, et. al., 
1979; MacEvoy, et. al., 1986; Aimer, et. al., 1985; 
Asplin, et. al., 1984; Karjalainen, at. al., 1989). 
Nearly all of these studies report a lower incidence of
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anti-insulin antibody in patients possessing HLA-DR3 and 
HLA-B8 whereas some workers have shown that the level of 
antibody is increased in patients with HLA-DR7 antigen.
Sklenar et. al., (1982) have found that diabetic 
patients who are DR3 carriers have a low responder status 
to pork but not to beef insulin. DR4 carriers and 
DR4/DR3 heterozygotes, on the other hand, show a high 
responder status to beef as well as to pork insulins. The 
high responder status of the DR4/DR3 carriers to pork 
insulin suggests that the gene(s) associated with HLA-DR4 
(and responsible for a high response to pork insulin) is 
(are) dominant to gene(s) associated with HLA-DR3 (and a 
low response) with regard to the production of antibodies 
to pork insulin.
Recently, the level of insulin antibody production has 
been reported to be influenced by a gene(s) linked to the 
IgG heavy chain complex (Gm allotype), and not to the MHC 
(Nakao, et. al., 1981; Reeves et. al., 1984). These 
conflicting results undoubtedly reflect the outbred 
nature of the human population and the complexicity of 
the genetic regulation of the immune system.
All five major classes of immunoglobulins (G,M,A,E and D) 
have been found in insulin-treated diabetic patients 
(Page-Faulk, et. al., 1971); quantitatively, the most
significant antibodies are those of the IgG class. Most 
studies, investigating the humoral immune response to
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insulin, have only concentrated on the level of total IgG 
anti-insulin antibody. Few, if any, have looked at the 
anti-insulin IgG subclasses. Yet, animal experiments 
suggest that the subclass of IgG may play an important 
role in determining the rate of immune complex clearence 
in vivo. In the guinea pig, for example, two 
anti-insulin IgG subclasses can be identified and 
purified (Yagi, et. al., 1962), IgGl, which does not 
activate complement and IgG2, which binds Clq and 
specific Fc receptors on macrophages.
Since the physicochemical and biological properties of 
the four human IgG isotypes are known to be different 
(Shakib, 1986), the class and subclass of anti-insulin 
immunoglobulins could be of great clinical significance. 
Koch , et. al., (1966) have made a preliminary
investigation, but the number of patients used were 
limited (24 patients) and they failed to look at the 
possible relationship between IgG subclass and clinical 
background of the diabetic patients.
In the present study, the class of immunoglobulin 
produced by diabetic patients (IgM and IgE), the level of 
anti-insulin IgG and IgG subclasses were determined in an 
attempt to investigate their possible clinical relevance. 
The effect of beef insulin and human insulin therapy on 
the level and type of anti-insulin antibody produced was 
also compared.
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3.2. MATERIALS AND REAGENTS
(i) Serum samples : 5 to 10 ml blood samples were
collected from Type I Diabetic patients and control
subjects. The blood was allowed to clot at 4°C for 
several hours before being spun down at 400 x g for 10 
minutes. The Serum layer was recovered and aliquoted 
into glass tubes and stored at -20°C until further use.
(ii) Standard and Quality Control (QC) serum samples were 
kindly donated by Dr. T.J. Wilkin and Miss A. Tuck of 
Southampton General Hospital, Southampton.
(iii) Conjugate 1. (GAHu/IgG(H+L)/P0 : Goat anti-human
IgG (Fc + Fab) conjugated to Horseradish Peroxidase - 
affinity purified (Nordic Immunological laboratories, 
Madienhead, Berkshire). Diluted 1 in 10 with sterile
d.d. water and stored at 4°C. The conjugate was further 
diluted 1 in 200 with PBS-Tween 20 (pH 7.2) to give a 
working dilution of 1 in 2000.
(iv) Conjugate 2. (GAM/IgG/PO : Goat anti-mouse IgG
labeled with Horseradish Peroxidase - (Nordic 
Immunological laboratories, Madienhead, Berkshire, Cat. 
No. 04.18.02).
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(v) Conjugate 3. (GAHu/IgE(Fc)/P0) : Goat
anti-human/IgE(Fc specific) conjugated to Horseradish 
Peroxidase, 1 ml lyof. reconstituted with 1 ml d.d. water
(Nordic Immunological laboratories, Madienhead, 
Berkshire)
(vi) Mouse monoclonal antibodies to humun IgG subclasses:
IgG subclass Cat. No. WHO/IUIS Clone No.
study code
Anti-IgGl - M15015 HP6012 NL16
Anti-IgG2 - M14017 HP6009 G0M2
Anti-IgG2 - (from Sigma) HP6014*
Anti-IgG3 - M08010 HP6010 ZG4
Anti-IgG4 - M11013 HP6011 HJ4
All anti-IgG subclasses, except *, were obtained from 
Oxoid Ltd., Bassingstoke, England. The above monoclonal 
antibodies (Mab) were derived from Murine hybridomas.
(vi) Anti-IgM, code No. M02012, clone No. AF6 (Oxoid
Ltd.).
(vii) Human Immunoglobulin G standard (10 mgs ml-1), 
(Sigma Chem Co. St. Louis MO).
(viii) Human Immunoglobulin E (0.1 mg ml-1) (Serotec 
Ltd., Blackthorn, Bicester, England).
(ix) Insulin : Novo human (monocomponent (me),
biosynthetic), pork (me) and beef (me) were obtained on
prescription from the Local Chemist. The Insulins came
as 100 u (3.85 mg ml-1) clear solutions, which were made 
up in carbonate/bicarbonate buffer pH 9.6.
(x) CNBr-activated Sepharose 4B beads, freeze dried
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(Pharmacia LKB Biotechnology, England. Code No. 
17-0430-01).
(xi) 1-Component ABTS substrate : Containing buffered 
2.2'-azino-di [3-ethyl-benzthiazoline sulphate (6)] 
(ABTS), and hydrogen peroxide stabilized in one solution 
(Kirkegaard & Perry Ltd. Billinghurst, Cat. No. 
50.66.00).
(xii) Carbonate/bicarbonate buffer, pH 9.6 : 1.5 x 10-2 M 
sodium carbonate (Na2C03); and 3.49 x 10~2 M sodium 
bicarbonate (NaHCOs).
(xiii) Phosphate Buffered Saline (PBS) with Tween-20, pH
7.2 : 0.14 M sodium chloride; 2.68 x 10-3 M potassium
chloride; 8.1 x 10“3 M disodium hydrogen phosphate 
(anhydrous salt); 1.5 x 10“4 M potassium di-hydrogen 
orthophosphate and 0.05% v/v Tween-20, made up with 
deionized distilled (d.d.) water.
(xiv) 1 % Sodium dodecyl sulphate (SDS)
(xv) 1 x 10-3 M Hydrochloric acid.
(xvi) Coupling buffer, pH 8.9 : 0.1 M Sodium hydrogen 
carbonate containing 0.5 M sodium chloride.
(xvii) Acetate buffer, 0.1 M Sodium acetate containing
0.5 M sodium chloride.
(xviii) 1 M Ethanolamine in coupling buffer pH 8.0.
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(xix) Tris buffer, pH 8.0 : 0.1 M Tris HC1 containing 0.5 
M sodium chloride.
(xx) 1% BSA and 1% BSA made up in 0.01% Sodium 
ethylmercuri-thiosalicylate (thimerosal).
(xxi) KCNS Ammonia : 1 M Potassium thiocyanate, 0.5 M 
Ammonium hydroxide.
(xxii) 96-well flat-bottomed Nunc Immunoplate II. Cat. 
No. 4-42404 (Gibco laboratories, uxbridge, middlesex).
(xxiii) Skatron A/S Microwash II, automatic plate washer.
(xxiv) M600 Microplate Header (Dynatech Laboratories 
Ltd., Billingshurst, Sussex.
(xxv) 5412 Eppendorf Microfuge.
(xxvi) Eppendorf microcentrifuge tubes, 1.5ml volume.
(xxvii) Scintered glass funnel (code No. SF4B32 - 
Quickfit, England).
(xxviii) Dialysing tubing, 18/32 of an inch, from 
Scientific Instruments Centre Ltd., Hampshire, England.
(xxix) LKB 2138 UVIC0RD - UV chart recorder.
(xxx) Philips PU 8800 UV/VIS Spectrophotometer.
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3.3. METHODS
3.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
Determination of Serum Anti-Insulin Antibody Titer.
Monocomponent human, beef or pork insulin was adhered to 
96-well flat-bottomed microtiter plates as follows :
1.5 ug well-1 (100 ul of 15 ug ml-1) freshly prepared 
insulin solution made-up in carbonate/bicarbonate buffer 
(pH 9.6) was added and incubated at 4°C overnight or at 
room temperature for 3 hours.
Unbound insulin was removed by washing the plate with 
PBS-Tween 20 using an automatic Skatron A/S microwash II. 
Each washing step consisted of five cycles.
In each insulin coated plate, serial dilutions (lOOul 
well-1) of a serum (with known concentration of 
anti-insulin antibody content) were added as standards. 
Test serum samples were used at 1 in 30 dilution in 
PBS-Tween 20 (lOOul well-1 in duplicate). Following 1 
hour's incubation at room temperature the plate was 
washed. 100 ul of 1 in 2000 diluted, goat anti-human IgG 
(H+L) conjugated to peroxidase (GAHu/IgG(H+L)/PO), was 
added to each well and incubated for a further 1 hour at 
room temperature. The plate was washed again to remove 
excess conjugate.
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100 ul well-1 of 1-component ABTS substrate was added. 
The enzyme-substrate reaction was allowed to proceed 
until a O.D. 4i O n m  of 1.7 for the highest concentration 
of standard was reached. The reaction was stopped with 
100 ul well-1 1% sodium dodecyl sulphate (SDS).
The light absorbance reading was made on a Dynatech MR
600 Microplate reader using a sample wavelength of 410nm 
and reference wavelength of 490nm. The O.D. for
threshold level was set at 1.99 and calibration value was
set at 1.00. The plate reader was blanked in a well 
which had recieved all reagents but no test sample.
Note. The outer wells of the Nunc 96-well microtiter 
plate were not used for sample analysis because variation 
in signal strength was sometimes observed in these wells,
i.e. there was an “edge effect".
3.3.2. ELISA - IsG Subclass Determination.
Micro plates were coated with 15 ug ml-1 human (or beef) 
insulin made up in carbonate/bicarbonate buffer (pH 9.6). 
The plates were incubated at 4°C overnight. Between each 
stage of the assay the plates were washed as described 
previously.
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Samples (lOOug well-1) were added at a dilution of 1 in
30 :
Each plate was divided into four equal segments so that 
each sample was tested in duplicate in each segment, a3 
shown below.
Layout of serum samples and anti-IgG subclasses on a 96 
well microtiter plate:
IgGl \ IgG2
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Numbers 1 to 5 are test serum samples.
Following 1 hour's incubation at room temperature, the 
plates were washed. Into the wells of each segment of 
the plate, lOOul of a different mouse anti-IgG subclass 
(diluted 1 in 500) was added so that each sample was 
tested for the presence of all four anti-insulin IgG
subclasses on the same plate.
After 1 hour at room temperature, the plates were washed 
and 100 ul of 1 in 1000 diluted, goat anti-mouse Ig 
conjugated to horseradish peroxidase (GAM/Ig(Y)/P0) was 
added to each well. Following a further hour's
incubation at room temperature, the plates were washed 
with PBS-Tween 20. lOOul of 1-component ABTS-substrate 
was added to each well. The enzyme-substrate reaction 
was allowed to proceed until a maximum O.D. (at 4 i o n m )  
of 1.7 was reached. The reaction of each sample was 
stopped separately with lOOul well-1 1% SDS.
3.3.3. Coupling of Insulin to CNBr-activated Seuharose4B 
beads
Two grams of freeze dried CNBr-activated Sepharose 4B 
beads was suspended in 1 mM HC1 (each gram of beads gave 
approximately 3.5 mis of swollen gel). The gel was 
washed with 1 mM HC1 for 15 minutes on a scintered glass 
filter. Approximately 200 mis of 1 mM HC1 was used to 
wash each gram of freeze dried beads. The ligand (human 
insulin or 1% BSA) was diluted in coupling buffer pH 8.9 
(0.1 M NaHC03 containing 0.5 M NaCl) at 1.155 mg ml-1. 
The gel was transferred to 15 mis of ligand solution and 
mixed by end-over-end rotation for 2 hours at room 
temperature.
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Excess ligand was washed away with coupling buffer and 
any remaining active groups on the beads were blocked 
with 1 M ethanolamine (pH 9.0), for at least 4 hours at 
4°C. The product was washed with three cycles of 
alternate pH. Each cycle consisted of a wash with 0.1 M 
acetate buffer (pH 4.0) containing 0.5 M NaCl, followed 
by a wash with 0.1 M Tris buffer (pH 8.0) containing 0.5 
M NaCl. The resulting product was stored at 4°C as a 50% 
slurry in PBS/0.1% Sodium ethylmercuri-thiosalicylate 
(thimerosal).
Absorbance reading of insulin solution before coupling :
2 8 0 nm = 2.3 (1.155 mg ml"1)
Absorbance reading after coupling to Sepharose 4B beads :
2BOrun — 0 . 286
Therefore, % of insulin absorbed by the beads:
2.3 - 0.288 = 2.012
2.012 / 2.3 x 100 = 87.48% .
Amount of insulin used :
1.155 (mgs ml-1) x 15 (mis) = 17.325 mgs.
87.48 % of 17.325 = 15.155 mgs per 2 gins of beads.
Therefore, 7.57 mgs of insulin is coupled to each gram of 
Sepharose 4B beads.
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3.3.4. Absorption of Human Serum with Sepharose 4R
Beads coupled to Insulin.
Plastic micro centrifuge tubes were coated with 1 ml of 
1% BSA made up in PBS/ethimerosal, by end-over-end 
rotation overnight at 4°C. This blocks non-specific 
binding of antibody to the tubes. The tubes were washed 
3 times with PBS and dried on paper towels.
100 ul of 50% slurry CNBr-activated Sepharose 4B beads 
coupled to human insulin was placed into each tube and 
centrifuged for 1 minute in an 5412 eppendorf microfuge. 
The supernatant was removed and 270 ul of PBS-Tween 20 
was added to each tube. 30 ul of serum sample was also 
added (this gave a serum dilution of 1 in 10).
The mixture was rotated gently at room temperature for 2 
hours. The tubes were centrifuged for 3 minutes and the 
supernatants (absorbed sera) were harvested to be assayed 
using the ELISA method outlined in section 3.3.1.
The above procedure was repeated using 50% slurry of 
CNBr-activated Sepharose 4B beads coupled to 1% BSA in 
place of insulin coated beads.
Note: The serum is now 1 in 10 diluted. However, 1 in 30 
dilution is required for ELISA (see section 3.3.1). 
Therefore, the above sera were further diluted 1 in 3 
with PBS-Tween 20.
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3.3.5. Affinity Purification Of Human___Anti-Insulin
Anti body
The anti-insulin antibody titer in the sera of diabetic 
patients was originally determined in terms of Binding 
Units (B.U.). Standards obtained from Dr. T.J. Wilkin 
and others, Southampton General Hospital, were used to 
determine the 'B.U.' values. Since the expression of 
antibody titer in terms of binding units was purely 
arbitrary, quantitation of the anti-insulin antibody in 
micrograms per ml of serum was necessary.
Serum samples, which gave high binding unit values, were 
pooled and the anti-insulin antibody was affinity 
purified on a human insulin conjugated CNBr- activated 
Sepharose 4B column.
Procedure: affinity purification of anti-insulin
antibody.
15.16 mgs of human insulin was coupled to 2 gms of CNBr- 
activated Sepharose 4B beads as described in section
3.3.3.
A 7 ml column of insulin coupled CNBr-Sepharose 4B beads 
was prepared and washed through with PBS. The column was 
pre-eluted with KCNS-Ammonia (1 M potassium thio 
cyanate, 0.5 M sodium Ammonia) and washed again with PBS. 
The chromatography was monitered using an UV
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detection-chart recorder. 6 mis of pooled sera was 
diluted with an equal volume of PBS and gently added to 
the column and allowed to run through. Unbound serum 
components were washed through with PBS, until the 
absorbance reading on the chart recorder reached 
baseline.
The bound insulin antibody was eluted with KCNS-ammonia 
until the O.D. c2 sonm) returned to that of KCNS-ammonia 
(0.5M).
The eluate was collected into a weighed glass vial and 
the pH was immediately adjusted to 7.3. The resulting 
affinity purified anti-insulin antibody was placed in a 
18/32 inch dialyzing tubing (which had been boiled for 
two minutes in 0 .1% acetic acid to remove unwanted 
sulphur products). The antibody was dialysed against PBS 
overnight at 4°C.
The dialysed anti-insulin antibody concentration was 
determined by spectrophotometric means :
Volume of dialysed antibody = 7.297 mis (7.297 gms)
Absorbance reading 2 SOmn = 0.29 Extinction Coefficient
for IgG = 14.3 for a 1% solution; 1 cm pathlength. 
Concentration (mgs ml-1) = Absorbance 2 sonn / E°-1% icm. 
Therefore, 0.29/1.43 = 0.2028 mg ml- 1  of serum, or 202.8 
ug ml- 1  of serum.
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3.3.6. Determination Of IgM
The relative IgM distribution in the sera of diabetic 
patients and control subjects was determined using an 
indirect ELISA protocol.
96 well microtiter plates were coated overnight at 4°C 
with lOOul of 1 in 30 diluted serum in 
carbonate/bicarbonate buffer (pH 9.6). Into each plate a 
standard IgM sample, which was known to contain high IgM 
titer was also assayed as a quality control. The plates 
were washed with PBS-Tween 20 (five cycles). lOOul of 
mouse anti-human IgM, diluted 1 in 100 with PBS-Tween 20, 
was added to each well and the plates incubated at room 
temperature for 1 hour.
Following five more wash cycles with PBS-Tween 20, lOOul 
of anti-mouse IgG.HRP (Unipath) diluted 1 in 150, was 
added to each well and incubated for 1 hour at room 
temperature.
The plates were washed with PBS-Tween 20, and lOOul of 
1-component ABTS-substrate was added. The colour 
reaction was allowed to proceed until a maximum 
O.D. 4 iorun of 1.7 was reached by the quality control 
sample. The reaction was then stopped by adding lOOul of 
1% SDS to each well, the OD readings were recorded with 
the plate reader.
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3.3.7. Determination Of IgE In Serum
The distribution of IgE in serum was determined using a 
direct ELISA method.
Plates coated with lOOul well- 1  serum samples (diluted 1 
in 30 with carbonate/bicarbonate buffer, pH 9.6) were 
washed and incubated with lOOul of goat anti-human IgE 
conjugated to peroxidase (GAH/IgE(Fc)/PO; diluted 1 in 
200). Following 1 hour at room temperature, the plates 
were washed and lOOul of 1-component ABTS-substrate was 
added to each well. Into each plate, a quality control 
which was known to have a high IgE titer was placed. The 
colour reaction was allowed to proceed until a maximum 
O.D. 4 ionm of 1.7 was reached by the quality control 
sample. The reaction was then stopped with lOOul of 1% 
SDS added to each well and the 0D readings were recorded 
with the plate reader.
3.3.8. Determination of serum Interleukin-2 (IL-2) 
concen tra tion.
The concentrations of IL-2 in the sera of diabetic 
patients and control subjects were determined using a 
human interleukin-2 intertest-2 kit (Genzyme corporation, 
Boston). The method was as described by manufacturers. A 
Polystyrene 96 well plate was coated with mouse 
monoclonal anti-IL2 antibody which is specific for human 
IL-2. Following 24 hours incubation at 4°C, the plate
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was washed with PBS Tween 20 and specimens and 
appropriate standard samples were added to the plate and 
incubated for a further 24 hours at 37°C. Unbound 
material was removed by aspiration and washing of the 
wells. The rabbit polyvalent antibody to human IL-2 was 
then added and incubated for 1 hour at 37°C. Again 
unbound antibody was removed by washing. The third 
antibody, an enzyme labelled goat anti-rabbit polyclonal 
reagent, was incubated in the wells for an hour at 
37°C. Unbound third antibody was removed by washing. 
Bound, immunoreactive IL-2 was quantitated by an 
enzymatic reaction resulting in a color change by a 
Dynatech MR 600 microplate reader. The measured 
absorbance (due to color change) is proportional the the 
concentration of IL-2 that was present in the original 
sample.
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3.3.9. Determination of the Optimum Conditions for 
ELISA
In order to determine the optimum conditions for the
ELISA system, various parameters were analysed. The 
resulting protocols are shown above (sections 3.3.1. to 
3.3.7. ) .
(a) Optimal antigen coating of microtiter plates.
In order to determine the optimum concentration of
insulin required for coating, human insulin was titrated 
across a 96-well flat-bottomed microtiter plate. All 
other assay conditions were as described in section
3.3.1. The assay was repeated with conjugate 
(GAHu/1gG(H+L)/PO) diluted 1 in 1000, 1 in 2000, 1 in 
4000, and 1 in 8000.
Figure 3.1. illustrates the variation in signal strength 
with concentration of coating protein (insulin). The 
absorbance readings obtained with 1 in 1 0 0 0  diluted 
GAHu/IgG(H+L)/PO were above the 0D maximum (2.0) in the 
Dynatech MR 600 microplate reader, and therefore, have 
been omitted. Figure 3.1. shows that between 30 to 15 
ug.ml- 1  insulin the signal strength obtained with all 
three dilutions of conjugate was relatively constant. 
However, below 15 ug.ml- 1  insulin, the signal strength 
decreases significantly with 1 in 2000 and 1 in 4000
diluted conjugate. Thus 15ug.ml_;L insulin was used for
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the standard protocol.
Figure 3.1. also shows the effect of conjugate 
(GAHu/IgG(H+L)/PO) dilution on the signal strength. In 
the presence of 1 in 1000 diluted conjugate, the O.D. 
readings were found to reach the O.D. maximum within 2 
minutes of adding the substrate. This made 1 in 1000 
dilution unsuitable for the assay. 1 in 2 0 0 0  diluted 
conjugate was found to give the optimum results at a 
slower rate (4-5 minutes).
(b) Absorption and Specificity of Serum Antibody.
The amount of insulin-coated sepharose 4B beads required 
to achieve optimum absorption of antibody was determined. 
Serum from a type I diabetic patient was absorbed with 
10-200ul of insulin coated or BSA coated beads (50% 
slurry). The absorbed serum was analysed using the 
standardized protocol outlined in section 3.3.1. Table
3.1.(a) shows the effect of varying amount of beads on 
antibody absorption.
The data for BSA coated beads represents non-specific 
binding of antibody to BSA, data for insulin coated beads 
represents the amount of insulin-antibody removed by 
absorption on the insulin coated beads. Therefore, the 
difference in absorbance readings of BSA and insulin 
coated beads is the amount of insulin antibody present in 
the serum. The data presented in Table 3.1.(a) indicates
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Figure 3.1.
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that the optimum absorption of insulin antibody is 
achieved with 1 0 0  ul of insulin coated Sepharose 4B beads 
(50% slurry).
Table 3.1.(a)
Amount of Sepharose 4B beads (50% slurry) required for 





+ SD after absorption with: 
beads BSA coated beads
%
diff.
2 0 0 0.139 + 0.002 1.255 + 0.024 88.9%
1 0 0 0.142 ± 0.014 1.189 + 0.005 8 8 .1%
50 0.275 ± 0.004 0.830 ± 0.002 66.9%
25 0.561 + 0.006 0.931 ± 0.01 39.7%
1 0 0.789 t 0.01 0.874 ± 0.002 9.7%
SD=standard deviation. X diff.= X difference in 
absorbance between insulin coated beads and BSA coated 
beads, i.e. X antibody absorbed.
In order to determine whether the antibody detected by 
the assay outlined in section 3.3.1., is insulin 
specific, serum samples from all subjects (diabetic 
patients and controls) were absorbed with lOOul (50% 
slurry) insulin coated or BSA coated beads and reassayed. 
The procedure is outlined in section 3.3.4. Absorption
of antibody with the two types of bead coatings are 
compared in Table 3.1.(b).
As expected, analysis of negative sera showed little 
difference in antibody concentration detected in sera 
absorbed with insulin coated beads and BSA coated beads. 
Therefore, only positive sera are analysed in Table
3.1 .(b).
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Table 3.1.(b) shows that the antibody detected is 
insulin-specific, since absorbtion with insulin coated 
beads reduced the antibody detected by nearly 80%. 
There was also some absorption with BSA coated beads 
(control) which was probably due to non-specific binding.
Table 3.1.(b)
Specificity of Antibody: Positive serum samples only.
Concentration Of Antibody detected 
after absorption with:
BSA coated beads Insulin coated beads
%
Reduction
N 42 42 42
Minimum 6.7 ug.ml" 1 0.7 ug.ml” 1 54.6
Maximum 116.7 ug.ml- 1 6.4 ug.ml" 1 97.8
Range 1 1 0 . 0 5.7 43.2
Mean 18.2 ug.ml- 1 2 . 8  ug.ml- 1 79 .0
SD 18.1 1 . 1 1 0 . 2
N=number of samples. 
SD=standard deviatIon.
In Figures 3.2.(a) and (b), monoclonal antibodies for 
detecting the IgG subclasses are titrated. Figure
3.2.(a) shows the titration of anti-IgG subclasses 
against normal serum. Sera from healthy control subjects 
were pooled and diluted 1 in 30 with 
carbonate/bicarbonate buffer (pH 9.6). The diluted sera 
was used to coat all 96 wells of a microtiter plate. 
Mouse monoclonal anti-IgG subclasses were titrated in 
duplicate across the microtiter plate, all other steps 
were as described in section 3.3.2. This gave the 
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In Figure 3.2.(b), anti-IgG subclasses tirated against 
insulin coated plate is shown. A microtiter plate was 
coated with 15 ug.ml- 1  human insulin, followed by serum 
from a diabetic patient known to have high insulin 
antibody titer. Anti-IgG subclasses were titrated across 
the plate in duplicates, and the distribution of IgG 
subclasses were detected using GAM/Ig(Y)/PO, as described 
in section 4.3.2.
Both Figure 3.2. (a) and (b) show optimum dilution for 
all four anti-IgG subclasses to be 1 in 500.
In Figure 3.3., titration of GAM/Ig(Y)/P0 shows that 
optimum dilution is 1 in 1 0 0 0 .
Figure 3.4. illustrates the titration of MAHu/IgM,
anti-M IgG.HRP, and GAHu/IgE (Fc)/P0. A 96 well
microtiter plate was coated with 1 in 30 diluted serum
sample from a diabetic patient. A two-way titration of
MAHu/IgM and anti-M IgG.HRP was made as follows: MAHu/IgM 
was titrated across the plate at 4 different dilutions (1 
in 100; 1 in 200; 1 in 400; 1 in 800). For each
dilution, 8 wells were used. To the remaining wells PBS 
Tween 20 was added. Following 1 hour incubation at room 
temperature, the plate was washed and anti-M.IgG.HRP was 
titrated down the plate (in duplicates) in wells coated 
with MAHu/IgM. In the remaining wells, GAHu/IgE(Fc)/Po 
was tirated. The results (Figure 3.4.) show that optimum 
dilutions for MAHu/IgM was 1 in 100, for anti-M.IgG.HRP 
was 1 in 150, and for GAHu/IgE(Fc)/P0 was 1 in 200. The
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standard error bars for duplicate wells are not shown 
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3.4. RESULTS
The humoral immune response to insulin by insulin treated 
diabetic patients was measured in terms of total 
anti-insulin IgG in serum. Anti-insulin antibody titer 
was determined using an Enzyme Linked Immunosorbent Assay 
(ELISA).
The O.D. readings (at 4ionm) of individual wells of a 
96-well microtiter plate were captured on disc and 
subsequently analysed by a 'four parametric logistic fit' 
model (Rodbord & Hutt, 1974) using a programme on the Eli 
Lilly corporate computer. This model was used because the 
four parameters of a curve, namely, zero response, slope,
ECso and infinite response (Max) are not fixed in an 
ELISA. In each microtiter plate serial dilution of a 
standard(with known high anti-insulin antibody content 
was made, the anti-insulin antibody concentration in the 
serum of individual patients and controls were determined 
by extrapolation from the standard curve. Figure 3.5. 
shows a typical standard curve. The mean + SD of the 
four parameters of 75 such curves are tabulated below.
Table 3.2.
Statistical summary of 75 standard curves:
Parameter N Mean SD
Zero Response 75 0.0087 0.082
Slope 75 1.1781 0.302
EC50 75 26.439 11.08
Inf. Response 75 2.2230 0.295
Minimum detectable concentration = 4.5988 binding units* 
Maximum measurable concentration = 176 binding units*
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Figure 3.5.
i n s u l i n .p c l s t d :
NAME OF MERGED FILE: 3 1 30489D .MR3
STANDARD CUF-VE
0.O 0. 3 0.6 0.9 1.2 1.5 1.3 2.1 2.4
LOG BU/ML
NOTE: 7 OBS HIDDEN
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* The results were determined in terms of 'binding 
units' and later converted to 'ug.ml-1, (see' methods' 
section 4.3.5.) 1 binding unit = 3.45 ug.ml- 1  of serum.
Each plate also contained negative and high response
controls. The coefficient of variation of 60 plates was
6 % for the positive control and 8 % for the negative
control. Serum samples were analysed in duplicate. In 
most cases, the standard deviation between the two
replicates was less than 3%; samples which gave a SD 
value greater than 1 0 % were reassayed.
3.4.1. Anti-In&alin Immunoglobulin G
Patients On Human Insulin Therapy
Seventy-six IDDM patients were tested for the 
anti-insulin antibody concentration in their serum. Their 
clinical details, and total anti-insulin IgG levels are 
shown in Table 3.3. In Table 3.4. the anti-insulin 
antibody concentration detected in the serum of 
non-diabetic control subjects are compared with that of 
diabetic patients using non-parametric statistics.
Table 3.4. illustrates that the concentration of 
anti-insulin antibody in the serum of diabetic patients 
was significantly higher than that of control subjects. 
The results of control
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subjects represents the threshold value of non-specific 
anti-IgG binding to insulin coated plates (baseline 
value). A significant antibody response was, therefore, 
defined as one which exceeded the mean antibody 
concentration of non-diabetic controls by 2 standard 
deviation.
Of the 76 Group I patients, 42 (55%) possessed
significant anti-human insulin antibody, 39 (51%) had 
anti-pork insulin antibody and 40 (53%) showed
significant anti-beef insulin antibody. In Table 3.5. 
the difference in concentration of anti-human, anti-pork 
and anti-beef insulins in the sera of Group I diabetic 
patients was assessed using a two-sample Wilcoxon test 
for paired data. The Spearman's correlation coefficient 
(ra) between the three types of insulin are also shown in 
Table 3.5.
Table 3.5. shows that there is a highly significant 
difference in the concentrations of the three different 
types of anti-insulin antibodies. There was also a 
significant correlation between the three types of 
anti-insulin antibody titers (r=0.Q67 to 0.898 P<0.0001)
indicating cross-reactivity of antibody with the three 
types of insulin. This is most apparent in the level of 
antibody detected on beef insulin coated plates since 
most of the Group I patients have not been treated with 
beef insulin and therefore would not be expected to 
possess specific anti-beef insulin antibodies.
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Table 3.3.
Total anti-insulin IgG concentration (ug.ml**1) in sera of
Group I diabetic patients.
Clinical Background Concentration of total IgG
No. Age DID Dose %HbAl anti-HI anti-PI anti-BI
1 43 1 2 0.75 ND 25.88 20.94 35.19
2 24 7 1.03 10.5% 24. 19 11.08 16.53
3 28 4.5 0.67 ND 42.33 28.77 48.82
4 42 27 0.76 ND 2 2 . 0 1 13.97 23.63
5 26 17 0.78 1 0 .8 % 27.60 14.90 25.81
6 53 28 0.77 1 0 .8 % 124.89 52.06 111.44
7 39 9 0.90 10.7% 24.12 21.74 34.02
8 35 23 0.50 15.9% 24.70 16.53 24.08
9 23 1 0 0.63 15.0% 33.29 23.56 36.71
1 0 36 2 0.39 13.1% 38.64 16.77 25.01
1 1 35 5 0.55 13.8% 27.22 24.46 21.05
1 2 27 4 0.27 13.1% 2 0 . 0 1 19.32 29.22
13 2 2 4 1.04 12.9% 18.29 13.32 16.56
14 50 3 0.52 13.6% 52.65 14.74 21.74
15 25 1.5 0.31 10.3% 35.54 26.22 42.78
16 45 6 0 . 6 6 11.4% 24.12 8.83 16.08
17 31 5 0.65 14.7% 41.40 34.85 40.12
18 40 30 0 . 6 6 1 2 .6% 21.87 17.39 18.29
19 2 2 3 1.06 7.7% 112.57 129.00 110.70
2 0 47 2 0.50 12.7% 71.07 72.93 62.58
2 1 34 1 0 0.61 15.3% 26.77 19.39 19.98
2 2 19 9 1.13 11.7% 27.70 21.39 17.94
23 17 7 1.69 1 1 .2 % 30.36 25.88 29.67
24 53 26 0.78 12.9% 45.75 42.09 42.44
25 41 9 0.84 12.9% 18.63 13.73 26.05
26 28 14 1 . 0 1 1 2 .1% 26.91 18.11 27.08
27 44 4 0.26 1 1 .8 % 28.74 20.84 37.54
28 31 1 0.53 9.4% 36.54 28.74 36.78
29 54 1 1 0.61 1 1 .0 % 34.05 27.53 24.67
30 39 9 0.71 12.3% 117.65 143.14 99.19
31 27 1 2 1.62 10.4% 42.44 32.64 32.88
32 46 35 0.80 8.4% 124.23 136.93 117.51
33 33 1 0.31 8 .1% 50.96 46.33 37.95
34 16 14 1.65 16.0% 66.93 67.21 44.89
35 40 31 0.51 13.7% 15.84 13.56 8.94
36 27 5 0.83 10.9% 12.59 9.45 4.97
37 35 5 1.14 13.9% 11.70 10.14 6.87
38 50 35 0.54 14.0% 29.33 29.08 27.26
39 44 27 0.51 1 1 .8 % 41.30 31.53 28.39
40 51 30 1.92 10.7% 32.60 33.29 55.68
41 29 13 0 . 8 8 9.4% 64.27 58.96 58.75
42 37 30 0 . 8 6 12.3% 22.67 25.43 19.15
43 34 24 0.34 ND 12.90 9.04 9.21
44 31 7 0 . 6 6 14.5% 22.49 18.94 19.32




Clinical Background Concentration of total IgG
No. Age DID Dose %HbAl anti-HI anti-PI anti-BI
46 29 1.5 0.23 7.4% 16.56 14.35 11.04
47 30 1 1 0.80 ND 13.52 11.04 6 . 0 0
48 51 2 1 0.87 1 0 .1% 51.06 48.65 74.87
49 31 2 1 0.98 12.7% 32.19 26.12 21.98
50 47 24 0 . 6 6 9.0% 19.67 16.97 34.33
51 50 2 0 0.75 ND 29.67 24.70 15.63
52 17 4 1 . 0 1 ND 23.29 14.90 13.90
53 30 23 0.69 15.5% 26.84 23.08 17.42
54 35 18 0.69 ND 49.34 53.30 31.22
55 48 4 0.43 9.3% 25.12 2 2 . 1 2 14.11
56 34 7 0 . 6 8 8.3% 84.35 55.89 56.41
57 42 2 2 0.79 1 1 .8 % 13.08 7.31 7.31
58 35 2 1 0.60 ND 25.53 22.77 15.53
59 45 1 2 0.78 ND 17.04 13.77 12.59
60 33 9 0.77 ND 11.97 6.90 7.31
61 42 16 0.64 ND 13.90 10.83 8.87
62 28 1 0 1.29 ND 21.39 4.52 11.87
63 48 13 0.77 ND 41.75 57.20 54.48
64 36 26 0.73 ND 15.42 6.35 11.35
65 51 2 2 0.78 ND 59.89 46.40 31.02
6 6 39 23 0.94 ND 59.38 55.41 30.74
67 50 6 0.58 ND 25.19 19.60 14.97
6 8 30 6 0.81 ND 18.63 3.45 10.59
69 17 4 0.28 ND 56.99 90.29 49.34
70 37 8 0.44 ND 4.69 7.90 5.21
71 24 1 0.40 ND 5.35 9.07 6.52
72 34 25 0 . 8 6 ND 35.98 45.71 37.36
73 40 NK NK ND 16.77 23.22 14.84
74 43 NK NK ND 8.28 11.94 8.31
75 25 NK NK ND 8.63 13.04 6.62
76 2 1 NK NK ND 88.42 93.01 77.73
N 76 72 72 76 76 76
mean 35.8 13.5 0.75 35.42 30.77 30.57
SD 1 0 . 1 9.8 0.33 26.53 28.72 25.00
med. 35.0 10.5 0.72 26.88 21.56 24.37
anti -HI=anti-human insulin antibody; anti-PI=anti-pork 
insulin antibody; anti-BI=anti-beef insulin antibody; 
DID=duration of disease (years); Dose=units/day/Kg body 
weight; %HbAl=% glycosylated haemoglobin; ND=not 
determined; NK=not known. No.=patient number; N=number of 









I patients with non
(ug.ml-1)
-diabetic
Type & Concentration of Anti-Insulin I^ 
Human Pork Beef
NON-DIABETIC N 2 2 2 2 2 2
CONTROLS mean 15.31 12.32 12.62
SD 4.98 4.7 5.32
median 14.92 14.92 12.08
*(mean + 2 SD) 25.27. 21.72 23.26
GROUP I N 76 76 76
DIABETIC mean 35.42 30.77 30.57
PATIENTS: SD 26.53 28.72 25
median 26.88 21.56 24.37
Mann-Whitney U = 231 339.5 339
z = 5.01 4.04 4.05
Probability >z = 0 0 0
*non-specific binding - > mean anti-insulin antibody
concentration of control 3era + 2 SD. N=number of
patients. SD=standard deviation. z=standard normal
deviate.
Table 3.5.
Difference (Wilcoxon T) & Correlation (Spearman's ra) in 
concentration of anti-human, anti-pork and anti-beef 
insulin IgG in the sera of Group I patients:
Type of
anti-insulin IgG N Wilcoxon T z P (rfl)'
Human vs Pork: 76 634 4.29 0 . 0 0.898
Human vs Beef: 76 630 4.31 0 . 0 0.889
Pork vs Beef: 75 163 0.169 NS 0.867
* all correlation values were highly significant (P<0.001). 
N=number of patients 
z=standard normal deviate 
P= probability > z
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Group I diabetic patients who gave positive antibody 
response were divided into three sub-groups on the basis 
of their anti-insulin antibody concentration.
Low responders: > negative response + 2 SD; < mean value 
for all patients on human insulin therapy.
Medium responders: > mean; < mean + 2 standard deviation. 
High responders'. > mean + 2 SD.
On the basis of the above definitions, the number and 
percentage of Group I patients in each group are 
tabulated in Table 3.6. Among Group I diabetic 
patients, eight subjects have been exposed to human 
insulin therapy only. Of these, 4 gave negative
responses, 2 gave low responses and the remaining 2 gave 
medium responses, the maximum response was 50.96
ug.ml- 1  serum.
Patients' 'age', 'duration of diabetes', 'duration of 
insulin therapy', 'daily insulin dose requirement' and 
'diabetic control' were all considered for their
potential effect on the antibody titer. In Table 3.7.,
the influence of these factors on the level of 
anti-insulin antibody concentration are analysed.
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Table 3.6.
Antibody responder status of 76 Group I diabetic
patients:
Type of anti-insulin IgG
Responder Status anti-HI anti-PI anti-BI
Nega tive Response - <25.3* <21.7* <23.3*
N 34 38 36
% 44.7% 50.0% 47.4%
Low Response — 25.3-35.4* 21.7-30.8* 23.3-30.6*
N 16 16 1 1
% 2 1 .1% 2 1 .0 % 14.5%
Medium Response - 35.5-88.5* 30.9-88.2* 30.7-80.6*
N 2 2 17 25
% 28.9% 22.4% 32.9%
High Response 3 >88.5* >8 8 .2 * >80.6*
N 4 5 4
% 5.3% 6 .6 % 5.3%
Values were rounded-off to one decimal point. 
*=anti-insulin IgG concentration in ug.ml-1 serum. 
N=number of patients in each group.
%=percentage of patients in each group.
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Table 3.7.
Relationship between clinical background and sera 
anti-insulin IgG concentration. Spearman's Rank 
Correlation Coefficient (re) values:
Concentration of Anti-Insulin IgG (ug.ml”1)
anti-HI anti-PI anti-BI
AGE r a - 0.0690 0.0835 0.0661
(years) p= NS NS NS
DURATION OF rs= 0 . 0 0 1 0.0963 0.0272
DISEASE (years) P= NS NS NS
DURATION OF ra= 0.0087 0.1023 0.0296
INSULIN THERAPY 
(years)
P= NS NS NS
DAILY INSULIN re= 0.0779 0.0660 0.0794
DOSE (U/D/Kg) p= NS NS NS
DIABETIC CONTROL r*= -0.2330 -0.2475 -0.3010
(% HbAl)* P= NS NS <0.05
number of patients=72. *=number of patients=49. anti-HI - 
anti-human insulin antibody; anti-PI - anti-pork insulin 
antibody; anti-BI = anti-beef insulin antibody. 
ro=Spearman rank correlation coefficient. P=probability. 
NS=not significant.
Among Group I diabetic patients there were 46 male and 30 
female, the antibody response to insulin was found not 
to be influenced by sex (z=0.319; P=NS).
Further aspects of the relationship between patients' 
daily insulin dose and the level of anti-insulin 
antibody were investigated. There was no relationship 
between dose and antibody titer even when patients with 
extremely high (>1.08 U/D/Kg (= mean daily insulin dose 
of all patients + 1 SD)) and low (<0.422 U/D/Kg (=mean 
daily insulin dose of all patients - 1 SD)) dose were
used in the analysis. The duration of disease
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of patients with low insulin dose, was however,
significantly lower than those on high insulin dose 
(Mann-Whitney U=5; z=2.56; P^O.0053). The overall
correlation between insulin dose and duration of disease 
was not significant.
Table 3.7. shows an apparent inverse correlation
between % HbAl level and antibody titer. However, the 
correlation just fails to be significant with anti-human 
and anti-pork insulin antibodies. Figure 3.6. shows the 
relationship between % HbAl value and anti-beef insulin 
antibody concentration. In order to investigate the 
relationship between diabetic control and antibody
concentration in detail, Group I diabetic patients were 
divided into three sub-groups on the basis of their 
glycosylated haemoglobin level: those with a stable
glycosylated haemoglobin level of < 1 1 % determined on
several occasions over a one year period are thought to 
have well controlled diabetes; those with > 13% HbAl and 
frequent change in insulin dose are thought to have 
poorly controlled diabetes; the remaining patients with % 
HbAl within 10-13% are classified as patients with 
intermediate control. In Table 3.8., Mann-Whitney U test 
was used to determine whether the antibody concentration 
of patients with good diabetic control was significantly 
higher than in those with poor diabetic control.
Patients with good diabetic control were found to have
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significantly higher anti-insulin antibody titer than
patients with poor diabetic control. The difference in
antibody concentration in sera of patients with
intermediate diabetic control did not significantly 
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Relationship between diabetic control and anti-insulin 
IgG concentration.
Concentration Of Anti-Insulin IgG (ug.ml-1)
anti-HI anti-PI anti-BI
PATIENTS WITH GOOD N 19 19 19
DIABETIC CONTROL mean 49.65 41.4 47.44
(<11% HbAl) SD 10.43 10.35 9.90
median 35.54 28.74 36.78
PATIENTS WITH N 15 15 15
INTERMEDIATE mean 36.05 32.50 31.33
CONTROL SD 7.72 1 0 . 0 2 6.67
(HbAl 11-13%) median 27.70 21.39 26.05
PATIENTS WITH POOR N 15 15 15
DIABETIC CONTROL mean 27.98 23.03 23.31
(HbAl >13%) SD 3.94 3.99 3.09
median 26.77 19.32 21.75
Mann--Whitney U* 85.0 91.0 74.0
z 1.99 1.79 2.38
Probability** 0.023 0.037 0.0088
anti-HI=anti-human insulin antibody; PI=anti-pork insulin 
antibody; BI=anti-beef insulin antibody. z=standard 
normal deviate. *Mann-Whitney U value for testing the 
significance of difference between patients with good and 
poor diabetic control. **P value is given for a 
one-tailed test; For a two-tailed test the P values 
should be doubled.
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3.4.2. Anti-Insulin IgG Subclasses
Positive sera from Group I diabetic patients were 
analysed for their anti-insulin IgG subclass 
distribution. For each patient, the sum of IgGl, 2, 3 
and 4 was calculated and taken as 100% value in order to 
assess the relative abundance of each IgG subclass 
implicated in anti-insulin immune response. Table 3-9. 
shows the distribution of anti-human insulin IgG 
subclasses in the serum of individual diabetic patients 
as well as the group mean +SD and the patients' clinical 
background..
The results showed that all patients possessed 
anti-insulin IgGl and in most cases, it was the 
predominant anti-insulin IgG subclass. The next most 
prevalent subclass was IgG3 followed by IgG2 and IgG4. 
The distribution of anti-insulin IgG2 and IgG4 varied 
considerably from patient to patient. For example, in 
patients 24 and 34 IgG2 was the mo3t prevalent subclass 
at 58.6% and 38.8% respectively. Patient 30 on the other 
hand lacked any detectable anti-insulin IgG2. Similarly, 
in five patients the IgG4 subclass reached as high as 
27-34%, yet it was not detected in two patients (nos. 10 
and 23). All patients possessed anti-insulin IgG3; in 
seven patients it was the dominant subclass.
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As with total IgG concentration, IgG subclass 
distribution was thought to be potentially influenced by 
the clinical background of the patients. These possible 
relationships are analysed in Table 3.10.
There was a significant inverse correlation between the 
level of IgG2 (relative to the other IgG subclasses) and 
patients' insulin dose, indicating that the higher the 
patients' daily insulin dose requirement the lower was 
the level of IgG2. Figure 3.7. represents the 
relationship. Anti-insulin IgG4, on the other hand, 
increased with a rise in insulin dose (r=0.416; P<0.01), 
as is shown in Figure 3.8. There was also a 
statistically significant inverse correlation between % 
IgG4 and age (r=-0.397; P<0.01). However, Figure 3.9. 
which represents the correlation, does not show a 
clear-cut relationship. Anti-insulin IgGl and IgG3 
levels did not affect and/or was not affected by any of 
the clinical parameters investigated.
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Table 3.9.
Clinical background and distribution of anti-insulin IgG 
subclass in sera of Group I diabetic patients. Results 
are expressed as relative abundance.
Patient Clinical Background Relative % IgG subclass
No. AGE DID Dose HbAl IgGl IgG2 IgG3 IgG4
1 43 1 2 0.75 ND 36.84 11.58 34.42 17.16
2 28 4.5 0.67 ND 45.06 18.60 23.25 13.10
3 26 17 0.78 1 0 .8 % 35.71 12.54 30.20 21.56
4 53 28 0.77 1 0 .8 % 36.90 11.57 28.53 23.00
5 23 1 0 0.63 15.0% 52.58 9.23 24.30 13.80
6 36 2 0.39 13.1% 54.17 13.38 21.80 1 0 . 6 6
7 35 5 0.55 13.8% 35.34 32.03 30.22 2.41
8 50 3 0.52 13.6% 36.23 7.62 53.77 2.38
9 25 1.5 0.31 10.3% 38.54 36.67 18.77 6 . 0 2
1 0 31 5 0.65 14.7% 54.83 4.26 40.92 0 . 0 0
1 1 2 2 3 1.06 7.7% 55.01 5.62 28.68 10.69
1 2 47 2 0.50 12.7% 80.44 4.39 12.97 2 . 2 0
13 34 1 0 0.61 15.3% 46.36 15.45 27.11 11.08
14 19 9 1.13 11.7% 48.31 4.24 25.34 2 2 . 1 2
15 17 7 1.69 1 1 .2 % 48.36 5.74 16.48 29.43
16 53 26 0.78 12.9% 44.27 16.51 30.10 9.13
17 28 14 1 . 0 1 1 2 .1% 47.32 10.42 34.37 7.89
18 44 4 0.26 1 1 .8 % 28.63 15.35 50.83 5.19
19 31 1 0.53 9.4% 43.43 15.07 34.42 7.09
2 0 54 1 1 0.61 1 1 .0 % 52.51 19.85 22.82 4.82
2 1 39 9 0.71 12.3% 2 2 . 2 1 15.15 58.93 3.71
2 2 27 1 2 1.62 10.4% 38.41 6.30 22.39 32.90
23 46 35 0.80 8.4% 63.24 2.06 34.71 0 . 0 0
24 33 1 0.31 8 .1% 2 0 . 0 0 58.61 19.30 2.09
25 16 14 1.65 16.0% 59.96 1.60 4.74 33.70
26 50 35 0.54 14.0% 59.46 6.08 30.24 4.22
27 44 27 0.51 1 1 .8 % 49.45 10.62 26.23 13.70
28 51 30 1.92 10.7% 41.09 1 2 . 0 0 28.82 18.09
29 29 13 0 . 8 8 9.4% 72.53 16.42 9.74 1.32
30 51 2 1 0.87 1 0 . 1% 80.82 0 . 0 0 15.64 3.54
31 31 2 1 0.98 12.7% 26.89 8 . 2 2 34.05 30.84
32 50 2 0 0.75 ND 36.79 17.62 41.71 3.89
33 30 23 0.69 15.5% 28.62 7.07 58.84 5.47
34 35 18 0.69 ND 25.19 38.83 27.44 8.55
35 34 7 0 . 6 8 8.3% 37.50 33.49 25.00 4.01
36 35 2 1 0.60 ND 52.80 5.94 36.71 4.55
37 48 13 0.77 ND 74.49 5.67 17.21 2.63
38 51 2 2 0.78 ND 42.90 12.87 40.76 3.47
39 39 23 0.94 ND 69.64 3.64 24.70 2 . 0 2
40 17 4 0.28 ND 69.00 6.24 18.83 5.96
41 34 25 0 . 8 6 ND 60.12 1.15 16.79 21.95
42 30 15 1.15 ND 48.57 3.94 20.60 26.90
mean 36 14 0.79 11.79% 47.63 12.94 28.63 10.79
SD 1 1 9.7 0.37 2.28% 15.29 11.75 12.09 9.77
med. 34.5 12.5 0.73 1 1 .8 % 46.84 10.52 27.28 6.55
AGE (years); DID=duration of diabetes (years); Dose 
(Uni ts/day/Kg body weight); HbAl=%Glycosylated




Relationship between clinical background and serum 
anti-insulin IgG subclass distribution. Spearman's Rank 
Correlation Coefficient values (ra):
Anti-Insulin 
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3.4.3. Patients Transferred From Beef to Human Insulin
Therapy (Group II).
The level of anti-insulin antibody detected in the sera 
of control subjects represented non-specific binding of 
antibody to insulin coated plates. Therefore, in order 
to determine whether significant levels of anti-insulin 
antibodies are present in the sera of Group II diabetic 
patients, Mann-Whitney U test, was used to compare the 
serum anti-insulin IgG concentration of Group II patients 
with control subjects. Table 3.11., which tabulates the 
results, shows that all three serum samples from Group II 
diabetic patients contained significantly higher 
anti-insulin antibody compared to control samples.
Table 3.12. shows the difference in concentration of the 
three types of anti-insulin antibodies as well as their 
correlation value. The difference in concentrations of 
the three types of anti-insulin antibody was analysed 
using a two-sample Wilcoxon T-test for paired data and 
the correlation was determined using Spearman's Rank 
Correlation Coefficient test (r»). Although there were 
highly significant correlations in the concentration of 
anti-human, anti-pork and anti-beef insulin IgG 
antibodies, the concentration of anti-beef insulin and 
anti-human insulin IgG did significantly differ from each 
other in all three samples. In sample 1 anti-beef 
insulin concentration also differed significantly from 
anti-pork insulin antibody concentration.
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The possible effect of change in insulin therapy on the
humoral immune response to insulin was investigated. All 
three serum samples from each patient were analysed for 
total anti-insulin IgG antibody on the same microtiter 
plate by ELISA. Figures 3.10(a) and 3.10(b) shows the 
change in anti-beef and anti-human insulin antibody level 
of individual patient. In Table 3.13. the difference in 
antibody concentration of the three samples and their 
statistical significance are tabulated.
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Table 3.11.
Difference in anti-insulin IgG concentration of Group II
diabetic patients and control subjects:
Type Of Anti-Insulin IgG
Human Pork Beef
NON-DIABETIC N 2 2 2 2 2 2
CONTROLS mean 15.31 12.32 12.62
SD 4.98 4.7 5.32
median 14.92 14.92 12.08
GROUP II N 31 31 31
DIABETIC mean 47.08 45.30 41.80
PATIENTS: SD 62.55 48.67 92.27
1st SAMPLE median 24-25....... 27.6 18.49.......
Mann-Whitney U Ill 56.5 160
z 4.15 5.14 3.27
P 0 . 0 0 . 0 0 . 0 0 1
2nd SAMPLE N 23 23 23
mean 35.15 31.12 27.63
SD 25.58 23.14 17.86
median 27.43 21.67 21.94
Mann-Whitney U 90 69 82
z 3.7 4.18 3.88
P 0 . 0 0 . 0 0 . 0 0 0 2
3nd SAMPLE N 24 24 24
mean 35.70 40.27 42.67
SD 31.71 35.35 37.52
median 25.39 31.50 33.81
Mann-Whitney U 150 124 39
z 2.51 3.08 4.95
P 0 . 0 1 2 2 0 . 0 0 2 0 . 0
1st sample - taken prior to change from human to beef
insulin therapy; 2nd sample - 3-8 months on human
insulin therapy; 3rd sample - >12 on human insulin




Anti-human, pork & beef insulin antibody: Specificity of 
antibody and correlation (ra) in response.
Type of
anti-insulin IgG N Wilcoxon T z P (ra)*
1st SAMPLE
Human vs Pork: 31 218 0.58 NS 0.980
Human vs Beef: 31 118 2.55 0.0108 0.805
Pork vs Beef: 31 57 3.73 0 . 0 0 0 2 0.831
2nd SAMPLE
Human V3 Pork: 23 88.5 1.49 NS 0.882
Human vs Beef: 23 29 3.30 0 . 0 0 1 0.935
Pork vs Beef: 23 78 1.81 NS 0.944
3rd SAMPLE
Human vs Pork: 24 103 1.33 NS 0.933
Human vs Beef: 24 74 2.16 0.031 0.908
Pork vs Beef: 24 123 0.757 NS 0.795
1st sample - taken prior to change from human to beef
insulin therapy; 2nd sample - 3-8 months on human insulin 
therapy; 3rd sample - >12 on human insulin therapy.
N=n umber of patients. z=standard normal deviate. P= 




Difference in anti-insulin antibody concentration of 







Difference be tween 1st and 2nd samples:
Mann-Whitney U 347 293 323
z 0.166 1 . 1 1 0.586
P NS NS NS
Difference between 1st and 3rd samples:
Mann-Whitney U 334.5 346.5 242
z 0.636 0.433 2 . 2 1
P NS NS 0.0274
Difference between 2nd and 3rd samples:
Mann-Whitney U 250 256 188
z 0.553 0.426 1.87
P NS NS NS*
1st sample - taken prior to change from human to beef
insulin therapy; 2nd sample - 3-Q months on human insulin
therapy; 3rd sample - >12 on human insulin therapy.
z=standard normal deviate. P =significance level;
*P=0.061
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Table 3.13. shows that the change in insulin therapy, 
ie. from beef to human insulin has no significant effect 
on the anti-insulin IgG concentration. There is, however 
a significant increase in anti-beef insulin IgG 
concentration between the 1st and 3rd samples. A closer 
look at the three samples of individual patients (Figure
3.10.) shows that Group II diabetic patients fall into 
three basic subgroups with respect to their antibody 
response to insulin:
Negative responder ie. antibody concentration less than 
mean + 2 SD of control sera (non-specific binding),
Low to medium responders > non-specific binding + 2 SD; 
< mean of all three samples + 1 SD (ie. >25.27; <80
ug.ml-1).
High responders > mean of all three samples + 1 SD, (ie. 
>80 ug.ml-1).
The low to medium responder did not significantly differ 
in their antibody response when transferred to human 
insulin. The high responders did however show a 
substantial decrease in both anti-human and anti-beef 
insulin antibody concentration when transferred to human 
insulin, this is illustrated in Figures 3.10.(a) and
3.10.(b). Unfortunately, the number of patients with 
high antibody response (numbers 1 , 8 , 1 1 and 1 2 were too 
few for statistical analysis.
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Figure 3.10(a).
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3.4.4. Effects Of Transferrins From Beef To Human
Insulin Therapy On The Distribution Of Anti-Insulin 
IgG Subclasses
Of the 31 Group II diabetic patients, 9 (29%) gave a
positive antibody response to insulin while they were on 
beef insulin therapy (1st sample). The anti-insulin IgG 
subclass distribution of these positive sera was 
determined. The results in Table 3.14. indicate that the 
distribution of anti-insulin IgG subclass of Group II 
diabetic patients were similar to that of Group I 
patients. In the sera of patient number 19, the 
predominant anti-insulin IgG subclass was IgG3 in all 
three samples. Furthermore, the % anti-human IgG3 level 
increased from 46.9% (44.9% anti-beef IgG3) to 55.5%
(49.6% anti-beef IgG3). In patient number 30, anti-human 
insulin IgG3 of the 1st sample was not the most abundant 
subclass (24.6%), but when this patient was transferred 
to human insulin therapy, anti-human IgG3 increased to 
49.6% which exceeded IgGl (19.4%). The anti-beef insulin 
IgG4, in this patient also increased from 32.5% to 50.2%.
There was also a gradual increase in IgG4 from 45.1% (45% 
anti-beef) to 51.4% (47.7% anti-beef) in patient number 
24. In patient number 22, the anti-human IgG4 increased 
from 26.1% to 45.1% (see Table 3.14.). In all other 
patients IgGl was the predominant subclass.
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The distribution of anti-beef insulin IgG subclasses did 
not differ significantly from the distribution of 
anti-human insulin IgG subclasses. In fact, there was a 
highly significant correlation between the two types of 
anti-insulin IgG subclasses (r > 0.9; P < 0.001). The
distribution of IgG subclasses in the 1st, 2nd and 3rd 
serum samples were
compared. Table 3.15. gives the effect of beef and 
human insulin therapy on the relative abundance of 
anti-human and anti-beef insulin IgG subclasses.
Table 3.15. shows that the anti-insulin IgG subclass 
distribution of 1st, 2nd and 3rd samples did not 
significantly increase or decrease. One exception being 
anti-beef IgG2 which decreased from a mean value of 12.8% 
in the 1st sample to 8.2% in the 3rd sample iP=0.035).
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Table 3.14.
Anti-human (anti-beef) insulin IgG subclass distribution 
of positive sera from Group II diabetic patients: Results 
are expressed as relative abundance.
Patient Relative % IgG subclasses
No. IgGl IgG2 IgG3 IgG4
1st SAMPLE
4 51.1 50.9) 11.3 9.8) 20.4 21.9) 17.2 (17.4)
5 55.8 58.0) 7.6 8 .8 ) 27.5 23.9) 9.1 (9.3)
8 46.1 49.4) 7.9 13.1) 27.1 27.5) 18.9 (1 0 .1 )
14 53.2 34.7) 14.4 29.4) 26.5 16.8) 5.9 (19.1)
19 33.7 32.8) 8.3 9.6) 46.9 44.9) 1 1 . 2 (12.7)
2 1 53.6 53.2) 1 2 . 8 13.0) 24.5 25.2) 9.1 (8 .6 )
2 2 44.1 42.7) 14.6 13.8) 15.2 18.8) 26.1 (24.7)
24 41.0 39.3) 4.5 6.4) 9.5 9.3) 45.1 (45.0)
30 30.9 38.7) 1 2 . 1 11.4) 24.6 17.4) 32.4 (32.5)
mean 45.5 44.4) 10.4 1 2 .8 ) 24.6 2 2 .8 ) 19.4 (19.9)
SD 8.9 (3.8) 3.5 (S.7) 10.3 (<9.9) 12.9 (12.3)
median 46.1 42.7) 11.3 11.4) 24.6 21.9) 17.2 (17.4)
2nd SAMPLE
4 57.4 54.8) 6 . 0 5.5) 20.3 23.0) 16.2 (16.7)
5 67.7 66.9) 8.9 10.4) 17.4 17.1) 6 . 1 (5.7)
8 45.4 42.7) 6.3 5.7) 39.9 42.3) 8.4 (9.5)
14 57.1 57.8) 12.3 1 1 .2 ) 25.6 25.8) 4.9 (5.1)
19 29.3 30.4) 9.6 7.5) 48.1 47.3) 12.9 (14.8)
2 1 62.6 61.0) 12.3 1 2 .0 ) 20.3 21.9) 4.9 (5.1)
2 2 48.8 46.3) 8.9 9.3) 1 1 . 8 1 0 .8 ) 30.6 (33.6)
24 41.2 40.6) 4.6 6 .0 ) 1 0 . 2 1 1 .2 ) 43.9 (42.2)
30 ND ND ND ND
mean 51.2 50.1) 8 . 6 8.4) 24.2 24.9) 16.0 (16.6)
SD 12.5 1 2 .1 ) 2 . 8 2 .6 ) 13.3 13.4) 14.2 (14.0)
median 53.0 50.6) 8.9 8.4) 20.3 22.5) 10.7 (1 2 .1 )
3rd SAMPLE
4 54.1 45.4) 7.1 5.3) 24.7 35.9) 14.1 (13.4)
5 73.8 61.3) 4.4 6 .8 ) 19.0 25.4) 2 . 8 (6.5)
8 ND ND ND ND
14 72.6 61.5) 8 . 1 10.4) 18.2 22.7) 1 . 1 (5.4)
19 30.2 30.9) 5.6 8 .0 ) 55.5 49.6) 8.7 (11.5)
2 1 43.2 57.3) 13.1 9.3) 32.0 23.9) 1 1 . 8 (9.4)
2 2 8.9 49.1) 14.8 8.9) 31.2 16.0) 45.1 (26.1)
24 44.2 38.3) 0 . 8 6.7) 3.7 7.2) 51.4 (47.7)
30 19.4 16.8) 1 0 . 6 1 0 .1 ) 49.6 22.9) 20.4 (50.2 )
mean 43.3 45.1) 8 . 1 8 .2 ) 29.2 25.5) 19.4 (21.3)
SD 23.4 15.8) 4.6 1 .8 ) 17.0 12.7) 18.9 (18.2)
median 43.7 47.3) 7.6 8.5) 28.0 23.4) 13.0 (12.5)
The relative anti-beef insulin IgG subclasses are shown 
in brackets. SD=standard deviation. 1st sample - taken 
prior to change from human to beef insulin therapy; 2nd 
sample - 3-8 months on human insulin therapy; 3rd sample 
- >12 on human insulin therapy.
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Table 3.15.
Statistical summary of the effect of transferring from 
beef to human insulin therapy on the distribution of 
anti-human (anti-beef) insulin IgG subclasses.
Anti-Human (Anti-Beef) IgG Subclas3
IgGl IgG2 IgG3 IgG4
Difference between 1st and 2nd samples:
Wilcoxon T 3 (2) 8 (3) 6 (13) 1 1 (8 )
z 1.77(1.94*) 0.93(1.77) 1.27(0.09) 0.42(0.93)
P NS NS NS NS
Differe nee between 1st and 3rd samples:
Wilcoxon T 14 (8 ) 3 (1) 1 1 (8 ) 13.5 (8 )
z 0.09(0.93) 1.77(2.11) 0.42(0.93) 0.0(0.93)
P NS NS (0.035) NS NS
Difference between 2nd and 3rd samples:
Wilcoxon T 12 (9) 10 (7) 7.5 (7) 10 (14)
z 0.25(0.76) 0.59(1.1) 1 .0 1 (1 .1 ) 0.59(0.1)
P NS NS NS NS
Values for anti-beef insulin IgG subclasses are shown in 
brackets. 1st sample - taken prior to change from human 
to beef insulin therapy; 2nd sample - 3-8 months on human 
insulin therapy; 3rd sample - >12 on human insulin
therapy. *P=0.052). N=7. z=normal standard deviate.
P=probabi1ity.
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3.5. DISTRIBUTION OF IgM AND IgE IN SERUM
3.5.1. Group I Patients.
In a preliminary study, the distribution of IgM and IgE 
in the sera of type I diabetic patients was determined in 
order the investigate other types of antibody produced in 
response to insulin therapy and their possible role. 
Table 3.16. shows the mean + SD of the levels of IgM and
IgE protein in the sera of Group I diabetic patients and
control subjects. Differences in IgE and IgM of Group I 
patients were compared with control subjects.
Table 3.16. shows that the distribution of IgM in the 
sera of Group I diabetic patients was significantly lower 
than that of control subjects. The distribution of IgE, 
on the other hand was not significantly different from 
control subjects. It is widely speculated that IgE is 
the main type of antibody produced in an allergic 
reaction. Since insulin allergy has been reported in
some patients, it is of interest to investigate the
possible relationship between IgE and insulin therapy. 
Table 3.17. show the relationship between IgE and IgM 
and the patients' clinical background.
Table 3.17. shows a negative correlation between 'age' 
and IgE level, i.e. there is a decrease in IgE level 
with age. This is illustrated in Figure 3.11. In Figure 
3.12., the association between patients' daily insulin
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dose and IgE is shown. It shows that an increase in 
insulin dose requirement is correlated with a rise in IgE 
level. No correlation between IgM and patients' clinical 
background was established.
3.5.2. Distribution Of IgM And IgE In The Sera Of Group
II Diabetic Patients
The influence of beef and human insulin therapy on the 
distribution of IgM and IgE was investigated. Table 
3.18. shows the effect of transferring from beef to human 
insulin therapy on the production of IgE.
The IgE production of Group II diabetic patients did not 
differ significantly from that of non-diabetic patients. 
The IgE distribution of 1st, 2nd and 3rd serum samples of 
Group II diabetic patients did however significantly 
differ from each other; the IgE titer decreased when the 
patients were transferred from beef to human insulin 
therapy. Figures 3.13(a) and 3.13(b) shows the effect of 
change in insulin therapy on the IgE titer in 16 diabetic 
patients. Group II diabetic patients also showed a 
negative correlation between 'age' and IgE in their sera, 




Statistical summary of IgM and IgE in sera of Group I 
diabetic patients and control subjects: Results are





NON-DIABETIC N 2 2 2 2
CONTROLS mean 0.908 0.832
SD 0.138 0.183
median 0.941 0.755
GROUP I N 76 76
DIABETIC mean 0.741 0.878
PATIENTS SD 0.103 0.080
median 0.724 0.860
Difference between Group I patients and control subjects:
Mann-Whitney U 291.0 586.5
z 4.66 1.84
Probability 0 . 0 0.066(NS)
N=number of subjects. 
z=standard normal deviate.
Table 3.17.
Relationship between IgM & IgE and clinical background 
(of Group I patients): Spearman's Rank Correlation
Coefficient (ra):
Patients' Clinical Background 
AGE DID DIT Dose % HbAl
Type Of Antibody (O.D. 41 Onm )
IgM N 72 72 72 72 72
ra= -0.0277 0.2263 0.2106 -0.0378 0.052
P= NS NS NS NS
IgE N 72 72 72 72 72
r«= -0.3064 -0.0334 -0.0296 0.3577 -0.0852
P= <0.01 NS NS <0 . 0 1 NS
AGE (yrs); DID=duration of disease (yrs); DI T=dura tion of
insulin therapy (yrs); Dose (U/day/Kg body weight); % 
HbAl= glycosylated haemoglobin. N=number of patients. 




Distribution of IgE in the sera of Group II diabetic 
patients. Results are expressed as mean +SD O.D. at





N 31 24 24
mean 0.787 0.760 0.725
SD 0.057 0.066 0.098
median 0.770 0.740 0.720
Difference between 1st, 2nd & 3rd samples:
Mann-Whitney U z Probability
1st & 2 nd Samples: 251.5 2.05 0.0408
1st & 3rd Samples: 210.5 2.74 0.0061
2nd & 3rd Samples: 232.0 1.15 NS
1st sample - taken prior to change from human to beef 
insulin therapy; 2nd sample - 3-8 months on human insulin 
therapy; 3rd sample - >12 on human insulin therapy.
N=number of patients. SD=standard deviation. z=standard 
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Interleukin-2 (IL-2) In Sera Of Diabetic And 
Control Subjects.
The concentration of IL-2 in sera of 15 Group I diabetic 
patients and 8 non-diabetic control subjects was 
determined using a human IL-2 ELISA kit (Intertest-2) 
purchased from Genzyme Cooperation, Boston, MA, USA. 
Table 3.19. gives the concentration of IL-2 found in the 
sera of individual subjects as well as the group means +■
SD for diabetic patients and controls.
Table 3.19.
Concentration of IL-2 in sera of Group I diabetic 







No. 1 0.550 ! No. 1 0.340
2 0.019 2 . 2 0 0
3 0.123 ! 3 0.840
4 0.017 : 4 1.500
5 0.420 5 1.125
6 0.058 : 6 1.090
7 0.330 ; 7 1.500
8 0 . 2 1 0 ; s 2.275
9 0 . 0 0 1 i»
1 0 0.410 ii
1 1 0.550 i




N 15 I1 8
mean 0.392 11 1.359
SD 0.436 11 0.657
median 0.330 11 1.310
N= number of patients; No. = patient number; SD =
standard deviation.
The concentration of IL-2 in sera of diabetic patients
was found to be significantly lower than in sera of
control subjects (Mann-Whitney U = 14; z = 2.97; P =
03). 184
3. 6. DISCUSSION
With the recent advances in the production of 
immunochemicals which are more sensitive and specific 
than those used previously, it has been possible to 
design an ELISA with optimum conditions for the detection 
of anti-insulin antibody. The use of automated wash 
procedures and direct analysis of data by computer, 
reduces operator error to a minimum level. However, ELISA 
has one major drawback, insulin-coated plates are not 
suitable for studying the species specificity of antibody 
binding as there is much cross reactivity. Nevertheless, 
significant differences in the levels of anti-human, 
anti-pork and anti-beef insulin antibodies are reported 
in this study.
The data presented here largely confirm and extend 
previously published reports concerning anti-insulin 
antibody levels in sera of diabetic patients treated with 
human insulin (Group I.) or beef insulin (Group II).
The anti-insulin antibody concentrations of sera of both 
Group I and Group II diabetic patients were found to be 
significantly higher than that of non-diabetic controls 
(which representa non-specific binding of antibody to 
insulin coated plates). Approximately 55% of 76 diabetic 
patients on human insulin therapy, possessed anti-insulin 
antibody, although the concentrations were quite low.
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Similar results are quoted by other workers (Wilson, et. 
al., 1985; Di Mario,et al. , 1986; Rogala, et. al., 1986; 
Lunetta, et. al., 1986). It is important to note at
this point that almost all of the patients in Group I 
were simultaneously administered with short-acting 
(Actrapid MC and Humulin Soluble) and intermediate acting 
insulins (zinc suspension - Monotard, Ulcratard and 
isophane insulins - Insulatard, Humulin). Since it is 
well established that zinc-insulin crystals may cause a 
significant increase in insulin immunogenicity (Galloway 
& Bressler, 1978; Diem, et. al., 1982; Nell, et. al.,
1985) such therapeutic regimes may explain the high 
percentage of Group I diabetic patients with anti-insulin 
antibody.
For example, Lunetta, et. al., (1986) and Reeves et. 
al., (1984) found that the immunogenic ity of short-acting 
monocomponent insulin preparations (both human and pork) 
was negligible. Patients administered with
zinc-suspension preparations, however, gave a significant 
antigenic response. Unfortunately, in this study, it was 
not possible to assess the effects of zinc-insulin 
therapy on the level of anti-insulin antibody produced 
because only one patient of the 76 studied, was under 
Actrapid MC therapy alone. He was a 43 year old man 
(patient number 1; Table 3.3) who showed considerable 
insulin resistance (he was administered >200 units per 
day. by means of a continuous infusion insulin pump). His
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serum anti-human insulin concentration was found to be 
25.88 ug.ml~L, which is a low positive antibody response 
according to the classifications used in this study.
It is interesting to note that all four Group I patients 
(patient numbers 6, 19, 30 and 32; Table 3.3) who
produced high levels of anti-insulin antibody (>88.5 
ug.ml~1 of serum) had at some time in their diabetic life 
been administered PZI beef insulin. Two of these four 
patients had diabetes retinopathy and one showed insulin 
allergy. It appears that the treatment with conventional 
insulin preparations can cause complications which are 
not necessarily reduced if the patient is transferred to 
human insulin. Patients who have been given human 
insulin from the onset of insulin therapy (8 patients) 
showed no or very low levels of insulin antibodies, thus 
implying that if human insulin is administered from the 
onset of insulin therapy, it is less immunogenic than 
conventional insulins.
The residual immunogenicity of therapeutic preparations 
of human insulin may also be due to molecular alterations 
which are thought to develop during manufacture, storage 
or following injection. For example, dimerisation or 
deamidation of the insulin molecule may take place which 
would create new determinants recognized by T- and 
B-cells.
The influence of HLA genotype on the level of insulin 
antibody is well documented (McEvoy. et. al., 1986;
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Aimer, et. al., 1985; Asplin, et. al., 1984). 
However, since it was not within the scope of this study 
to determine the patients' genotype, it's influence can 
not be ruled out as an explanation for the results 
obtained.
It has been supposed that anti-insulin antibodies are
only produced against the variable residues in the
therapeutically administered insulin molecule. However,
a large proportion of the antibodies produced in response
to the administration of heterologous insulin (beef and
pork) is reactive with determinants present on the
homologous molecule. i.e. autoreactive antibodies are
produced (Reeves, 1986). This may explain the high
degree of correlation observed between the three species
of anti-insulin antibodies (i.e. human, pork and beef).
The number of possible antibodies produced in response to
insulin is vast, over 115 types has been identified using
monoclonal antibodies which recognize unique sites on the
insulin molecules (Schroer et. al., 1983). Most of these
recognize epitopes present in all three species of 
\
insulin due to the high degree of homology between them. 
Insulin antibodies can bind to almost any part of the 
insulin surface and their chief metabolic effect is to 
withdraw significant amounts of insulin within the 
vascular compartment.
The data out-1 ined in this study do not confirm any effect 
of age, sex, duration of disease, duration of insulin
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treatment, or the daily insulin dose on the level of 
anti-insulin antibody concentration. Since Group I 
diabetic patients do not include the very young who are 
reported to produce higher levels of antibody (Andersen,
1972), and the very old (age range of Group I patients 
was 16 to 55 years), it may explain the lack of 
correlation between age and antibody response. It is 
well established that most long-standing, insulin treated 
diabetics are insulin resistant (Gray,et. a l 1965). 
Such insulin resistance may be a function of prevailing 
degree of metabolic control and duration of diabetes, and 
is unrelated to the presence of insulin antibodies when 
insulin action is assessed under steady state conditions 
(Gray, et. al., 1965). This observation accords with the 
failure to show a direct relation between daily insulin 
dose and insulin antibody binding.
There was, however, a significant correlation between the 
level of anti-insulin antibody and diabetic control as 
determined by glycosylated haemoglobin level. This was 
especially significant in the level of anti-beef insulin 
antibody.
Haemoglobin Aid (HbAid) is the major glycosylated 
haemoglobin present in red blood cells of healthy adults 
and diabetic patients. It is the product of a chemical 
reaction between glucose and the N-terminal valine of the 
beta chain of haemoglobin Ao. The concentrations of 
HbAia, as well as those of three minor haemoglobins are
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elevated in diabetic patients. The concentration of HbAl 
(HbAia + HbAit> + HbAic = HbAl) is mainly dependent on the 
prevailing plasma glucose level, and it is commonly used 
as means of assessing metabolic control in diabetic 
patients. Results outlined in the present study show 
that patients with stable diabetic control (stable HbAl 
value, <11%, determined over one year period) have 
significantly higher levels of anti-insulin antibody than 
those with unstable control (>13% HbAl, and frequent 
changes in insulin dose).
Insulin binding antibodies were found to be present in 
the serum of approximately 50% of the patients studied. 
They are said to act as insulin transporting proteins 
(Dixon, et. al., 1975). Insulin entering the vascular 
space from its injection depot site is thought to combine 
with insulin antibody so that only a proportion of the 
insulin remains free in serum to exert its physiological 
action. Mien the depot site is exhausted or when the
flux of insulin into serum is inadequate, the 
antibody-insulin complex dissociates and insulin is
released. This prevents the concentration of insulin 
falling to low levels (Dixon et. al., 1975). This 
'buffering effect" of anti-insulin antibodies has the 
effect of damping oscillations in free insulin levels and 
thereby leads to stable diabetic control. Unstable 
diabetes results when insulin antibodies do not act as a
buffer, either because the serum concentration of
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anti-insulin antibody is low or the antibody avidity for 
insulin is high (Dixon, et. al., 1975).
The hypothesis that diabetic stability may be associated 
with the presence of anti-insulin antibodies is also 
suported by other workers (Dixon, et. al., 1975; Gray, 
et. al., 1981; Gray, et. al., 1985; McEvoy, et. al., 
1986; Walford, et. al., 1982; Keilaker. et. al., 1982; 
Keilaker, et. al., 1986), although Asplin et. al., 
(1978) and Goldman et. al. , (1979) failed to find such a 
relationship.
Anti-Insulin IgG Subclasses.
Human IgG consists of four subclasses based on antigenic 
differences in their heavy polypeptide chains. The IgG 
subclasses are isotypes of IgG, and their distribution 
pattern is inherited. Each subclass contains special Gm 
factors. The IgG subclasses are found in different 
proportions in normal serum with the relative 
concentrations for IgGl - 60 to 70%, IgG2 - 14 to 20%,
IgG3 4 to 8 %, and IgG4 2 to 6 % (Steinberg et. al.,
1973). The IgG subclass distribution, expressed in terms 
of proportion of total IgG in the sera of non-diabetic 
control subjects was found to be 59.9% IgGl, 18.3% IgG2, 
9.2% IgG3 and 12.6% IgG4. The results obtained in this 
study were similar to that quoted by Steinberg et. al., 
although the level of IgG4 was found to be highr than 
expected. This may be due to the high avidity of
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anti-IgG4 monoclonal antibody used in this study.
The mean anti-insulin IgG subclass distribution in
insulin-dependent diabetic patients were found to be 47% 
IgGl, 13% IgG2, 28% IgG3 and 1 1 % IgG4. In most patients 
IgGl was the predominant subclass, second most abundant 
subclass being IgG3. In 5 out of the 42 patients' sera 
tested, IgG3 was the most dominant subclass. This is 
most interesting in view of the fact that secondary 
systemic antibody responses to protein and viral antigens 
are predominantly of the IgGl and IgG3 subclasses with 
the proportions varying with the antigen and between 
individuals (Shakib, 1986).
Anti-insulin IgG2 has been reported to be deficient
and/or absent in diabetic patients by Koch et. al.,
(1986) and Oxelius (1984). These results may be due to 
the use of incorrect anti-IgG2 monoclonal antibodies. For 
example, Koch et. al. used BAM 10 - clone G0M1. This 
particular clone was also used in this study to determine 
the anti-insulin IgG2 subclass distribution and similar 
results to Koch et. al., were obtained. However, 
further analysis of the clone using normal serum revealed 
its inappropriateness for the ELISA technique as very low 
levels of anti-IgG2 were obtained in all the sera from 
control subjects. Jefferis, et. al., (1985), also came 
to similar conclusions. They found that only two of the 
nine anti-IgG2 monoclonal antibodies commercially 
available, had high avidity for IgG2. Therefore, a more
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appropriate clone (HP6014) was used for reassessment of 
the anti-insulin IgG subclass distribution. Such 
methodological problems reflect the importance of proper 
assessment of reagents used for a particular ELISA 
system.
In four patients, IgG4 was as high as 30 percent or 
more. In these patients the high level of IgG4 may be 
associated with chronic antigenic stimulation (Aalberse, 
et. al., 1983; Shakib, 1986). These four patients' 
daily insulin dose requirement was among the highest 
(three of the four patients required >1.62 U/D/Kg; the 
fourth patient required 0.98 U/D/Kg). Interestingly, one 
of these patients, with 33.7% IgG4 (he required a daily 
insulin dose of 1.65 U/D/Kg), was a 16 year old boy who 
suffered from severe hypersensitivity to insulin at the 
injection site, i.e. he was allergic to insulin. 
Furthermore, a significant positive correlation between 
IgG4 and the patients' daily insulin dose requirement was 
observed which may reflect the effects of chronic 
antigenic stimulation.
Aside from insulin-dependent diabetes, haemophilia is 
another disease in the course of which a protein is 
frequently administered. It i3 worth noteing that- the 
profile of anti-factor VIII immunization also shows an 
abnormal IgG distribution, 3 ince it is characterized by a 
higher than expected abundance of IgG4 (Shakib, 1986). 
Admittedly, coagulation factor VIII is a glycoprotein
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whereas insulin does not contain any saccharidic 
components, but it is possible that proteins and
glycoproteins induce an abnormal level of IgG4 and that 
this level is dose dependent.
Compared to IgG4, an inverse relationship was observed 
between insulin dose and IgG2. This phenomenon is less 
easily explained. IgG2 is reported to be deficient in 
several autoimmune diseases (Oxelius, 1994; Shakib,
1986), including type I diabetes (Koch et. al., 1986).
In this study 8 of 42 patients investigated produced 
little or no IgG2. It would be interesting to determine 
whether lack of IgG2 is a reflection of the autoimmune 
process, i.e., patients with little beta cell function, 
require a higher insulin dose (Goldman et. al., 1979; 
Ludvigsson, 1984), and are unable to synthesise normal 
levels of IgG2. There was also an apparent decrease in 
IgG2 with duration of disease, but it just failed to be 
statistically significant (r=-0.289; P=0.053).
The relative percentage of IgG4 decreased with 'age'. 
IgG4 is presumably harmless, it does not fix complement 
and may possibly be protective against complement-induced 
damage, this protective effect of IgG4 may be lost with 
age and could lead to many of the immunological
complications associated with old age in diabetic 
patients. Further investigation of the relationship 
between IgG4 and diabetic complications is obviously
necessary in order to validate this hypothesis.
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Effects Of Transferring From Beef To Human Insulin 
Therapy
Approximately 48% of Group II diabetic patients possessed 
anti-human insulin antibodies and 32% possessed anti-beef 
insulin antibodies while they were undergoing beef 
insulin therapy. Significant differences in the level of 
anti-human and anti-beef insulin were observed in all 
three serum samples.
In the majority of Group II diabetic patients, the 
concentration of anti-insulin antibody was unaffected by 
the type of insulin therapy. High levels of antibody 
were seen in so few patients (4 of 31 patients studied) 
that statistical analysis was difficult, but it was
evident that in those with very high antibody titer, 
there was a substantial decrease in anti-insulin antibody 
concentration when the patients were transferred from 
beef to human insulin therapy. It is possible that beef 
insulin is more immunogenic than human insulin in a 
selective number of patients who are sensitive to insulin
due possibly to genetic factors. According to the
overall results, however, the level of anti-beef insulin 
antibody significantly increased 12 months after the 
patients were transferred to human insulin. Such 
findings rather refutes the idea that beef insulin is 
more antigenic than human insulin due to the difference 
in amino acid sequence between homologous insulin and 
beef insulin. Other factors clearly play a role in the
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antigenicity of the therapeutic insulin preparations, 
such as purity, additives such a3 zinc, proinsulin 
content, mode of administration and so on.
For example, Wilson, et. al., (1985) found that a 
reduction in proinsulin contamination of beef insulin to 
< 1 ppm lowers antibody levels in patients previously 
"immunized" with a conventional beef insulin preparation. 
Highly purified beef insulin (Neuphane and Neusulin with 
very little proinsulin) had been administered to Group II 
diabetic patients. Therefore, the lack of significant 
reduction in insulin antibody titer when the patients 
were transferred to human insulins (Human Velosulin and 
Insulatard) may be due to the fact that highly purified
beef insulin is not very immunogenic anyway (Wilson et. 
al., 1985).
Di Mario, et. al., (1988) also found that a switch to
biosynthetic human insulin in patients already treated
with highly purified insulins, (as is the case in Group 
II patients), did not modify the levels of anti-insulin 
antibodies. It is possible however, that with long-term 
use of human insulin, the patients may reveal positive
immunological modifications, which was not detected in 
this short-term investigation of one year. For example, 
recent studies on the immunogenicity of human insulin has 
shown that the level of anti-insulin antibodies continues 
to decrease after 1 2 months following the transfer of 
patients to human insulin therapy (Chandraprasert &
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Bunnag, 1985; Rogala et. al., 1986). Thus the antibody 
measured may in fact be anti-insulin antibody induced by 
beef insulin therapy prior to change to human insulin 
therapy. The level of anti-human insulin antibody in the 
1st sample, may also be explained by the fact that 
antibodies induced by beef insulin cross react to a large 
extent with the human insulin molecule (Wilson et. al., 
1985). Such a phenomenon may explain the the lack of
reduction in antibody response when transferred to human 
insulin and a further year of follow up study is
necessary on the same patients before a substantial
lowering of anti-insulin antibody might be observed. It 
is important to note, however, that the level of 
anti-human insulin antibody produced by Group II patients 
(at all three occasions), did not differ significantly
from that produced by Group I diabetic patients, most of 
whom have been on human insulin therapy for more than two 
years.
Because the number of patients studied (31 in Group II) 
was low the results outlined in this study is not
necessarily representative of the effect of beef and 
human insulin therapy on the immune response to insulin. 
Other factors such as HLA type (Ludvigsson, 1984; Reeves 
et. al., 1984; Aimer, et. al., 1985) probably play an 
important role. For example, patients with HLA-15, DR4 or 
DR3/4 phenotype have a high responder status, whilst 
patients with HLA-B8 , or lacking B7, have a low responder
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status to both beef and pork insulins. Patients 
possessing the HLA-DR3 phenotype respond normally to beef 
insulin, but are of low responder status to pork insulin 
(Sklenar, et. al., 1982).
Effects Of Beef And Human Insulin Therapy On IgG Subclass 
Distribution.
The relative percentage of anti-insulin antibody IgG3 
and/or IgG4 subclasses increased in four of the 9 
patients tested, but the overall distribution of any one 
subclass did not change significantly when the patients 
were transferred to human insulin therapy. The increase 
in antibodies of the IgG3 and IgG4 subclasses in some 
patients is difficult to account for without knowledge of 
the clinical background of Group II patients. The HLA 
type of these patients may also be of great interest in 
that the HLA type may influence the IgG subclass 
distribution. It is speculated that human insulin 
therapy induces more IgG3 and IgG4 than beef insulin 
therapy.
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A qualitative analysis of IgM and IgE present in serum of 
diabetic patients were performed. The levels of 
anti-insulin IgE and IgM were found to be too low to 
detect using the assay system availabe at the time of 
study. The lack of a suitable anti-insulin IgE or IgM 
standard also made it difficult to quantitate these two
isotypes of anti-insulin antibodies. Therefore the total
IgE and IgM protein levels were determined. IgM was
found to be significantly lower in diabetic patients than 
in non-diabetic controls.
IgE is associated with homocytotropic antibody activity 
in man. It is the main class of antibody produced in
response to allergic reactions (Shakib, 1986). The level 
of IgE in diabetic patients was not found to be 
significantly different from that of non-diabetic 
controls. This suggests that insulin allergy probably is 
not a common feature amoung the patients investigated in 
this study.
The level of IgE protein was found to decrease with age 
and increased with the patients' daily insulin dose 
intake. The high level of IgE in patients requiring high 
insulin dose may reflect a degree of insulin allergy in 
some patients. For example, one patient with insulin 
allergy, which manifested as lumps formed at the 
injection site, produced a high level of IgE compared to
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most diabetics studied. The decreased level of IgE 




RELATIONSHIP BETWEEN CELLULAR AND HUMORAL IMMUNE
RESPPONSE TO INSULIN.
4.1. RESULTS
4.1.1. Relationship between cellular immune response to 
insulin and anti-insulin IgG. ...................
The possible relationship between cellular (both SI and % 
suppression) and humoral immune response to insulin in 
Group I diabetic patients was investigated using 
Spearman's Rank correlation coefficient test. The 
results are tabulated in Tables 4.1. and 4.2.
Table 4.1. and 4.2. show that in most cases the 
correlation between cellular response (stimulation index 
& % suppression and total anti-insulin IgG concentration
was not significant. There was, however a significant 
correlation between IgM and the stimulation index in the 
presence of lOug.ml-1 human insulin and 10ug.ml~L beef 
insulin (see Figures 4.1. and 4.2. respectively). Figure 
4.3. shows that the level of IgE also correlated with SI 
in the presence of lOOug.ml-1 pork insulin. Although the 
correlation between % suppression at 10 ug.ml-1 human 
insulin and IgE was not significant, plotting these two 
parameters (Figure 4.4.) shows a clear cut positive 
relationship between IgE and % suppression. The 
relationship became significant if the two patients who
201
gave very high negative % suppression values (-315% and 
-729.8%) were removed from the analysis (r=0.356;
P<0.05). The corresponding levels of IgE were 0.947 and 
0.880 (O.D. at 4ionm) respectively.
In Table 4.3., the relationship between total 
anti-insulin IgG, anti-insulin IgG subclass antibodies, 
IgE and IgM are tabulated. Only IgG4 showed a 
significant correlation with IgE; an increase in IgE 
seems to be associated with a rise in IgG4, Figure 4.5. 
illustrates this relationship. No other correlation was 
observed.
Table 4.1.
Relationship between cellular (SI) and humoral immune 
response to insulin in Group I diabetic patients.
Spearman's Rank Correlation Coefficient (rs):
Cellular Immune Response To 





N 22 22 35 35 35 35
Antibody Response
anti-HI Ab -0.013 -0.040
anti-PI Ab -0.037 -0.047
anti-BI Ab -0.122 -0.158
N 39 39 59 61 60 61
IgM -0.352
P < 0 . 0 6
-0.274 -0.071 -0.134 -0.274
P c O . 0 6
-0.118
IgE -0.066 -0.198 -0.216 -0.286 
P < 0 . 0 6
-0.097 -0.119
N-number of patients. SI=stimulation index.
Ab=ant.ibody, HI =human insulin: PI-pork insulin; Bi-beef 
insulin at 10 and lOOug.ml*1. SI:Type and concentration 
of insulin in culture: H=human; P=pork; and B-beef; 
H=human insulin at 10 and lOOug. ml ~ 1
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Table 4.2.
Relationship between % suppression and antibody




P10 P100 B10 B100
N 2 2 2 2 35 35 35 35
Antibody Response
anti-HI Ab 0 . 0 0 2 0.139
anti-PI Ab 0 . 1 0 1 0 . 1 0 2
anti BI Ab 0.058
N 39 39 . 59 61 60 61
IgM -0.014 0.276 -0.063 0 . 0 2 1 0.134 0 . 1 1 2
IgE 0.314* -0.050 0.050 -0.053 0.040 -0 . 1 0 0
Type and concentration of insulin in culture: H=human; 
P=pork; B=beef insulin at 10 and lOOug.ml-1. Ab=antibody. 
*=P<0.053.
Table 4.3.
Relationship between total IgG, IgG subclasses and IgM & 
IgE. Spearman's Rank Correlation Coefficient (re) values:
Anti-Insulin IgG Anti-Insulin IgG Subclasses
anti-HI anti-PI anti-BI IgGl IgG 2 IgG3 IgG4
N 76 76 76 41 41 41 41
IgM i o o CD
COo01 -0 . 0 2 1 i o to o i o 0.17 -0.07
IgE -0.05 -0.03 0.04 1 c o
01 -0.15 0.441
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4.1.2. Relationship Between Cellular Immune Response To 
Insulin And Anti-Insulin IgG Subclass Distribution.
The relationship between SI (and % Suppression) and IgG 
subclass distribution was analysed. Tables 4.4. and 
4.5. shows the Spearman's rank correlation coefficient 
values.
The relationship between cellular immune response to 
insulin and anti-insulin IgG subclasses was not 
significant, except in the case of IgG4 which increased 
with a rise in % suppression in the presence of 10 
ug.ml-1 human insulin. Figure 4.6 illustrates this 
relationship.
Table 4.4.
Relationship between cellular immune response (SI) to insulin 
and anti-insulin IgG subclass distribution. Spearman's Rank 
Correlation Coefficient (ra):
Cellular Immune Response To 





N 22 oo 35 35 35 35
Anti-Insulin 
IgG Subclasses 
anti-IgGl 0.292 0.152 0.042 0.221 0.113 0.243
anti-IgG2 -0.063 -0.103 0.040 -0.187 -0.247 -0.264
anti-IgG3 -0.285 -0.095 -0.293 -0.279 -0.296 -0.123
anti-IgG4 -0.165 -0.095 -0.065 0. 110 -0.153 -0. 177
N=number of patients. Type and concentration of insulin 




Relationship between % suppression and anti-insulin IgG 




P10 P100 310 B100
N 22 22 32 32 32 32
Anti-Insul in 
IgG Subclass 
anti-IgGl -0.012 -0.199 -0.063 -0.132 -0.206 -0.086
anti-IgG2 -0.185 -0.145 -0.076 -0.038 0.087 -0.028
anti-IgG3 0.038 0.229 0.163 0.170 0.179 0.071
anti-IgG4 0.461 
P<0.05
0.033 0.065 -0.144 0.235 -0.142
N=Number of patients. % Suppression in the presence of 
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4.2. DISCUSSION
The Relationship Between The Cellular And The Humoral 
Immune Response To Insulin
The immune system is an intricate balance between 
cellular components which include antigen presenting 
cells, T-lymphocytes and components responsible for the 
humoral response, mediated by B-cells. The purpose of 
this study was to concentrate on the T- and B-cell 
response to insulin in IDDM patients. As these two types 
of responses are integrated it was of interest to 
investigate the relationship between them.
There was no correlation between T-cell proliferation 
(measured in terms of stimulation index) and the 
concentration of total anti-insulin IgG in the sera of 
diabetic or control subjects. There was, however, an 
inverse relationship between T-cell proliferation in the 
presence of lOug.ml- 1  human and beef insulins and the 
level of IgM. The level of IgE found in the sera of 
group I diabetic patients also decreased with increase in 
SI values obtained when lymphocytes from diabetic 
patients were cultured in the presence of lOOug.ml- 1  pork 
insulin. Such associations may reflect the influence of 
T-cells on the immunoglobulin isotype synthesised by 
B-cell3 as well as the amount of IgM and IgE produced by 
diabetic patients.
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The levels of IgG4 and IgE in sera of group I diabetic
patients were found to increase with increase in
suppressor cell activity (% suppression in the presence 
of lOug.ml- 1  human insulin). Interestingly, all three 
types of responses (IgG4, IgE and % suppression) 
increased with increase in insulin dose. These three
phenomena appear to be a function of insulin dose. It is
possible that in patients who require a high insulin 
dose, there is a degree of insulin resistance which may 
be due to IgG4 and IgE antibodies forming complexes with 
insulin that does not necessarily lead to insulin 
allergy, but affects the insulin dose. Alternatively, 
high insulin dose induces increased IgG4 and IgE 
production. The level of IgG4 and IgE may then trigger a 
negative feed-back mechanism which activates suppressor 
cells. Such a hypothesis is purely speculative as there 
is no evidence to suggest that such complexes are formed.
The levels of IgG4, IgE and together with % lymphocyte 
suppression (in the presence of lOug.ml- 1 human insulin) 
also decreases with age. The relationship between these 
factors and age may be part of a general loss of immunity 
as a result of the ageing process.
There was a direct relatiionship between IgE protein and 
IgG4 anti-insulin antibodies. i.e. the level of 
anti-insulin IgG4 antibody increased with an increase in 
IgE. Increaseed IgG4 has been reported in patients with
213
allergy and parasitic infections (Oxelius, 1984; Shakib, 
1986; Aalberse, et. al., 1933), IgG4 and IgE antibodies 
appear to be important in allergic diseases and since 
serum specific IgE antibody responses are influenced by 
MHC genes (Marsh, et. al., 1981), it is possible that 
similar genetic restrictions govern the level of 
anti-insulin IgG4 produced in insulin-treated diabetics. 
IgG4 is known to be cytophilic for basophils, and 
heterologous anti-IgG4 antisera can stimulate peripheral 
blood leucocytes from normal or allergic individuals to 
degranulate and release histamine (Shakib, 1986). 
However, anti-insulin IgG4 was found in sera of diabetic 
patients with no apparent clinical sensitivity to 
insulin, thus IgG4 cannot be implicated in allergic 
reactions. The high level of anti-insulin IgG4 found in 
some patients is therefore, thought to reflect prolonged 
antigenic stimulation known to elicit IgG4 response 
(Aalberse et. al., 1983). From an immunopathological 
point of view, IgG4 antibodies are thought to be 
harmless, and possibly protective against
complement-induced damage (Allberse, et. al., 1983).
In patients with poor diabetic control (high % HbAl), 
cellular immune response (SI) was found to be higher than 
in those with good diabetic control (low % HbAl) (Chapter 
II; Table 2.17). The reverse was true of the humoral 
response (anti-insulin IgG concentration), which was 
lower in patients with poor control than in those with 
good diabetic control (Chapter III; Table 3.8). It
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appears that diabetic control may influences the cellular 
immune response to insulin in some way, although the 
exact mechanism is unclear. The antibody response on the 
other hand has a direct affect on diabetic control i.e. 
in patients with good diabetic control the increased 
levels of insulin antibody in their sera, acts as a
buffering system and prolongs the effects of insulin thus
reducing the level of glycosylated haemoglobin.
Finally, a preliminary analysis of the serum 
interleukin-2 (IL-2) level was determined in 15 Group I 
diabetic patients and 8 non-diabetic subjects. The 
results confirm previously reported findings (Kaye, et. 
al., 1986; Rodman, 1984), i.e. the level of IL-2 found in 
the sera of diabetic patients were significantly lower
than in the sera from normal controls.
Deficient IL-2 production is also reported in other 
autoimmune diseases such as systamiclupus erythematoses 
(SLE). The level of IL-2 is reported to be normal in 
type II diabetic patients (Kaye, et. al., 1986). Rodman,
(1984), also established a genetic link, IL-2 deficient 
Type I diabetics were found to be positive for HLA-DR3, 
although Kaye, et. al., found no such genetic link. It 
was not possible to establish any relationship between 
serum IL-2 concentration and the clinical background of 
the patients, as the number of patients was too low. 
Further study with more patients will be necessary in 
order to investigate the possible relevance of the above
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The cellular and humoral immune responses to insulin in 
IDDM patients and non-diabetic control subjects were 
investigated. The work presented in this study largely 
confirm and extend previously published reports 
concerning the immunogenicity of exogenously administered 
human and/or beef insulins.
Cellular immune response to insulin, assessed by the in 
vitro cellular proliferation to human, pork and beef 
insulins, showed that insulin-specific lymphocyte 
transformation occurs in approximately 40% of Group I 
diabetic patients. Nearly all the diabetic patients 
studied have long established insulin-dependency. It is 
reasonable to assume therefore, that these patients have 
developed cellular immunity in the form of an 
insulin-sensitized lymphocyte subpopulation. Since the 
level of the stimulation index (SI) was found not to be 
influenced by the patients' age, duration of disease, 
duration of insulin therapy, insulin dose, or any 
immunological complications (such as insulin resistance 
and insulin allergy), such insulin-sensitized lymphocytes 
are thought to be of little clinical significance.
Most patients, undergoing human insulin therapy, showed 
very low stimulation indices (< 2.5), the maximum
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response being a SI value of 8.76. Approximately 60% of 
the Group I patients failed to show a significant SI
value. Thus, it is concluded that therapeutic human 
insulin is not immunogenic in the majority of patients. 
In patients treated with human insulin from the onset of 
insulin therapy, it was found to be even less
immunogenic.
The level of % glycosylated haemoglobin was found to be 
elevated in patients who gave a positive response to
insulin. The relationship between diabetic control and SI 
is unclear but it may be associated with the level of
anti-insulin antibody. For example, 18 of 24 patients
who gave a positive proliferative response to insulin 
also showed significant levels of insulin antibody in
their serum. It is possible that positive responders 
(ie. those patients who gave a positive SI value)
possess insulin sensitized T-cells which influence a
B-cell response and the level of insulin antibody
produced. Thus patients with insulin sensitized T-cells 
produce more antibody which positively affect the
patient ' 3  diabetic control by acting as a buffering agent 
between insulin injections. Unfortunately, no correlation 
between SI and anti-insulin IgG concentration was
observed.
The proliferative response to insulin was found to be
partly regulated at the cellular level by suppressor
cell activity, i.e. a negative correlation between SI
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and insulin specific % suppression was observed. The 
immune response to insulin was also reported by others to 
be controled at the cellular level by suppressor cells 
(Jensen & Kapp, 1985; Baskin & Rosenthal, 1980). This 
finding may be of great importance in view of the 
autoimmune process of type I diabetes.
Insulin-specific suppressor cell activity in the presence 
of at least one type of insulin was observed in 50 of the 
63 patients studied. The remaining 13 patients failed to 
give positive suppressor cell activity with all three 
types of insulin in culture. Of these 13 patients, three 
are known to have diabetes retinopathy, one showed signs 
of insulin resistance (daily dose > 2 0 0  units) and one had 
diabetes neuropathy. Of the 50 patients who did show 
suppressor cell activity, only four had diabetes 
retinopathy. It is, therefore, tempting to speculate 
that lack of insulin specific suppressor cells may have 
detrimental effects, which results in various 
complications associated with insulin therapy. Further 
investigation is obviously required.
The effect of insulin antibody on insulin dose 
requirement is controversial. Some investigations failed 
to show a correlation (Asplin, et. al., 1978; 
Chandraprasert, 1985; Gray, et. al., 1985;), while
others (Andersen, 1972; Ludvigasson, 1984; Wajchenberg, 
et. al., 1986) report that patients with high antibody 
titers require higher insulin doses. The results
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obtained in the present study confirm the former reports.
The presence of insulin antibodies is thought to be 
detrimental to islet beta cell function (Ludvigsson, 
1984), and therefore, may exacerbrate the autoimmune 
process of the disease. The mechanism is unclear, but it 
is speculated that insulin antibodies could have an 
'exhausting' effect by binding endogenously secreted 
insulin and proinsulin (Ludvigsson, 1984). Alternatively, 
insulin antibodies and complexes of antibodies may act as 
antigens and contribute to inflammatory reactions in the 
islets of Lagerhans. Because it was not within the scope 
of this investigation to determine the level of beta-cell 
function in the diabetic patients studied, it is not 
possible to confirmed or refuted the above hypothesis.
The importance of insulin antibodies depend on whether 
they offer clinically significant advantages or 
disadvantageous to diabetic patients treated with 
insulin. For example, it is suggested by various 
investigations that alterations in the pharmacokinetics 
and localisation of insulin in the presence of insulin 
antibodies have significant effects on the adequacy of 
diabetic control (Reeves, 1986; Dixon, et. al., 1975).
In view of the finding that insulin antibody may 
influence diabetic control, it is important to consider 
the antibody status of an individual when determining on 
the most appropriate therapeutic insulin regime. For 
example, in some patients, with poor diabetic control,
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stimulation of the immune system to produce antibody 
similar to the levels found in patients with good control 
may be beneficial. It is possible that, in view of the 
discomfort associated with sudden hypoglycemia 
experienced by some patients treated with human insulin 
(which may be associated with low levels of insulin 
antibodies), some patients may in fact benefit from 
therapy with the more immunogenic beef insulin rather 
than with human insulin.
However, it is important to remember that almost all 
cases of diabetic complications thought to be associated 
with insulin antibodies have a history of previous 
treatment with conventional beef insulin preparations.
There was little evidence to suggest that transferring 
patients from highly purified beef to highly purified 
human insulin therapy has any suppressive effect on the 
cellular immune response to insulin. There was, however, 
a reduction in the serum concentration of total 
anti-insulin IgG in patients who gave very high antibody 
titers, and the level of IgE in the serum of Group II 
patients decreased when they were transferred to human 
insulin therapy. Since insulin allergy is associated 
with beef insulin therapy rather than human insulin 
(Reeves, 1980; 1986), the decrease in IgE, when
transferred to human insulin therapy, may be due to the 
likelihood that human insulin is less immunogenic than
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its beef counterpart.
The most interesting findings made in this study were 
related to anti-insulin IgG subclass distribution. 
Insulin therapy seems to preferentially stimulate IgGl 
and IgG3 subclasses with the levels of IgG2 and IgG4
varying considerably from patient to patient. This
contrasts with the normal distribution of total IgG 
subclasses, which was 59.9% IgGl, 18.3% IgG2, 9.2% IgG3 
and 12.5% IgG4.
Increased levels of anti-insulin IgG4 was found in some 
cases and was correlated to insulin dose, thus it may be 
associated with chronic antigenic stimulation. The level 
of anti-insulin IgG4 antibodies and IgE protein was found 
to increase with % suppression (at lOug^l - 1  human
insulin). All three factors appear to be a function of 
insulin dose. There was strong correlations between % 
suppression, IgG4 and IgE, all of which decreased with 
age. The decrease in IgG4, IgE, and insulin-specific % 
suppression, may all be part of the side-effects of the 
ageing process.
The level of anti-insulin IgG2 was found to be very low 
or absent in some diabetic patients. IgG2 deficiency is 
thought to be associated with autoimmune diseases 
including systemic lupus erythematosus (SLE) and 
insulin-dependent diabetes mellitus (Shakib, 1986; 
0 xeliu3 , 1984; Koch, et. al., 1986). Deficiency in IgG2 
and IgG4 are also reported to be associated with IgA
22 2
deficiency.
Thus, insulin appears to stimulate its own characteristic 
pattern of IgG subclasses with IgGl and IgG3 being 
predominant in most patients. The level of IgG4 and IgG2 
varied considerably from patient to patient and appears 
to be influenced by the patients' daily insulin dose and 
their age. The significance of the increased level of 
IgG4 in some patients, and the absence of IgG2 in others 
is not clear but such restrictions are thought to be due 
to the antigenic nature of insulin and the prolonged 
duration, and route of immunization.
In conclusion, human insulin therapy is immunologically 
sound as judged by the low level of SI values which were 
obtained in only 40% of patients. The antibody response 
was equally low as only 4 patients, of the 76 studied, 
gave high anti-insulin IgG titers. Human insulin is 
probably less immunogenic than beef insulin, especially 
in patients with high antibody titers. Patients treated 
with human insulin from the onset of insulin therapy 
showed little cellular and humoral responses. It would be 
interesting to expand this study to include a greater 
number of patients on human insulin and determine the 
immunological effects of human insulin therapy only. 
Since genetic factors may be involved it may be of 
interest to determine the HLA background of these 
patients and perhaps establish any genetic link present.
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